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Diffuse gliomas, comprising of oligodendroglial tumors (OTs), astrocytomas 
and glioblastoma multiforme (GBM), are the most common primary brain neoplasms 
in adults. Unlike other glioma subtypes, OTs show distinct clinical features of better 
outcome and sensitivity to chemotherapy. Concurrent deletion of chromosome arms 
Ip and 19q is the most frequent genetic alteration detected in 60%-80% of OTs. The 
lp/19q codeletion or Ip loss alone has been associated with favorable prognosis and 
chemosensitivity in OT patients. It is believed that the Ip arm carries important OT-
related genes, whose inactivation is involved in OT development. In an attempt to 
identify tumor suppressor genes located on the Ip arm, numerous research groups 
have reported the isolation of candidate genes. Although these genes were 
demonstrated to be downregulated in OTs, no conclusive evidence was provided 
with regard to their role in OT formation. The pathogenesis of OTs remains elusive. 
MicroRNAs (miRNAs) are an abundant class of small (19-25 nucleotides) non-
protein-coding RNAs, which repress expression of their target genes at post-
transcriptional level. Recent investigations have implicated a link between miRNA 
deregulation and development of various cancers, including gliomas. A better 
understanding of the biology of miRNAs and their targets may shed light on the 
molecular pathogenesis of gliomas and on the potential of these RNA molecules as 
therapeutic targets in treatment of this group of brain tumors. 
A recent study reported that microRNA-137 (miR-137) expression was 
significantly decreased in astrocytomas of all grades with inhibitory role in GBM 
cell proliferation. In addition, miR-137 was able to ihduce neuronal-like 
differentiation in mouse neural stem cells and tumor stem cells derived from GBM 
iii 
and mouse OT. MiR-137 is therefore suggested as a potential growth suppressive 
miRNA in gliomas. The objectives of this study are to investigate the potential 
involvement of miR-137 in pathogenesis of OTs and GBM，and to elucidate its 
biological function through identification and characterization of its targets. 
A collection of 36 primary OTs (13 oligodendrogliomas, 7 anaplastic 
oligodendrogliomas, 13 oligoastrocytomas and 3 anaplastic oligoastrocytomas) were 
recruited for this study. Quantitative RT-PCR (qRT-PCR) revealed significant 
downregulation of miR-137 in 90% (18/20) of oligodendrogliomas (p=0.016) and 
100% (16/16) of oligoastrocytomas (p=0.009) examined when compared to the mean 
expression level of 3 normal brain samples. Reduced miR-137 expression was 
observed in 3 OT and 7 GBM cell lines as well. Statistical analysis showed that 
reduced miR-137 expression was associated with tumor grade (p=0.010) and higher 
Ki-67 labeling index (p=0.009), but not with allelic deletion of chromosome Ip and 
� of chromosomes lp/19q, gender or age. Moreover, miR-137 expression was restored 
in OT cells after treatment with demethylating agent and histone deacetylase 
inhibitor (p<0.001). These findings suggested that miR-137 expression might be 
modulated by epigenetic modifications and its downregulation might contribute to 
the development and progression of OTs. 
To determine the biological role of miR-137 in glioma, several functional assays 
were carried out. Ectopic expression of miR-137 suppressed cell growth in eight 
glioma cell lines (derived from two oligodendrogliomas, one oligoastrocytoma and 
five glioblastomas) examined by MTT assay and cell counts (p<0.015). Soft agar 
assay indicated that miR-137 inhibited cell anchorage-independent growth in OT and 
GBM cells O<0.001). Suppression of DNA synthesis and enhanced apoptosis were 
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observed following miR-137 transfection in these cells as evaluated by BrdU 
incorporation and cleaved-PARP level. Matrigel invasion assay revealed that miR-
137 significantly suppressed glioma cell motility (p<0.001). In addition, ectopic 
expression of miR-137 in GBM cells induced upregulation of p-tubulin III, a 
neuronal marker, suggesting that miR-137 was able to induce neuronal-like 
differentiation in GBM cells. Collectively, these results suggested that miR-137 
might act as a potential tumor suppressive miRNA in OT and GBM. 
To identify target genes of miR-137, a computational approach using four 
miRNA prediction algorithms (Targetscan, PicTar, miRanda and microCosm) was 
employed. Five predicted candidate genes (CSEIL, ERBB4, NRPl, CDC42 and 
AKT2) that have been implicated in tumorigenesis were selected to further analysis. 
Dual-luciferase reporter assay demonstrated that luciferase activity was significantly 
reduced in cells cotransfected with miR-137 and reporter construct containing a 
� putative miR-137 binding site in the 3'UTR ofCSElL or ERBB4 (><0.001)，but not 
of the other three candidate genes. No reduction of luciferase activity was observed 
in control cells cotransfected with miRNA negative control or with construct 
carrying mutant miR-137 recognition site. These findings indicated that miR-137 
interacted specifically with the 3' untranslated regions of CSEIL and ERBB4 in 
glioma cells. Further study showed that miR-137 transfection reduced expression of 
CSEIL protein, but not mRNA, levels in glioma cells. Taken together, the results 
suggested that that miR-137 negatively regulated CSEIL through translational 
inhibition in glioma. 
To investigate the role of CSEIL in glioma, qRT-PCR was performed to 
determine CSEIL expression. The results showed that the CSEIL mRNA level was 
XV 
significantly elevated in 30% (6/20) of oligodendrogliomas (p=0.039) and 75% 
(12/16) of oligoastrocytomas (p=0.006) examined, compared to normal brain. 
Enhanced CSEIL transcript was also detected in 2 of 3 OT cells and 6 of 7 GBM cell 
lines studied (p=0.014). Immunohistochemistry study further demonstrated 
overexpression of CSEIL protein in both oligodendrogliomas and oligoastrocytomas 
compared with 13 non-neoplastic brain tissues (p<0.001). Although the abundance of 
CSEIL mRNA or protein did not correlate with miR-137 level in OTs 0=0.326 and 
/?=0.300, respectively), these data have unveiled upregulation of CSEIL in OTs at 
both mRNA and protein levels, suggesting CSEIL may play a role in glioma 
development. 
In the functional characterization of CSEIL, small interfering RNA-mediated 
knockdown of CSEIL resulted in suppressed proliferation, induced apoptosis and 
reduced invasiveness in glioma cells O<0.001). These effects were similar but to a 
� less extent to those induced by miR-137 overexpression, suggesting that miR-137 
may exert its functional effects partially through CSEIL. 
In summary, the results demonstrated frequent downregulation of miR-137 in 
OTs, whose restoration inhibits proliferation, invasion and induced apoptosis and ， 
differentiation in OT and GBM cells, suggesting that miR-137 may act as a growth 
suppressor and differentiation promoter in gliomagenesis. A nuclear transport factor, 
CSEIL is identified as a novel target of miR-137 and its overexpression is common 
in OTs. It was suggested that both miR-137 and its target, CSEIL may play 
important roles in the development of glioma. The therapeutic potential of miR-137-
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CHAPTER 1 INTRODUCTION 
1.1 Gliomas 
Gliomas refer to a collection of most common intracranial neoplasms, which 
account for more than 70% of all tumors of central nervous system (Ohgaki et al, 
2005). According to current World Health Organization (WHO) classification of 
Tumors of the Central Nervous System, gliomas can be classified as astrocytic, 
oligodendroglial and ependymal tumors based on the tumor cell types and 
histological appearance (Louis et al, 2007). 
Gliomas are categorized into WHO grade I to IV based on the degree of 
malignancy evaluated by various histological characteristics, such as mitotic activity, 
necrosis and microvascular proliferation. High-grade (WHO grade III-IV) gliomas 
are more aggressive than low-grade (WHO grade I-II) gliomas. WHO grade I 
gliomas generally display benign behaviors, whereas WHO grade II-IV gliomas are 
malignant with diffuse infiltration throughout the surrounding brain tissues. As 
summarized in Table 1.1, astrocytic tumors are subsequently grouped as pilocytic 
astrocytoma (WHO grade I)，diffuse astrocytoma (WHO grade II)，anaplastic 
astrocytoma (WHO grade III) or glioblastoma (WHO grade IV). Oligodendroglial 
tumors (OTs) are classified as WHO grade II or anaplastic form, WHO grade III 
(Louis et al., 2007). 
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Table 1.1 Grading of astrocytic and oligodendroglial tumors by WHO 
WHO grade Astrocytic tumors Oligodendroglial tumors 
I Pilocytic astrocytoma 
II Diffuse astrocytoma Oligodendroglioma 
Oligoastrocytoma 
III Anaplastic astrocytoma Anaplastic oligodendroglioma 
Anaplastic oligoastrocytoma 
IV Glioblastoma multiforme 
‘ 2 
1.1.1 Oligodendroglial tumors (OTs) 
OTs can be categorized histologically as oligodendrogliomas (ODs) or 
oligoastrocytomas (OAs). The latter displays morphological components of both 
oligodendroglial and astrocytic tumors. The incidence rate of OTs is 0.5 per 100,000 
people annually in Europe, constituting approximately 10% of all gliomas. OTs arise 
mostly in adults with a peak incidence at 35-50 years of age and a slight male 
preference (Ohgaki et al, 2005; Reifenberger et al, 2007; Rodriguez et al, 2010). 
Pure oligodendrogliomas have a better prognosis than oligoastrocytomas and 
astrocytomas of the same grade. A favorable median survival time of OTs is 
associated with WHO grade II，combined chromosomes Ip and 9q loss and 
proliferative activity. Moreover, OTs are more sensitive to chemotherapy compared 
to other glioma types of the same grade. Treatments of OTs consist of surgical 
，. resection and subsequent chemotherapy and/or radiotherapy (Ohgaki et al, 2005; 
Reifenberger et al, 2007; Rodriguez et al, 2010). 
1.1.2 Glioblastoma multiforme (GBM) 
GBM is the most aggressive (WHO grade IV) and the most common astrocytic 
tumor, comprising up to 70% of all gliomas. Generally, there are about 3-4 new 
cases diagnosed in 100,000 people per year in European and North American 
countries. GBM preferentially develops in adults, with peak incidence occurring 
between 45 to 70 years of age. Males are more susceptible than females to GBM 
with a male/female ratio of 1.26-1.28:1 .(Kleihues et al, 2007) 
The vast majority (>90%) of GBM manifest rapidly de novo without any 
precursor lesion identified and arise typically in elder patients. These tumors are 
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termed primary GBM. In contrast, secondary GBM develops by progression from 
low-grade diffuse astrocytoma or anaplastic astrocytoma within 5-10 years and 
mostly diagnosed in mid-age patients. Primary and secondary GBMs share similar 
clinical features, including rapid proliferation, high invasion activity and resistance 
to therapeutic treatment. However, genetic studies have revealed that these tumors 
may originate from distinct pathways. Due to its infiltrative growth pattern and 
inherent property, GBM is refractory to complete resection and is generally 
recalcitrant to chemo/radiotherapy. Therefore GBM is regarded as a lethal tumor 
with a median patient survival of 4.7-7.8 months (Ohgaki et al, 2005; Kleihues et 
al, 2007; Ohgaki et al, 2007). 
1.1.3 Molecular pathology of gliomas 
Intensive research in the past two decades has unveiled a variety of genetic 
alterations associated with the development of gliomas. These genetic aberrations 
provide clues to the process of tumor development (Figure 1.1) and more 
importantly, help diagnosis, prognosis and therapy design. 
1.1.3.1 Genetic alterations in OTs 
By comparative genomic hybridization (CGH) and microsatellite analysis, 
earlier investigations have uncovered chromosomal imbalances in OTs, including 
gains on chromosome 7, 8q and 1 Iq, and losses on chromosomes Ip, 4，9q，lOq, 14， 
17p 19q and 22q. Losses of 9q and lOq are more frequent in anaplastic variants and 
are thought as progression-associated aberrations, (Reifenberger et al, 1994; Zhu et 
al, 1998; Bigner et al, 1999; Reifenberger et al, 2003; Jeuken et al, 2004; Kitange 
et al, 2005) Some gene abnormality have been identified in these chromosomal 
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regions, such as deletion of cyclin-dependent kinase inhibitor 2A {CDKN2A) in 9q 
and mutation of phosphatase and tensin homolog {PTEN), a negative regulator of the 
phosphoinositide-3-kinase (PI3K) pathway, in lOq. (Bigner et al, 1999; Watanabe et 
al, 2001; Reifenberger et al, 2003; Jeuken et al, 2004; Reifenberger et al, 2007; 
Bromberg et al, 2009) 
Among these chromosomal instabilities, loss of heterozygosity (LOH) on 
chromosomal arms Ip and 19q is the predominant genetic alteration in OTs and is 
detected in 67-87% of tumors (Bello et al, 1994; Reifenberger et al, 1994; Bigner et 
al, 1999; Husemann et al, 1999; Smith et al, 1999). The abnormality mostly affect 
the entire Ip and 19q arms (Felsberg et al, 2004; Barbashina et al, 2005), probably 
resulting from an unbalanced t(l;19)(ql0;pl0) translocation involving chromosomes 
1 and 19 (Griffin et al, 2006; Jenkins et al, 2006) and the concomitant loss of one 
copy each of Ip and 19q. The high frequency of lp/19q codeletion suggests the 
， existence of OT-related genes on these chromosomes. 
There has been extensive effort to identify the OT-related gene on chromosome 
Ip for understanding the molecular basis of OT development. It was postulated that 
alteration of the OT-related genes may attribute to gene rearrangement at the 
breakpoints of t(l;19)(ql0;pl0) translocation, haploinsufficiency of genes or 
potential epigenetic inactivation. 
Located at the juxta-centromeric region of Ip is the NOTCH2 gene, which has 
been implicated in oligodendrocyte differentiation (Hu et al, 2003). Loss of 
N0TCH2 was associated with a favorable prognosis in oligodendroglioma and GBM 
patients (Boulay et al, 2007). However, there is no physical rearrangement or 
somatic mutation of NOTCH2 detected in oligodendrogliomas carrying 
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t(l;19)(ql0;pl0) (Benetkiewicz et al, 2009). Other candidate genes that have been 
associated with OTs, include CDKN2C (Husemann et al, 1999), TP73 (Dong et al, 
2002), DFFB (McDonald et al., 2005)，AJAPl (McDonald et al, 2006), CAMTAl 
(Barbashina et al, 2005)，STMNl (Ngo et al, 2007)，CITED4 (Tews et al, 2007), 
DIRAS3 (Riemenschneider et al, 2008) and KIAA0495/PDAM (Pang et al, 2010). 
These genes were inactivated due to mutation, chromosomal deletion, transcriptional 
silencing and/or epigenetic modification. More recently, numerous genes on Ip or 
19q were found deregulated in lp/19q codeleted oligodendrogliomas by high-
throughput gene expression profiling analysis (Tews et al., 2006). Whether any of 
these deregulated genes are involved in OT formation require further investigation. 
Besides genes that are mapped to Ip or 19q, other altered genes have been 
discovered. Tumor protein p53 (TP53) gene encoded protein p53 is implicated in 
tumorigenesis as a tumor suppressor (Aylon et al, 2007). Usually mutually 
, exclusive with lp/19q co-deletion, TP53 mutation is rare (10-15%) in 
oligodendrogliomas, but more common (30 �50%) in oligoastrocytomas 
(Reifenberger et al, 2003; Jeuken et al, 2004; Okamoto et al, 2004; Reifenberger et 
al, 2007; Watanabe et al, 2009; Bourne et al, 2010; Kim et al., 2010). However, 
p53/MDM2/MDM4/pl pathway inactivation is present in 21% of 
oligodendrogliomas and 50% of anaplastic oligodendrogliomas (Watanabe et al, 
2001). 
Another newly identified genetic alteration in gliomas is mutation of isocitrate 
dehydrogenase 1 (IDHl). The IDHl mutation is detected at a high incidence rate 
(>80%) in WHO grade II and III astrocytomas, secondary GBM and OTs but is rare 
in primary GBM (Balss et al, 2008; Watanabe et al., 2009; Yan et al, 2009; Kim et 
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al, 2010). Such mutation is found in most gliomas (>60%) harboring either lp/19q 
codeletion or TP53 mutation, strongly suggesting that IDHl mutation is a very early 
event in the development of gliomas and subsequent lp/19q loss or TP53 mutation 
directs the progression to oligodendroglial or astrocytic phenotype, respectively 
(Ichimura et al, 2009; Watanabe et al, 2009). 
Expression profiles of OTs with lp/19q loss have unveiled a subset (proneural) 
of OT exhibiting differential gene expression signatures resembling those of normal 
brain. Moreover, the proneural OT patients benefit a favorable clinical outcome than 
the GBM-like subtype. (Huang et al, 2004; Mukasa et al, 2004; Ducray et al, 2008; 
Ferrer-Luna et al, 2009; Cooper et al, 2010) 
Taken together, a vast majority of OTs exhibited IDHl mutation at early stage 
of OT pathogenesis. Subsequent lp/19q loss leads to development of 
oligodendroglioma, whereas oligoastrocytoma usually carries either lp/19q deletion 
or TP53 mutation. 
Despite these rapidly increasing knowledge of molecular pathogenesis of OT, it 
remain largely elusive which genes are pivotal for OT development. Therefore, 
identification and characterization of the OT-related genes are essential for better 
understanding of these tumors and the development of molecular-based therapy. 
1.1.3.2 Prognostic and predictive factors in OTs 
Better prognosis of OT patients can be predicted by some clinical factors, such 
as younger patient age, lower tumor grade, frontal location, more complete tumor 
resection and pure oligodendroglial histology. (Okamoto et al, 2004; Reifenberger 
et al., 2007; van den Bent et al, 2008) 
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The lp/19 codeletion or Ip loss alone has been demonstrated to be a strong 
predictor of longer survival and sensitivity to radio/chemo treatment in 1988 
(Cairncross et al, 1998). Since then, numerous studies have confirmed the clinical 
relevance .of lp/19q codeletion in OT patients treated with radiotherapy (Bauman et 
al, 2000) and adjuvant procarbazine, lomustine, and vincristine (PCV) (Cairncross 
et al, 1998; Ino et al, 2001; Cairncross et al, 2006; Jenkins et al, 2006; van den 
Bent et al, 2006) or with temozolomide (TMZ) (Hoang-Xuan et al, 2004; Brandes 
et al, 2006; Kouwenhoven et al, 2006). Notably, the results from large-scale 
clinical trials involving hundreds of anaplastic OT patients have strongly reinforced 
the prognostic relevance of concurrent loss of Ip and 19q (Cairncross et al, 2006; 
van den Bent et al, 2006). In addition, lp/19q codeletion is also prognostic in OT 
patients without any radio/chemotherapy (Kanner et al, 2006), raising the issue that 
lp/19q loss represents a prognostic rather than predictive marker in OTs. 
�. Other molecular alterations of prognostic significance include IDHl mutation 
and promoter methylation of O^-Methylguanine-DNA methyltransferase {MGMT). 
MGMT is a DNA repair enzyme that removes promutagenic alkyl groups from O -^
methylguanine adducts in DNA, to prevent cells from G:C—>A:T mutations in DNA 
replication. Both IDHl mutation and MGMT methylation are observed to be 
prognostic for both overall and progression-free survival in anaplastic OT patients 
treated with radiotherapy or combined radiotherapy/PCV treatment in a clinical trial 
study OTs (van den Bent et al, 2009; van den Bent et al., 2010). It was also 
observed that lp/19q codeletion, IDHl mutation and MGMT methylation correlated 
with each other in anaplastic OTs (van den Bent et al, 2009; van den Bent et al” 
2010) 
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1.1.3.3 Genetic alterations in GBM 
Genome-wide genetic investigations using cytogenetic, CGH and microsatellite 
analyses have identified multiple chromosomal aberrations in GBM. Most frequent 
aberrant regions include gain of chromosome 7，8q and 20q, and losses of 
chromosomes 9p，lOq，13q, 17p and 22q (Lang et al, 1994; Kim et al, 1995; Weber 
et al, 1996; Mohapatra et al, 1998; Hui et al, 2001; Ohgaki et al, 2004). Further 
molecular analysis, such as array-based CGH, fluorescent in situ hybridization 
(FISH) and gene sequencing, revealed minimal altered genomic segments and gene 
abnormality on the frequently unstable chromosomes. For instance, over 60% of 
both primary and secondary GBM show LOH lOq (Ohgaki et al, 2004), where 
PTEN was mapped. Inactivating mutation of PTEN was present in 5-40% of GBM 
(Tohma et al, 1998; Ohgaki et al, 2004; Ohgaki et al, 2009). Amplification of 
epidermal growth factor receptor (EGFR) in chromosome 7 (Ekstrand et al, 1992; 
� Watanabe et al, 1996; Ohgaki et al, 2004), TP53 mutation in chromosome 17p 
(Watanabe et al, 1996; Ohgaki et al, 2004) are also representative molecular 
abnormalities in GBM with a predominance in primary and secondary GBM, 
respectively. There are numerous alterations on other oncogenic or tumor suppressor 
• 
genes, including neurofibromin 1 {NFl) mutation, Mdm2 p53 binding protein 
homolog (mouse) {MDM2), Mdm4 p53 binding protein homolog (mouse) (MDM4) 
and cyclin-dependent kinase 4 {CDK4) amplification as well as CDKN2A deletion or 
promoter methylation (Ohgaki et al, 2004; Ohgaki 2005; Kleihues et al, 2007; 
Ohgaki et al, 2007; Kami et al, 2009; Ohgaki et al, 2009). 
Collectively, several major signaling pathways involved in cell cycle 
progression and cell survival regulation are deregulated in GBM, including 
‘ 9 
EGFR/RAS/NF1/PTEN/PI3K, p53/MDM2/MDM4/pl4^'^ and 
p 1 6'^^7CDK4/CDK6/RB 1 (Ohgaki et al, 2004; Ohgaki et al, 2009). 
New insight of identifying abnormal molecular pathways and glioma subtypes 
came from integrative genomic study. The Cancer Genome Atlas (TCGA) project 
determined changes of DNA copy number, somatic mutations of all known genes, 
expression profilings of mRNA and microRNA, and aberrant DNA methylation, and 
correlated the molecular findings with clinical information in a large series of GBM 
(The Cancer Genome Altas Research Network 2008). The integrated 
multidimensional genomic data have not only confirmed some established genetic 
alterations, such as TP53, PTEN, EGFR, NFl and RBI aberrations (The Cancer 
Genome Altas Research Network 2008), but also distinguished four GBM subtypes 
(classical, mesenchymal, proneural and neural) based on distinct genetic expression 
pattern. Patients with proneural subtype of GBM tended to have a longer survival 
�. than other subtypes (Verhaak et al, 2010). As complex data have been generated by 
TCGA genomic project, the ongoing data analysis will provide more valuable hints 
for GBM (Wrensch et al, 2009; Noushmehr et al, 2010). 
Knowledge of the genetic changes in GBM may lead to more targeted therapies, , 
improved quality of life, and prolonged survival. Overall, although a lot of efforts 
have been made to understand the pathogenesis of glioma, the molecular mechanism 
has not yet been clearly elucidated. 
1.1.3.4 Prognostic and predictive factors in GBM 
Clinical prognostic factors for GBM include patient age, extent of tumor 
resection and presence of necrosis (Ohgaki et al, 2004; Ohgaki et al., 2005; 
‘ 10 
Houillier et al” 2006; Kleihues et al, 2007; Ohgaki et al, 2007; Felsberg et al, 
2009). 
Promoter methylation of MGMT is frequently detected in 40-45% of GBM, 
reducing the MGMT activity (Esteller et al, 2000; Hegi et al, 2005; Weller et al, 
2009; Zawlik et al, 2009). A clinical relevance of MGMT methylation is uncovered 
by its association with better response to chemotherapy and favorable overall and 
progression-free survival in adjuvant TMZ-treated GBM patients, but not in patients 
who received radiotherapy only (Paz et al, 2004; Hegi et al, 2005; Criniere et al, 
2007; Felsberg et al, 2009; Weller et al, 2009). 
As mentioned earlier in section 1.1.3.1, IDHl mutation at codon 132 is 
differentially detected in primary (<5%) and secondary GBM (>80%) (Balss et al., 
2008; Watanabe et al, 2009; Yan et al., 2009), IDHl mutation may predict a longer 
survival for GBM and anaplastic astrocytoma patients (Parsons et al, 2008; 
� Nobusawa et a/., 2009; Weller et al, 2009; Yan et al, 2009). In addition, although 
showing a low frequency (<15%) (Nakamura et al, 2000), allelic loss of Ip has been 
associated with a longer survival in GBM (Homma et al, 2006), but not in some 
other studies (Houillier et al, 2006; Boulay et al, 2007; Felsberg et al, 2009; 














































































































































































































































































































































































































































































1.2 microRNA (miRNA) 
MiRNAs are a class of endogenous short (19-25 nucleotides) non-coding RNAs 
that regulate gene expression post-transcriptionally. The first discovered miRNA 
was lin-4, which showed antisense RNA-RNA interaction with the 3' untranslated 
region (UTR) of lin-14 mRNA in Caenorhabditis elegans, suggesting a novel 
endogenous negative control mechanism for gene regulation (Lee et al, 1993). Not 
until seven years later the second miRNA let-7 was identified. Let-7 functions as a 
modulator of multiple genes involved in Caenorhabditis elegans developmental 
timing via similar regulative mechanism as lin-4 (Reinhart et al, 2000). It was then 
discovered that let-7 and lin-4 were evolutionarily conserved from flies to human, 
prompting the speculation that miRNAs might play a universal role across species 
(Pasquinelli et al., 2000; Lagos-Quintana et al., 2002). In the following decade, 
miRNA has become a hotspot in biology. To date, 17,341 miRNAs have been 
identified in 142 species including human, mouse, flies, worms, plants and viruses 
according to miRBase database (http://www.mirbase.org/; release 16.0，September 
2010). Currently, there are 1,366 annotated human miRNAs, and the list is still 
rapidly growing (Griffiths-Jones 2010). 
1.2.1 miRNA biogenesis and function 
Genomic analysis indicated that mammalian miRNA genes are located mostly 
within defined transcription units (-70%), as well as in the intergenic areas, 
suggesting that transcription of miRNAs is either in parallel with their host 
transcripts or in autonomy (Rodriguez et al., 2004). In some cases, miRNAs are 
organized in close conjunction as genomic clusters and expressed polycistronically 
‘ 13 
as single transcriptional units (Lee et al., 2002), such as the miR-17-92 cluster on 
human chromosome 13ql3 (He et al., 2005), 
Mammalian miRNA biogenesis begins with transcription generating a kilobases-
long primary transcript (pri-miRNA) mediated by RNA polymerase II in nucleus. 
Containing a 5，methylguanylate cap structure and a 3' poly (A) tail, pri-miRNA 
folds into a hairpin structure with imperfect complementary stem-loop region. Pri-
miRNA is sequentially cleaved into �70-nucleotide precursor miRNA (pre-miRNA) 
by the ribonuclease (RNase) III enzyme Drosha and cofactor DiGeorge syndrome 
critical region gene 8 (DGCR8). The pre-miRNA is next translocated by ExpQitin-
5/RanGTP complex to the cytoplasm, where it is cleaved to yield �22-bp miRNA 
duplexes by another RNase III enzyme Dicer, assisted by a double-strand RNA 
binding protein, transactivation-responsive RNA-binding protein (TRJBP). The 
single-strand mature miRNA is then released through unwinding of the duplex by 
helicase, whereas the other strand (miRNA*) is usually degraded. After maturation, 
miRNAs are assembled with the argonaute (AGO) family proteins to form the 
effector miRNA-induced silencing complex (miRISC) or ribonucleoprotein (miRNP) 
complex (Kim 2005; Liu et al, 2008; Krol et al, 2010): 
Canonically, miRISC directs sequence-specific binding of miRNA to the 
miRNA recognition elements (MREs) located at 3'UTR of mRNAs. The target 
mRNA undergoes translational repression and/or transcript cleavage depending on 
the degree of complementarity between miRNA and the target mRNA. MiRNAs that 
show near perfectly base pairing triggers cleavage-dependent target mRNA cleavage, 
which resembles siRNA resultant inhibition. However, what occurs more often in 
animals is partial complementarity allowing mismatches and bulges that favors 
‘ 14 
translational repression of the target transcript (Filipowicz et al, 2008). In that case, 
perfectly base- pairing between the nucleotides (seed region) at the 5，end of 
miRNA with target mRNA is essential for miRNA target recognition (Bartel 2004; 
Lewis et al., 2005; Bartel 2009). The process of miRNA biogenesis and its 
functional mechanisms are shown in Figure 1.2. 
It has been estimated that miRNA could regulate more than 30% of the human 
genome (Lewis et al, 2005). Both computational and microarray analyses indicated 
that a mammalian miRNA can have hundreds of targets (Lewis et al, 2005; Lim et 
al, 2005), whereas a single mRNA can be regulated by distinct miRNAs 
cooperatively (Krek et al, 2005). As a result, a complicated regulatory network is 
formed by miRNAs and their target genes to control diverse biological processes, 
including cell proliferation, apoptosis, development, morphogenesis and metabolism. 
Nowadays, investigation of the miRNA-mRNA regulation network focuses on 
identification of miRNA target genes through combined computational and 
experimental approaches. A series of algorithms have been developed to predict 
potential miRNA targets, followed by experimental validation (Dalmay 2008; Bartel 
2009; Orom et al, 2010; Thomas et al, 2010). 
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Figure 1.2 Overview of miRNA biogenesis. 
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1.2.2 MiRNA involvement in Cancer 
1.2.2.1 Dysregulation of miRNAs in human malignancies 
The linkage between miRNA and cancer has been established since the premier 
study demonstrating downregulated miR-15a and miR-16-1 expression levels in B-
cell chronic lymphocytic leukaemia (CLL). Both of these miRNAs are clustered 
within the chromosome 13ql4 locus, which is commonly deleted in this disorder 
(Calin et al, 2002). Advanced genomic analysis highlighted the importance of 
miRNAs in human tumorigenesis by revealing that about half of all miRNA genes 
are mapped to cancer-related genomic regions or fragile sites (Calin et al, 2004). 
Subsequently, high-throughput profiling studies indicated that miRNA expressions 
were frequently altered in many different types of cancer and that specific miRNA 
expression signature is distinct among tumors of different origin. These findings 
suggest a pivotal role miRNAs play in oncogenesis (Liu et al, 2004; Lu et al, 2005; 
� Volinia et al, 2006; Visone et al, 2009). 
The aberrant expression of miRNAs in cancers may arise from several aspects, 
such as mutations (Calin et al, 2005; Raveche et al., 2007), single nucleotide 
polymorphisms (Hu et al, 2008), chromosomal instability (Calin et al, 2004; Zhang 
et al, 2006), epigenetic modifications (Fabbri et al, 2010)，transcriptional regulation 
(Chang et al, 2007; Woods et al, 2007; Ma et al, 2010) and deficient miRNA 
biogenesis machinery (Winter et al, 2011). 
1.2.2.2 Function and potential application of miRNAs 
On the basis of miRNA expression profiles, it was wondered whether this 
widespread deregulation of miRNA has an important role in tumorigenesis. 
‘ 17 
Functional studies have demonstrated that many abnormally expressed miRNAs are 
involved in crucial cellular processes in cancer formation, such as cell proliferation, 
apoptosis, migration, invasion, differentiation, and angiogenesis. MiRNAs show 
oncogenic or tumor suppressive properties through negative regulation of tumor 
suppressor or oncogene targets, respectively. For examples, miR-15/16 cluster 
displays a tumor suppressive role through repressing the anti-apoptotic B-cell 
CLL/lymphoma 2 (BCL2) expressioin and thereafter activates the apoptotic 
signalling pathway in CLL (Cimmino et al, 2005); whereas the oncogenic property 
of miR-155 is refleced by its direct targeting of TP53 inducible nuclear protein 1 
(TP53INP1)，an important mediator of TP53 pro-apoptotic activities in pancreatic 
ductal adenocarcinoma (Gironella et al, 2007). 
In summary, having shown a tumor-specific expression signature and diverse 
roles in cellular processes involved in tumorigenesis, miRNA has been implicated in 
cancer diagnosis, prognosis and therapeutic targets, which provide new insights into 
understanding and treatment of this malignancy (Tricoli et al, 2007; 丁rang et al, 
2008). 
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1.2.3 Role of miRNAs in glioma 
1.2.3.1 miRNAs in OTs 
To date, the significance of miRNA in OTs remains poorly understood. A 
limited number of papers deciphering miRNA in OTs have been published (Nelson 
et al, 2006; Silber et al, 2008; Sasayama et al, 2009) 
In an attempt to identify deregulated miRNAs in OTs, Nelson et al performed 
the miRNA microarray on formalin-fixed paraffin-embedded (FFPE) human brains 
and oligodendroglial tumors (Nelson et al, 2006). Their results exhibited miR-9 
upregulation and miR-124 downregulation in 20 human oligodendrogliomas 
compared to 6 adult cortex tissues confirmed by locked nucleic acid based in situ 
hybridization. No association between miR-9 expression and tumor grade or tumor 
cell proliferative activity was observed. Additionally, since three of the four AGO 
genes (AGOl, AGO3, and AGO4) map to chromosome Ip, the authors asked whether 
loss of Ip would affect the miRNA expression. The results showed that miRNA 
expression patterns between oligodendrogliomas with or without Ip allelic loss were 
similar, suggesting that allelic losses of three AGO genes did not substantially alter 
miRNAs in oligodendrogliomas (Nelson et al” 2006). 
In another study, miR-124 and miR-137 were among the miRNAs down-
regulated in high-grade astrocytoma by expression analysis. Reduced expression of 
these 2 miRNAs in mouse oligodendroglioma stem cells relative to mouse neuronal 
stem cells (NSCs) were also demonstrated (Silber et al, 2008)，suggesting an 
aberrant expression in early stage of OT formation. 
A recent study identified frequent miR-lOb overexpression in a cohort of glioma, 
‘ 19 
including 6 oligodendrogliomas (Sasayama et al, 2009). The miR-10b expression 
was correlated with that of RAS homolog gene family member C (RHOC), a well-
characterized pro-metastatic gene in 43 gliomas studied. The association was 
probably mediated through the direct suppression of a RHOC upstream regulator, 
homeobox DIO (HOXDIO) by miR-10b which was previously proved in breast 
cancer (Ma et al, 2007). These results were in line with the finding of elevated 
RHOC expression observed in a profiling study of 17 oligodendrogliomas (Huang et 
al, 2004). 
1.2.3.2 miRNAs in GBM 
There were multiple studies reporting global miRNA expression profiles in 
GBM (Ciafre et al, 2005; Godlewski et al, 2008; Silber et al, 2008; Guan et al, 
2010; Malzkorn et al, 2010; Rao et al, 2010). These investigations have highlighted 
numerous critical miRNAs that might be involved in the development and 
� . progression of GBM (summarized in Table 1.2 and Table 1.3). The dysregulated 
miRNAs indicated by more than 2 studied include upregulated miR-9，miR-10b, 
miR-15a, miR-16, miR-19a, miR-21, miR-25, miR-130a, miR-13Ob, miR-210 and 
miR-221, and downregulated miR-124, miR-128, miR-132, miR-137, miR-138, 
miR-139, miR-184, miR-218, miR-323 and miR-328. 
Given that up-regulated miRNA may function as oncogenes by targeting tumor-
suppressor genes, whereas down-regulated miRNA may function as tumor 
suppressors by repressing oncogenes, some of the dysregulated miRNAs are focused 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MiR-21 upregulation was consistently demonstrated in GBM by a number of 
studies (Chan et al, 2005; Ciafre et al, 2005; Gabriely et al, 2008; Godlewski et al, 
2008; Silber et al, 2008; Conti et al, 2009). Functional study demonstrated that 
knockdown of miR-21 in glioblastoma cells resulted in suppressed cell growth, 
increased apoptotic activity, reduced cell invasion and more importantly, decreased 
tumorigenicity in mouse model (Chan et al, 2005; Corsten et al, 2007; Gabriely et 
al, 2008; Li et al, 2009; Shi et al, 2010; Zhou et al, 2010). Target identification 
has uncovered multiple molecular mechanisms underlying the oncogenic role of 
miR-21. These downregulated targets include key factors involving in the p53 
pathway (TP63 and DAXX), the transforming growth factor-P pathway (TGFBR2 
and PDCD4) and the mitochondrial apoptosis tumor-suppressive signaling pathway 
(APAFl). Alterations of these targets were in line with miR-21 regulation on cell 
cycle and apoptosis (Chen et al, 2008; Papagiannakopoulos et al, 2008). 
� Additionally, miR-21 also targeted RECK and TIMP3 to promote glioblastoma cell 
migration and invasion by activating matrix metalloproteinases (MMPs) (Gabriely et 
al； 2008). The GBM-related tumor suppressor gene PTEN is also verified as a target 
of miR-21. However, it was also shown that knockdown of miR-21 could lead to 
suppression of EGFR, AKT2 and signal transducer and activator of transcription 3 
(STATS) pathways independent of PTEN status (Zhou et al, 2010). Interestingly, 
miR-21 regulation on leucine rich repeat interacting protein 1 (LRRFIPl) 
contributed to glioblastoma cell chemoresistance to VM-26 through NF-KB 
activation (Li et al, 2009). In addition, TMZ-induced apoptosis can be rescued by 
miR-21 expression in glioblastoma cells (Shi et al, 2010). Taken together, miR-21 
promotes glioblastoma proliferation and invasion and inhibited apoptosis through 
negative control of multiple targets in the carcinogenic network actively.‘ 
2 3 
The miR-221/222 cluster is overexpressed in GBM and cell lines (Ciafre et al, 
2005; Conti et al, 2009; Lukiw et al, 2009). The expression level of miR-221 is 
associated with glioma grade (Conti et al, 2009; Lukiw et al, 2009). Inhibition of 
miR-221/222 led to inhibited cell proliferation, induced G1 cell cycle arrest and 
suppressed tumorigenicity in glioblastoma cells. Consistent with such observation, 
the cyclin-dependent kinase inhibitors p27 and p57 were found to be under negative 
regulation by miR-221/222 (Gillies et al, 2007; le Sage et al, 2007; Zhang et al, 
2009). Moreover, it was shown that when quiescent glioblastoma cells were 
triggered to proliferate, miR-221 and miR-222 expressions were enhanced and such 
upregulation facilitated tumor cells to enter S phase (Medina et al：, 2008). 
Collectively, these findings strongly indicate that miR-221/222 plays an important 
role in cell cycle progression in GBM. 
In GBM, numerous downregulated miRNAs have been characterized. 
� Expression of miR-7 was decreased in GBM versus adjacent or non-neoplastic brain 
tissues (Kefas et al, 2008; Silber et al, 2008). Further elucidation revealed markedly 
lower level of pre-miR-7 but comparable abundance of pri-miR-7 in GBM, 
suggesting that miR-7 inactivation might result from impaired processing of pri-
miR-7. It was also demonstrated that delivery of miR-7 in glioblastoma cells induced 
apoptosis, inhibited viability and suppressed invasiveness. Notably, dramatic 
suppression of EGFR，IRSl and IRS2 proteins and activation of AKT and ERKl/2 
were observed following transfection of miR-7 (Kefas et al, 2008; Webster et al, 
2009). EGFR and IRS2 are further proven to be direct targets of miR-7 (Kefas et al, 
2008). It is well believed that the AKT pathway can be activated by its upstream 
regulators, IRSl and IRS2, as well as EGFR, of which amplification is frequent in 
GBM. Hence, the effect of miR-7 is probably mediated by its negative regulation on 
‘ 2 4 
the EGFR/AKT pathway, which plays key role in glioblastoma formation (Wong et 
al, 1987; Haas-Kogan et al, 1998). 
The brain-enriched miRNA, miR-128 has been observed downregulated in 
astrocytoma, including GBM and cell lines by several studies (Ciafre et al, 2005; 
Godlewski et al, 2008; Zhang et al, 2009; Cui et al, 2010). Its abundance was 
lower in malignant gliomas compared to low-grade gliomas (Cui et al, 2010). The 
reduced expression may be not due to epigenetic alteration, since treatment with 
DNA demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC), and/or the histone 
deacetylase inhibitor, trichostatin A (TSA), did not affect miR-128 level in T98G 
glioblastoma cells (Zhang et al, 2009). Functional analysis indicated that 
overexpression of miR-128 inhibited cell proliferation and suppressed xenograft 
growth in GBM (Godlewski et al, 2008; Zhang et al, 2009; Cui et al, 2010). 
MiRNA-128 is a negative regulator of BMIl, a poly comb factor implicated as an 
�. oncogene. Ectopic expression of miR-128 led to a decrease in histone H3K27me^ 
methylation and AKT phosphorylation as well as up-regulation, which was 
previously shown to be associated with BMIl knockdown. Moreover, 
overexpression of miR-128 in glioblastoma-derived stem-like neurosphere cultures 
blocked glioma stem cell self-renewal, supporting the notion that BMIl is a key 
modulator in stem cell self-renewal (Godlewski et al, 2008). This finding provided 
for the first time a linkage between miRNA and neuronal stem cell property. Another 
direct target of miR-128, E2F transcription factor 3 (E2F3), is a transcription factor 
participating in control of entry into S phase during cell-cycle progression. E2F3 was 
established as a functional target of miR-128 in glioblastoma cells based on the 
findings that E2F3 knockdown caused similar phenotype as miR-128 overexpression, 
and E2F3 could partly rescue the proliferation inhibition resulted from miR-128 
2 5 
(Zhang et al, 2009). Recently, a novel computational predicted target, angiopoietin-
related protein 5 (ARP5), was found to be negatively regulated by miR-128. Similar 
to BMIl and E2F3, ARP5 was overexpressed in low-grade gliomas and even at 
higher level in glioblastomas (Cui et al, 2010). Whether there exists a direct 
interaction between miR-128 and ARP5 transcript requires further investigation. 
Additional brain-specific miRNAs displaying decreased expression in 
glioblastoma are miR-124 and miR-137 (Silber et al, 2008). Both of them inhibited 
proliferation and induced GO/Gl cell cycle arrest in glioblastoma cells by targeting 
cyclin-dependent kinase 6 (CDK6), a crucial regulator in Gl-S transition that 
repressed pRB. Notably, miR-124 and miR-137 were also involved in differentiation 
of mouse NSCs. When mouse NSCs were induced for differentiation upon growth 
factor withdrawal, upregulation of miR-124 and miR-137 was detected. In line with 
such observation, ectopic expression of miR-124 and miR-137 induced neuronal-like 
� differentiation of mouse NSCs and glioblastoma-derived stem cells (Silber et al, 
2008). 
In addition, several lines of evidence suggest that miR-124 is involved in 
neurogenesis. First, miR-124 was induced during neuronal differentiation in mouse 
embryonic carcinoma cells and embryonic stem cells (ESCs) (Smirnova et al, 2005; 
Krichevsky et al, 2006). Second, miR-124 was preferentially expressed in neurons 
(Smirnova et al, 2005). Third, miR-124 directly inhibited polypyrimidine tract 
binding protein 1 (PTBPl), a repressor of neuron-specific splicing, and thereby 
allowing a switch from non-neuronal to neuronal-specific alternative splicing pattern 
during induced neuronal differentiation of mouse neuroblastoma cells (Makeyev et 
al, 2007). Fourth, miR-124 could suppress small C-terminal domain phosphatase 1 
2 6 
(SCPl), leading to resultant inhibition of the REST/SCPl anti-neural pathway 
(Visvanathan et al, 2007). Fifth, in the subventricular zone of the mouse cortex, 
miR-124 expression mediated neuron formation by inhibiting sex determining region 
Y-box 9 (S0X9), which drives stem cell self-renewal (Cheng et al, 2009). 
Thus downregulation of three brain-specific miRNAs, miR-124, miR-128 and 
miR-137, may contribute to tumorigenesis through maintaining proliferating and 
undifferentiated state of stem cells. The potential treatment of glioblastoma with 
these miRNAs targeting glioma stem cells may be a novel therapeutic approach and 
deserves further investigations. 
Downregulation of miR-181 family, miR-181a/181b/181c has been reported in 
both primary glioblastoma and cell lines (Ciafre et al, 2005; Shi et al, 2008; Conti 
et al, 2009). Among them, expression level of miR-181a appeared to be negatively 
correlated with tumor grade of grade II-IV gliomas, whereas miR-181b showed more 
pronounced deregulation in high-grade than in low-grade gliomas. Transfection of 
miR-181a or miR-181b in glioblastoma cell inhibited growth, triggered apoptosis, 
reduced anchorage-independent growth as well as suppressed invasive capacity (Shi 
et al, 2008). Moreover, miR-181a expression was observed decreased in 
glioblastoma cells upon radiation treatment. Ectopic expressed miR-181a sensitized 
glioblastoma cells to radiation treatment with concurrent reduction of Bcl-2 protein 
level, indicating stimulated apoptosis (Chen et al, 2010). In addition, miR-181b and 
miR-181c were significantly downregulated in glioblastoma in response to 
concomitant chemoradiotherapy with temozolomide (Slaby et al, 2010). Low 
expression of mir-181b has been shown associated with poor survival in astrocytoma 
patients (Zhi et al, 2010). Although direct targets have not yet been identified, miR-
2 7 
181 family may represent candidate glioblastoma suppressors and predictor for 
glioblastoma diagnosis, prognosis and sensitivity to therapeutic treatment. 
Another potential tumor suppressor regulating important cancer signaling 
pathways is miR-34a, whose expression is reduced in GBM compared with normal 
brain (Li et al, 2009). Transcriptionally activated by p53, miR-34a level was 
markedly lower in p53-mutant GBM relative to p53-wild-type GBM. Ectopic 
expression of miR-34a resulted in significantly reduced glioblastoma cell 
proliferation, survival, invasion in vitro and glioblastoma xenograft growth in vivo 
(Li et al., 2009; Luan et al, 2010). In glioma stem cells，similar results were also 
observed with an additional finding of induced differentiation following miR-34a 
enhanced expression (Guessous et al, 2010). The tumor suppressive role of miR-34a 
was addressed to its inhibitory effect on several oncogenic targets, such as MET, 
NOTCHl，N0TCH2 and SIRTl (Li et al, 2009; Luan et al, 2010). 
Collectively, miRNAs are demonstrated to play an important role in the 
development and progression of glioma through regulation of multiple cellular 
pathways. Table 1.4 summarizes the functions and targets of deregulated miRNAs 
identified in gliomas. These tiny RNA molecules are also promising therapeutic 






















































































































































































































































































































































































































































































































































































































































































































































































Since allelic loss of Ip has been reported as a frequent event in OTs, it was 
proposed that this region may harbor miRNAs that may be involved in gliomagenesis. 
There are 38 miRNAs mapped to chromosome Ip (Table 1.5) according to miRBase 
(http://www.mirbase.org/; release 16.0，September 2010). One candidate mapped to 
lp36.22 is miR-34a, which was shown to play an important role in the development of 
GBM (Li et al, 2009). Another candidate is miR-137. Expression of miR-137 was 
demonstrated to be downregulated in GBM in two profiling studies (Godlewski et al, 
2008; Silber et al, 2008). It is hypothesized that miR-137 may also be involved in 
development of other glioma subtypes. The following sections highlight the biology of 
miR-137. 
1.3.1 Biology of miR-137 
The miR-137 gene resides on chromosomal arm lp21.3 (98511626-98511727, 
negative strand). Both the precursor and mature miR-137 sequences are highly 
conserved across a broad range of vertebrate species, indicating the significance miR-
137 (Figure 1.3). miR-137 is recognized as a brain-enriched miRNA in both human and 
mouse (Lagos-Quintana et al, 2002; Sempere et al, 2004; Beuvink et al, 2007; 
Landgraf et al, 2007; Liang et al, 2007; Chiang et al, 2010). Human miR-137 
expression in brain was at least 2-fold higher than in other organs (Sempere et al” 2004). 
MiR-137 is also detectable in endocrine gland, placenta and peripheral blood 
mononuclear cells (Landgraf et al, 2007; Liang et al, 2007). 
• 3 0 
Table 1.5 A list of 38 miRNAs located on chromosome arm Ip according to miRBase 
ID Start End Strand 
miR-1302-2 30366 30503 + 
miR-200b 1102484 1102578 + 
.miR-200a 1103243 1103332 + 
miR-429 1104385 1104467 + 
miR-4251 3044539 3044599 + 
miR-551a 3477259 3477354 -
miR-4252 6489894 6489956 -
miR-34a 9211727 9211836 -
miR-1273d 10287776 10287861 + 
miR-3675 17185444 17185516 -
miR-1290 19223565 19223642 -
miR-1256 21314807 21314925 -
miR-4253 23189652 23189719 -
miR-3115 23370798 23370865 + 
miR-3917 26232853 26232945 -
miR-1976 26881033 26881084 + 
miR-4254 32224261 32224336 -
miR-3605 33797994 33798093 -
miR-552 35135200 35135295 -
miR-4255 37627164 37627235 + 
“ miR-3659 38554903 38555001 + 
miR-30e 41220027 41220118 + 
miR-30c-l 41222956 41223044 + 
miR-761 52302016 52302074 -
miR-3116-1 62544458 62544531 + 
miR-3116-2 62544461 62544528 -
miR-3671 65523438 65523525 -
miR-101-1 65524117 65524191 -
miR-3117 67094123 67094200 + 
miR-1262 68649201 68649293 -
miR-186 71533314 71533399 -
miR-760 94312388 94312467 + 
miR-137 98511626 98511727 -
miR-553 100746797 100746864 + 
miR-197 110141515 110141589 + 
miR-4256 113004392 113004455 -
miR-320b-l 117214371 117214449 + 


























































































































































































































































































































































































































































































1.3.2 Role of miR-137 in carcinogenesis 
1.3.2.1 Deregulation of miR-137 in cancer 
The relevance of miR-137 in human tumors was first highlighted by quantitative 
expression analysis of its expression levels in tumors and cancer cell lines relative to 
those of normal tissues or cells. Abnormal miR-137 expression was detected in 
numerous cancer types, with majority of them showing miR-137 downregulation 
(Table 1.6). As mentioned in section 1.2.3.2, miR-137 displayed significantly low 
level in astrocytomas of all WHO grades (Silber et al, 2008; Zhi et al, 2010). Its 
downregulation was more pronounced in high-grade astrocytomas than in low-grade 
(Zhi et al, 2010), indicating a significant association of miR-137 with clinical grade. 
Reduced miR-137 transcript level was also identified in central nervous system 
tumor (Gaur et al, 2007)， neuroblastoma (Chen et al, 2007)， colorectal tumor 
(Bandres et al, 2006; Balaguer et al, 2010), oral squamous cell carcinoma (Kozaki 
et al, 2008), lung adenocarcinoma (Dacic et al, 2010) and uveal melanoma (Chen et 
al, 2010). However, miR-137 overexpression was reported in squamous cell 
carcinoma of the tongue (Wong et al, 2008). Taken together, these findings have 
implicated a role of miR-137 in the development of multiple cancers. 
1.3.2.2 Regulation of miR-137 expression in cancer 
Since miR-137 was frequently suppressed in a number of cancers, the 
mechanism underlying such downregulation has also been investigated. Emerging 
studies showed that miR-137 inactivation was tightly linked to epigenetic regulation 
in several tumors including gliomas (Table 1.6). 
Genomic analysis revealed a high CpG content in putative promoter region of 
3 3 
miR-137, suggesting that miR-137 may be epigenetically modulated. Examination of 
methylation status demonstrated high incidence of DNA hypermethylation on the 
promoter region in gastric cancer (Ando et al, 2009), colorectal cancer (Bandres et 
al, 2009; Balaguer et al, 2010) and oral squamous cell carcinoma (Kozaki et al, 
2008; Langevin et al, 2010), but absence of such alteration in normal tissue or cells. 
An inverse correlation between the expression and promoter methylation status of 
miR-137 was observed in colorectal cancer (Balaguer et al, 2010) and squamous 
cell carcinoma of head and neck (Kozaki et al, 2008; Langevin et al, 2010). 
Moreover, miR-137 expression was restored in response to demethylation treatment 
in cell lines derived from glioblastoma (Silber et al, 2008)，colorectal cancer 
(Bandres et al, 2009; Balaguer et al, 2010) and uveal melanoma (Chen et al, 2010). 
The promoter of miR-137 was demethylated following demethylation treatment in 
colorectal tumor cells (Bandres et al, 2009; Balaguer et al, 2010). These 
observations suggested that epigenetic modulation was a major mechanism 
responsible for miR-137 expression. More importantly, patients with squamous cell 
carcinoma of head and neck carrying methylated miR-137 showed poor prognosis 
compared with patients with tumors harboring unmethylated miR-137, providing 
prognostic potential for epigenetic status of miR-137 (Langevin et al, 2010). 
In particular, Bemis et al, (2008) provided new insight into miR-137 regulation 
by indentifying a 15-bp variable nucleotide tandem repeat (VNTR), located 6-bp 
upstream of pre-miR-137 sequence, that was associated with miR-137 expression 
level in melanoma cell lines. Sequencing analysis detected the presence of 3 to 12 
VNTRs in different melanoma cell lines. When constructs containing pri-miR-137 
complementary DNA (cDNA) fragment with 3 or 12 VNTRs were transfected in 


































































































































































































































































































































































































































1.3.2.3 Biological functions of miR-137 in cancer 
Since miR-137 expression level is downregulated in many types of human 
cancer, it is believed that miR-137 plays a key role in tumor formation. Recently, 
several functional studies have demonstrated the biological effects of miR-137 in 
tumor cells identified its targets (Table 1.7). 
In human glioblastoma (Silber et al,, 2008) and oral squamous cell carcinoma 
cells (Kozaki et al” 2008), forced miR-137 expression suppressed tumor cell 
proliferation and induced GO/Gl cell cycle arrest. CDK6 was the first direct miR-
137 target identified through multiple experimental approaches in both tumor types. 
The protein level of CDK6 decreased following forced miR-137 expression, and the 
direct interaction was validated by luciferase reporter assay. As a cell cycle regulator, 
CDK6 promotes Gl-S transition and contributes to cell proliferation. Involvement 
� . of CDK6 in differentiation and transformation of human cancers has been reported 
as well (Meyerson et al, 1994; Grossel et al, 2006). Moreover, elevated CDK6 
expression has been demonstrated in these tumors (Lam et al, 2000; Poomsawat et 
al, 2010), suggesting that CDK6 may play an oncogenic role. 
Another study on melanoma indicated that miR-137 regulates mierophthalmia-
associated transcription factor (MITF) (Bemis et al, 2008). MITF has been 
characterized as a master regulator of melanocyte growth, maturation, apoptosis, as 
well as melanoma progression and prognosis (Garraway et al, 2005; Levy et al., 
2006). The regulation of miR-137 on CDK6 and MITF was also observed in uveal 
melanoma (Chen et al, 2010). In addition, both ectopic miR-137 expression and 
RNA interference (RNAi)-mediated MITF knockdown showed inhibitory effects on 
3 7 
uveal melanoma cell growth and cell cycle progression. These results strongly 
suggested miR-137 may act as a tumor suppressor miRNA via negative regulation of 
CDK6 and MITF in melanoma. 
The role of miR-137 in carcinogenesis is also investigated in colorectal cancer. 
In addition to inhibition on cell proliferation, miR-137 also affected invasive ability 
of colorectal tumor cells. The potential tumor-suppressive function of miR-137 was 
addressed to its direct inhibition of cell division cycle 42 (CDC42). CDC42 is a 
member of the Rho GTPase family, its elevated expression has been documented in 
several types of human tumors including colorectal cancer (Gomez Del Pulgar et al, 
2008). CDC42 has been implicated in diverse cellular processes, such as cell 
proliferation, migration and apoptosis, which resulted in its tight linkage to cancer 
initiation and progression. Indeed, CDC42 knockdown in colorectal tumor cells led 
to inhibition of cell cycle progression and invasion, these biological effects were 
� similar to those observed after miR-137 overexpression in vitro (Liu et al, 2010). 
Hence, miR-137 contributes, in part through negative regulation of CDC42, to the 
development of colorectal tumors. 
In addition, Balaguer et al” 2010 have identified another miR-137 target, lysine 
(K)-specific demethylase lA (LSDl，also known as KDMIA), in colon cancer. 
Elevated LSDl expression has been illustrated in prostate cancer (Metzger et al, 
2005) and neuroblastoma (Schulte et al., 2009), where LSDl is related to 
maintaining the undifferentiated phenotype and tumor cell proliferation. On the other 
hand, the demethylating activity of LSDl can stabilize DNA (cytosine-5-)-
methyltransferase 1 (DNMTl) in addition to demethylating histone H3 on lysine 4 
(H3K4) and lysine 9 (H3K9) (Wang et al, 2009). DNMTl is known to be crucial in 
3 8 
maintaining global DNA methylation and has been shown overexpression in many 
human cancers (Ting et al, 2004). Although the expression and biological role of 
LSDl in colon cancer remain largely elusive, the evidence gives rise to a potential 
miR-131-LSDl -DNMTl axis in epigenetic machinery, which may play a role in 
carcinogenesis. 
Overall, these studies suggest that miR-137 may play suppressive roles in tumor 
cell proliferation and invasion through negative regulation of multiple targets (CDK6, 
MITT, LSDl and CDC42) involved in diverse cellular processes. 
1.3.3 Role of miR-137 in differentiation and neurogenesis 
As miR-137 is a brain-enriched miRNA in human and rodent, several studies 
have provided evidence supporting a linkage between miR-137 and mouse neuronal 
differentiation by assessing its expression during stem cell differentiation process 
and its effects on stem cell self-renewal and differentiation. 
Silber et al, 2008 investigated miRNA expression alterations during in vitro 
differentiation of mouse NSCs isolated from the subventricular zone by withdrawal 
of growth factor in culture. Their results showed that miR-137 expression was 
elevated 20-fold in a 5-day interval, accompanied with enhanced expression of 
neuronal marker, P-tubulin III (Tujl). In line with this observation was induced miR-
137 upregulation in glioblastoma spheroid upon all-trans retinoic acid-induced 
differentiation (Ernst et al, 2010). Moreover, ectopic expression of miR-137 
increased percentage of Tujl positive (+) cell with a rounded or trapezoidal cellular 
morphologic characteristic in differentiating mouse NSCs. Meanwhile, the cell 
fraction that showed glial fibrillary acidic protein (GFAP, an astrocytic marker) was 
3 9 
not affected. Again, in mouse oligodendroglioma-derived and human glioblastoma-
derived tumor stem cells, ectopic expression of miR-137 also resulted in neuronal-
like differentiation without neuronal morphologic change. These studies implicate a 
role of miR-137 in neuronal differentiation. 
However, opposite effects of miR-137 were observed in proliferating mouse 
NSCs (Szulwach et al, 2010). Ectopic expression of miR-137 promoted DNA 
synthesis in actively proliferating NSCs both in vitro and in vivo. Meanwhile, the 
Tujl and GFAP expression were suppressed, suggesting miR-137 enhanced NSCs 
proliferation at the expense of differentiation when differentiation is not triggered by 
other stimulus. Another functional target of miR-137, enhancer of zeste homolog 2 
{Ezh2\ was identified, which showed declined expression during NSC 
differentiation (Sher et al” 2008) and has been functionally associated with NSCs 
fate decision. (Pereira et al, 2010). 
In addition, miR-137 also participates in maturation of young neurons by 
negatively regulating neuronal dendritic morphogenesis, phenotypic maturation, and 
spine development both in vitro and in vivo (Smrt et al, 2010). MiR-137-mediatd 
direct suppression of mindbomb homolog 1 (Mibl)，a ubiquitin ligase modulating 
neurodevelopment (Ossipova et al, 2009)，was shown. In the study, Mibl was 
demonstrated as a miR-137 target that was responsible for the inhibitory effect of 
miR-137 on dendritic complexity, the final step in neurogenesis. The above 
observations illustrated that miR-137 plays multiple roles in different stages of adult 
neurogenesis. 
The role of miR-137 in neurogenesis was further supported by investigation on 
mouse embryonic stem cells (ESCs) (Tarantino et al, 2010). Undetectable in 
4 0 
undifferentiated ESCs, miR-137 expression was induced upon differentiation. 
Furthermore, miR-137 cooperated with miR-34a and miR-100 to enhance expression 
of early neuronal differentiation maker in differentiating ESCs. Inhibition of this 
miRNA mix led to elevated sternness markers expression in ESCs undergoing 
differentiation induction. In this study, the authors identified lysine (K)-specific 
demethylase 5B (Jaridlb, also known as KdmSb) as a target of miR-137. Jaridlb is a 
histone H3K4 demethylase, whose constitutive expression in ESCs prevents cell 
differentiation and sustains the expression of sternness markers (Dey et al, 2008). 












































































































































































































































































































































CHAPTER 2 AIMS OF STUDY 
As previously reviewed, loss of chromosome Ip is the most frequent genetic 
abnormality in OTs, suggesting the presence of candidate tumor suppressor gene 
(TSG) (Bello et al, 1994; Reifenberger et al, 1994; Bigner et al, 1999; Husemann 
et al, 1999; Smith et al, 1999). Although numerous candidate TSGs located on Ip 
had been found downregulated in OTs, none of them showed a key functional role in 
OTs. (Husemann et al, 1999; Dong et al, 2002; Barbashina et al, 2005; McDonald 
et al, 2005; McDonald et al, 2006; Ngo et al, 2007; Tews et al, 2007; 
Riemenschneider et al, 2008; Benetkiewicz et al, 2009; Pang et al, 2010) Recently 
investigations discovered that miRNAs represent a new class of molecular 
� complexity in various cancer types including glioma. Therefore, it is speculated that 
chromosome Ip may carry glioma-related miRNAs. Identification and functional 
characterization of such miRNAs will improve our understanding on molecular 
mechanism of glioma and may stem new potential avenues for treatment of this 
malignancy. 
Among the 38 miRNAs mapped to chromosome Ip, miR-34a has been reported 
to function as a tumor suppressor in GBM (Li et al, 2009; Luan et al, 2010). 
However, the role of other miRNAs in glioma formation remains elusive. • Three 
independent profiling studies have reported reduced expression of miR-137, a brain-
4 3 
enriched miRNA, in astrocytomas compared to normal or non-neoplastic brain 
tissues (Godlewski et al, 2008; Silber et al, 2008; Zhi et al, 2010). The functional 
significance of miR-137 was demonstrated by the finding of its growth inhibitory 
effects on GBM, as well as melanoma and colorectal tumor (Kozaki et al, 2008; 
Silber et al, 2008; Balaguer et al, 2010; Chen et al, 2010; Liu et al, 2010). These 
findings strongly suggested that miR-137 might be involved in the development of 
glioma. Hence, this study aimed to investigate the potential involvement of miR-137 
in OTs and its biological functions in gliomagenesis. The specific aims were: 
i. To quantify miR-137 expression in primary OTs and glioma cell lines and 
evaluate the clinical significance of miR-137 in OT patients by correlating the 
miR-137 expression level with clinicopathological parameters, 
， ii. To investigate the mechanisms responsible for miR-137 differential expression 
in OTs by examining the Ip status and epigenetic involvement, 
iii. To characterize the functional roles of ectopic miR-137 expression in glioma 
cell proliferation, apoptosis, invasiveness and differentiation, 
iv. To elucidate miR-137 by identification of its downstream target(s) in glioma 
cells by combined computational and experimental approaches, 
V. To examine the transcript and protein expression levels of verified miR-137 
target in the same panel of OT specimens and explore the functional effects of 
miR-137 target in glioma cell proliferation, apoptosis and invasiveness 
following small interfering RNA (siRNA) mediated target gene knockdown. 
4 4 
CHAPTER 3 MATERIALS A N D METHODS 
3.1 Tumor samples 
A panel of 36 OTs was collected from Huashan Hospital, Fudan University, 
Shanghai, P. R. China. Histological classification of all tumors was performed 
according to WHO Classification of Tumors of the Central Nervous System (2007). 
Tumor tissues resected from surgery were immediately immersed in RNALater® 
solution (Ambion, Austin, U.S.A.) and stored at80°C until use to preserve RNA 
integrity. The series consisted of 13 oligodendrogliomas, 7 anaplastic 
oligodendrogliomas, 13 oligoastrocytomas, and 3 anaplastic oligoastrocytomas. In 
adult patients, the male/female ratio was 1.25:1 and the median age was 42 years, 
, ranging from 28 to 77 years. There was 1 pediatric case (Table 3.1). 
4 5 
Table 3.1 Clinicopathological and follow-up information of 36 OTs studied. 
Case • 1 o Age Survival time (months)^ 
, Diagnosis Sex , ^ � 
number (years) Overall Progression-free status 
HS390 OD M 10 T1 ^ 
HS460 OD M 29 50 50 alive 
HS380 OD M 35 80 62 alive 
HS469 OD F 36 49 49 alive 
HS378 OD F 38 80 80 alive 
HS466 OD F 40 49 49 alive 
HS324 OD M 42 93 93 alive 
HS331 OD F 46 78 78 alive 
HS400 OD F 49 48 48 dead 
HS329 OD F 69 78 78 dead 
HS303 OD M 48 - . 
HS332 OD M 53 - : 
HS467 OD F 56 - -
HS382 OA F 37 79 79 alive 
HS458 OA M 37 52 41 alive 
HS393 OA F 49 71 70 alive 
HS314 OA F 38 81 57 dead 
HS375 OA M 28 - . 
HS381 OA F 28 - _ 
HS384 OA M 30 - . 
‘ HS394 OA F 31 - . 
HS399 OA M 34 - _ 
HS462 OA M 39 - _ 
HS362^ OA M 41 - _ 
HS301 OA M 43 - - . 
HS368 OA F 61 - . 
HS333 AOD F 43 12 12 dead 
HS358 AOD F 50 42 8 . dead 
HS360 AOD M 51 2 2 dead 
HS461 AOD M 53 14 14 dead 
HS377 AOD M 77 48 42 dead 
HS302 AOD M 35 - . . . 
HS312 AOD M 53 - . 
HS366 AOA M 35 - . 
HS364 AOA F 48 . . 
HS457 AOA M 52 - -
1 OD, oligodendroglioma; OA, oligoastrocytoma; AOD, anaplastic oligodendroglioma; 
AOA, anaplastic oligoastrocytoma. 
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2 Due to lack of corresponding FFPE section, this case was not included in the 
immunohistochemical analysis. 
3 Survival time was measured from the date of surgery to January 2010 or to the time 
of death. data not available. 
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3.2 Cell lines and culture conditions 
Three human OT cell lines (GOS-3，HOG and TC620) and seven human 
glioblastoma cell lines (A172, LNZ308，T98G，U118MG, U138MG, U373MG and 
U87MG) were used in this study. GOS-3 cell was obtained from German Collection 
of Microorganisms and Cell Cultures (Braunschweig, Germany), HOG and TC620 
cells were kindly provided as gifts from Dr. Glyn Dawson, University of Chicago, 
U.S.A. and Dr. Rainer Probstmeier, University of Bonn, Germany, respectively. The 
A172, U118MG, U138MG, U373MG and U87MG cells were purchased from 
American Type Culture Collection (Manassas, U.S.A.). 
A172，GOS-3, HOG, LNZ308, TC620，U118MG and U373MG cells were 
cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, 
U.S.A.), U138MG and U87MG were grown in alpha-minimal essential medium 
(Invitrogen). All growth media were supplemented with 10% (v/v) fetal bovine 
serum (Invitrogen). The cell lines were maintained at 37°C in a humidified , 
atmosphere supplied with 5% carbon dioxide. The morphology of cells was 
continuously monitored under an inverted microscope during culture. Cells of � 7 0 % 
confluency were trypsinized and sub-cultivated at a ratio of 1:5. To prevent clonal 
selection during culture, fresh cells rejuvenated from cryopreservation every 3 
months were used. Mycoplasma test was also performed to guarantee the absence of 
contamination. 
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3.3 Fluorescence in situ hybridization (FISH) 
To determine the allelic status of chromosomes Ip and 19q, dual-color 
interphase FISH analysis was performed on FFPE tissue sections as reported (Dong 
et al, 2004). Sections of 5卞m thickness were deparaffinized, rehydrated, treated 
with 1 M sodium thiocyanate at 80°C for 10 minutes, digested in pepsin solution (5 
mg/ml in 0.2 N HCl; Sigma-Aldrich，St. Louis, U.S.A.) for 30 minutes, rinsed in 
phosphate buffered saline (PBS) and dehydrated. The sections were treated with 
microwave (600 W) for 10 minutes, baked at 80°C for 30 minutes and then subjected 
to hybridization. 
Four bacterial artificial chromosome (BAG) clones used to prepare locus-
specific FISH probes were RP11-62M23 on lp36.3 (target), RP11-162L13 on 
Iq25.3-q31.1 (reference), CTD-2571L23 on 19ql3.3 (target) and RP11-420K14 on 
19pl2 (reference). The genomic clones were purchased from Invitrogen Corporation. 
Five |ig of BAG DNA was labeled using nick-translation in a 50-|4,l reaction , 
containing 100 mM Tris-HCl (pH 7.5)，10 mM magnesium chloride (MgCb), 0.01% 
bovine serum albumin (BSA)，0.1 mM deoxyadenosine triphosphate (dATP)，0.1 mM 
deoxycytidine triphosphate (dCTP), 0.1 mM deoxyguanosine triphosphate (dGTP), 
0.1 nM deoxythimidine triphosphate (dTTP), 0.1 nM P-mercaptoethanol, 0.03 U of 
DNase I (Roche Diagnostics Ltd.，Hong Kong), 20 U of E. coli DNA polymerase I 
(Roche)，and 1.9 nmol of SpectrumOrangeTM-deoxyuridine triphosphate (dUTP) 
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(Enzo Life Sciences Inc.，Farmingdale，U.S.A.) for target probe or 0.85 nmol of 
digoxigenin-11 -dUTP (Roche) for reference probe at 15°C for 1 hour. The reaction 
was stopped by adding 1 |il of 0.5 M ethylenediaminetetraacetic acid (EDTA) and 
0.5 \i\ of 10% sodium dodecyl sulfate (SDS) followed by incubation at 65�C for 10 
minutes. 
Labeled probes were mixed with salmon sperm DNA (Invitrogen) and human 
Cot-1 DNA (Invitrogen) in Hybrisol VI solution (Appligene Oncor, Illkirch 
Graffenstaden, France) to suppress cross-hybridization to human repetitive DNA and 
to reduce the background. The probe mix was denatured and applied onto sections. 
Hybridization was carried out at 37°C overnight. Sections were washed with 1.5 M 
urea / Ix saline sodium citrate (SSC) at 45�C for 30 minutes, 2x SSC at 45°C for 15 
minutes, treated with anti-digoxigenin-fluorescein antibody (Roche) at 37°C for 1.5 
hours. The sections were then washed in phosphate-buffered detergent (Appligene 
Oncor, Ullkirch Graffenstaden, France) and counterstained with Vectashield 
mounting medium with anti-fade solution of 4,6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories, Inc., Burlingame, U.S.A.). 
Sections were viewed under an Axioplan 2 fluorescence microscope (Carl Zeiss 
Microimaging Co., Ltd., Oberkochen, Germany). Images were independently 
captured through three separate band pass filters for rhodamine, fluorescein 
isothiocyanate (FITC) and DAPI by a cooled charge-coupled device. At least 100 
5 0 
non-overlapping tumor nuclei were counted on each section. A sample with more 
than 60% of counted nuclei exhibited one target signal (red) and two reference 
signals (green) was considered having deletion of Ip or 19q locus. 
<、 
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3.4 Cell transfection 
3.4.1 Transfection of oligonucleotides 
3.4.1.1 Oligonucleotide preparation 
In the study of miR-137 overexpression in glioma cells, miRIDIAN hsa-miR-
137 mimic (5‘-UUAUUGCUUAAGAAUACGCGUAG-3') and the negative control 
#1 was used (Dharmacon, Inc., Lafayette, U.S.A.). For knockdown of CSEIL 
expression, 2 short interfering RNA (siRNA) oligonucleotides specifically targeting 
exon 18 and exon 15 of human CSEIL transcripts (NCBI reference sequence: 
NM一001316.2) were obtained from Applied Biosystems (Foster City, U.S.A.) 
(siCSElL-1, s3588: 5‘-GCAAUAUGUUUAUCCAUAAtt-3‘, and siCSElL-2，s3589: 
‘ 5 ‘ -GAACAUCUUUUAGUCUCGAtt-3 ‘). The siRNA negative control #1 
oligonucleotide (Applied Biosystems) was used as control. 
The miRIDIAN miRNA mimics and siRNA oligonucleotides were dissolved in , 
DEPC-treated H2O to 20 [iM and 5 |xM respectively as stock and stored at -20°C in 
aliquots until use. 
3.4.1.2 Optimization of transfection condition 
Cells were seeded on 24-well plate one day before to yield a confluency of 20%-
30% at the time of transfection. L i p o f e c t a m i n e T M 2000 (Invitrogen) was used to 
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introduce oligonucleotides into glioma cells according to the manufacturer's 
recommendation. In order to achieve optimized transfection efficiencies，different 
amounts of both Lipofectamine™ 2000 reagent and miRNA mimic or siRNA were 
tested for each cell line. 
For miRNA mimic, the transfection efficiency was monitored using siGLO green 
transfection indicator from Dharmacon. Transfected cells were viewed under a 
fluorescent microscope and optimized condition was determined when greater than 
80% cell showed green fluorescent signals. For siRNA, the transfection condition 
was optimized using a siGAPDH concentration that suppressed at least 70% of 
GAPDH protein level detected by western blotting. 
3.4.2 Cotransfection of plasmids and miRNA mimic 
3.4.2.1 Optimization of transfection condition 
When glioma cells were subjected to plasmid and miRNA mimic cotransfection, , 
cells of approximately 90% confluency were transfected using Lipofectamine'^^ 
2000 reagent. In optimization study, the firefly luciferase reporter plasmid pMIR-
REPORT™ miRNA Expression Reporter Vector (Ambioh) and reference renilla 
luciferase expressed plasmid pRL-TK Vector (Promega, Madison, U.S.A.) were 
involved. The transfection efficiency of both plasmids was evaluated by the 
luciferase activity of transfected cells using Dual-Luciferase® Reporter Assay System 
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(Promega). The percentage of miRNA mimic-transfected cell was monitored by 
siGLO green transfection indicator as mentioned in section 3.4.1.2. 
3.4.2.2 Procedure of transfection 
Cells grown at log phase were trysinized, plated onto a 24-well plate the day 
before transfection and maintained in growth medium. Lipofectamine'^^ 2000 of 1-
1.5 jil was diluted in 50 |al Opti-MEM® I reduced serum media (Invitrogen) and then 
incubated at room temperature for 5 minutes. Plasmid DNA (0.2-1 jig) and 10-20 
pmol of miRNA mimic were diluted in 50 |il of Opti-MEM® I reduced serum media. 
The DNA mixture and diluted Lipofectamine™ 2000 were mixed gently and 
incubated for 20 minutes at room temperature. The DNA (|ig): Lipofectamine (jil) 
ratio ranged from 1:1 to 1:5. The transfection mixture was added into relevant well 
and mixed by rocking the plate back and forth. Medium was removed after 24 hours 
and replaced by fresh growth medium. 
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3.5 Quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) 
3.5.1 RNA extraction from frozen tissues and cell lines 
Total RNA of frozen tumor tissues and cell lines was extracted using the 
TRIZOL® reagent (Invitrogen) according to the manufacturer's protocol. For frozen 
tissue, 1 ml of TRIZOL® per 50-100 mg tissue was added and the tissue was 
immediately homogenized using a Tissue-Tearor (BioSpec Products, Inc., 
Bartlesville, U.S.A.). For culture cells grown in monolayer, cells were washed twice 
with chilled PBS, added with TRIZOL® (1 ml per 10 cm^ culture dish surface area), 
and lysed by repetitive pipetting with a small bore tip to ensure complete cell 
breakage and to shear genomic DNA. After incubation for 5 minutes at room 
temperature, 0.2 ml of chloroform per 1 ml of TRIZOL® was added. The contents 
were mixed by vigorous shaking for 15 seconds and allowed to stand at room 
temperature for 2 minutes. Following centrifugation at 12,000 x g, 4°C for 15 , 
minutes, total RNA in the upper aqueous phase was carefully collected. RNA was 
precipitated by mixing with 0.5 ml of isopropanol per 1 ml of TRIZOL® and 
incubated for 10 minutes at room temperature. The RNA pellet was collected by 
centrifugation at 12000 x g for 10 minutes at 4°C，washed with 70% (v/v) ethanol in 
DEPC-treated water, air-dried completely and then dissolved in DEPC-treated water. 
All RNA samples were stored in aliquots at -80°C. 
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RNA concentration was determined by measurement of optical density (OD) at 
wavelength of 260 nm，using NanoDrop ND-1000 Spectrometer (NanoDrop products, 
Wilmington, U.S.A.). RNA concentration was calculated using a conversion factor of 
1 unit of OD at 260 nm equivalent to 40 }xg/ml RNA. An RNA sample with an 
OD260nm/OD280nm ratio of 1.8 to 2 and an OD260nm/OD230nm ratio of 1.8 or greater was 
considered of good quality. 
3.5.2 qRT-PCR for miR-137 
The expression level of mature miR-137 in normal brains and OTs was 
determined using TaqMan miRNA assay (Applied Biosystems). Briefly，reverse 
transcription (RT) was performed in a 15-|xl reaction containing 20 ng of total RNA, 
50 nM of miR-137-specific stem-loop RT primer, Ix RT buffer, 1 mM 
deoxyribonucleoside triphosphates (dNTPs)，50 U of MultiScribe™ reverse 
transcriptase and 3.8 U of RNase inhibitor. The reactions were incubated for 30 
minutes at 16°C to allow primer binding to miR-137, 30 minutes at 42°C for RT, and , 
5 minutes at 85°C to inactivate reverse transcriptase. 
PGR was performed in a lO-jxl volume containing 0.67 |j.1 (1 ng) of reversed 
transcribed product, 1 x TaqMan Universal PGR master mix, and 1 x TaqMan miRNA 
assay reagent. The reaction was performed in triplicates and carried out in 384-well 
optical tray on the ABI7900HT real-time PGR system (Applied Biosystems). The 
thermal cycling conditions were as follows: 95°C for 10 minutes to activate 
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polymerase, followed by 40 cycles of 95°C for 15 seconds to denature and 60°C for 
1 minute to anneal and extend. Threshold cycle (CT) was analyzed using the SDS 
software version 2.3 (Applied Bio systems). To adjust for variations in starting input, 
miR-137 expression was normalized with miR-16 as an internal reference. Total 
RNA of normal brains was obtained from BD Biosciences Clontech (Palo Alto, 
U.S.A.), BioChain (Hayward, U.S.A.) and Ambion. 
The expression fold change of miR-137 in tumors and cell lines relative to 
normal brains were assessed using the comparative CT (AACT) method. The ACT 
value is determined by subtracting the average Ct value of the target from that of 
internal reference. The AACT is obtained by subtracting the ACT value of tumors from 
that of normal brains. The calculated 2込口 represents the relative target expression 
fold in tumor samples normalized to internal control as compared to normal tissues. 
{Uvaket al. 2001) 
3.5.3 qRT-PCR for CSEIL and ERBB4 transcripts . 
To prevent amplification from genomic DNA, total RNA from each sample was 
subjected to DNase treatment. One \ig of RNA was incubated, in a total volume of 10 
containing 1 U of RQl RNase-free DNase and Ix DNase reaction buffer (Promega), 
at 37°C for 30 minutes. One [i\ of stop solution [20 mM ethylene glycol tetraacetic 
acid (EGTA)，pH 8.0] was added followed by incubation at 65°C for 10 minutes to 
inactive the DNase. PGR containing DNase-treated RNA without reverse 
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transcription was performed to ensure thorough elimination of genomic DNA. 
Complementary DNA (cDNA) was synthesized from total RNA using 
MultiScribe™ reverse transcriptase and random hexamers (Applied Biosystems) 
according to manufacturer's protocol. Briefly, one jig of DNase-treated total RNA 
was used as template in a reaction mix of 20 \i\ containing Ix RT buffer, 5.5 mM 
MgCli, 500 |iM dNTP mix, 2.5 \iM random hexamers, 8 U of RNase inhibitor and 25 
U of MultiScribe™ reverse transcriptase. The reaction was incubated at 25�C for 10 
minutes to maximize primer-RNA template binding, followed by 48°C for 30 
minutes to synthesize cDNA and 95°C for 5 minutes to inactivate reverse 
transcriptase. 
SYBR® Green-based PGR analysis was performed to quantify gene expression. 
This method is based on the binding of Sybr Green I dye to the minor-groove of 
double-stranded DNA and the amount of bound dye is a measure of DNA quantity. 
PGR reaction was performed in a 10- i^l reaction mix containing 0.6 |il of RT 
product, 1X FastStart Universal SYBR® Green master mix (Roche) and 0.4 \iM of 
forward and reverse primer. Amplification was carried out under the conditions of 
95�C for 10 minutes, followed by 40 cycles of 95�C for 15 seconds, and 60�C for 1 
minute. The product was subjected to melt curve analysis, in which a signal peak in 
dissociation curve indicates a single product and absence of nonspecific 
amplification including primer-dimers. Agarose gel electrophoresis was also 
5 8 
performed to ensure product was of correct size. 
Relative standard curves were generated with a serial dilution of RT product to 
confirm the same amplification efficiency of CSEIL, ERBB4, and GAPDH. The 
expression levels of CSEIL and ERBB4 were normalized to the endogenous 
reference gene GAPDH. Expressions of CSEIL and ERBB4 in tumors are compared 
with the mean expression level of 3 normal brain samples. The AACT method was 
used to determine change in CSEIL and ERBB4 expression. All quantitative PGR 
was carried out in triplicates, and the experiment was performed three times. Primers 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.6 5-aza-2'-deoxycytidine (5-aza-dC) and Trichostatin A (TSA) 
treatment 
DNA demethylating agent 5-aza-dC (Sigma-Aldrich) and histone deacetylase 
inhibitor TSA (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO) to 10 
mM and 1 mM, respectively, and stored at -80°C in aliquots. 
Human glioma cell lines A172, U373MG and TC620 were incubated with 
medium containing 2, 5 or 10 \iM of 5-aza-dC for a period equivalent to 2 cell 
doublings (3 days for A172, U373MG and 4 days for TC620). Growth medium 
containing fresh 5-aza-dC was replaced every day. For TSA treatment, cells were 
incubated with 0.33 or 1 |xM TSA for 24 hours. Combinational effect of 5-aza-dC 
“ and TSA was tested by treating cells with 5-aza-dC for 3 days followed by TSA for 
24 hours. Cells treated with same volume of DMSO were used as control. 
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3.7 Western blotting 
3.7.1 Preparation of cell lysate 
Cells were collected by trypsinization and washed twice with chilled PBS. Cell 
pellet was resuspended in radio-immunoprecipitation assay (RIPA) lysis buffer [50 
mM Tris-HCl (pH 7.4)，150 mM NaCl, 1% (v/v) NP-40, 0.1% (w/v) SDS, and 0.25% 
(w/v) sodium deoxycholate] freshly supplemented with protease inhibitors [Ix 
complete, Mini protease inhibitor cocktail (Roche) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF; Sigma-Aldrich)] and phosphatase inhibitors [5 mM sodium 
orthovanadate (Na2V04) and 10 mM sodium fluoride (NaF) (Sigma-Aldrich)]. The 
content was incubated on ice for 15 minutes followed by centrifugation at 14,000 
- rpm for 15 minutes. The supernatant containing soluble protein was collected and 
stored at -80°C until use. 
3.7.2 Measurement of protein concentration 
Protein concentration was measured by Bio-Rad Protein Assay (Bio-Rad, 
Hercules, U.S.A.) in a 96-well plate. Dye reagent was prepared by diluting 1 volume 
of Dye Reagent concentrate with 4 volume of MilliQ water and then filtered through 
3MM chromatography paper (Whatman Inc., Florham Park, U.S.A.) to remove 
particulates. A series of concentrations (0，0.0625，0.125，0.25, 0.375 and 0.5 |ag/|al) 
of BSA was used to generate a standard curve. Ten \x\ of protein standard or diluted 
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sample plated on a 96-well plate were added with 200 \x\ of diluted dye reagent. After 
incubation at room temperature for 10 minutes, OD at 595 nm for each sample was 
measured using VICTOR� Multilabel Readers (PerkinElmer, Waltham, 
Massachusetts, U.S.A.). The standard curve was generated by plotting BSA 
concentration against corresponding average value of OD595nm from triplicates. A 
linear equation obtained was used to calculate protein concentration of each sample. 
3.7.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE is used to separate proteins based on size. The SDS-coated, 
negatively charged protein molecules migrates in the gel and are resolved according 
, to their molecular weights. The Mini-PROTEAN Tetra Cell electrophoresis system 
(Bio-Rad) was used for polyacrylamide gel casting and SDS-PAGE. 
Polyacrylamide gels of 0.75 mm thickness were cast using the Mini-PROTEAN 
gel cassette assembly and casting stand according to the manufacturer's protocol 
(Bio-Rad). The stacking gel (4%) and resolving gel (7.5%, 10%, or 12.5%) solution 
were prepared by mixing a stock solution of 40% (w/v) acrylamide/N,N'-methylene-
bis-acrylamide (29:1) in Ix gel buffer [4x stacking gel buffer (0.4% SDS，0.5 M 
Tris-HCl，pH 6.8) or 8x resolving gel buffer (0.8% SDS, 3 M Tris-HCl, pH 8.8)]. 
Resolving gels of different percentages were used to separate proteins of different 
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sizes. The components for preparing stacking and resolving gels are listed in Table 
3.3. Polymerization catalysts 10% (w/v) ammonium persulfate (APS) (USB, 
Cleveland, U.S.A.) and N,N,N',N'-tetramethylethylenediamine (TEMED) (Bio-Rad) 
were added freshly to gel mix to start polymerization. 
After resolving gel solution was introduced into the gel cassette sandwiches and 
overlaid with isopropanol to prevent oxygen from inhibiting polymerization, the 
acrylamide/bis was allowed to polymerize for 1 hour at room temperature. 
Overlaying isopropanol was then removed and the resolving gel surface was rinsed 
with distilled water. After absorbing the residual water trapped between plates by 
filter paper, stacking gel solution was poured on top of resolving gel until top of the 
short plate is reached. A comb was inserted immediately into each gel sandwich. The 
stacking gel was allowed to be polymerized for 30 minutes and the comb was 
removed just before use. After wells were rinsed with running buffer (25 mM Tris, 
192 mM glycine, 0.1% SDS，pH 8.3)，gels were pre-mn 70 V for 10 minutes before 
samples were loaded. 
Samples were prepared by mixing cell lysates with 6x SDS loading buffer (375 
mM Tris, 12% SDS, 60% glycerol, 0.012% bromophenol blue, 30% p-
mercaptoethanol, pH 6.8) in a ratio of 5:1 (v/v)，denatured at 95°C for 5 minutes, and 
cooled down on ice. In this step, proteins were denatured, linearized and coated with 
negatively charged SDS molecules, and p-mercaptoethanol assisted protein 
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denaturation by reducing all disulfide bonds. Samples containing equal amounts of 
protein were loaded to the wells of acrylamide gels, as well as the molecular weight 
marker Spectra"^^ Multicolor broad range protein ladder (Fermentas Inc., Glen 
Burnie, U.S.A.) to monitor protein migration during SDS-PAGE and to estimate 
protein band size after blotting. Electrophoresis was performed at 120 V for 2 hours 
or until the dye front reached the bottom of the gels. 
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3.7.4 Electroblotting of proteins 
After electrophoresis, resolved proteins were transferred from gel to Hybond-P 
polyvinylidene fluoride (PVDF) Membrane (GJE Healthcare, Buckinghamshire, UK) 
using the Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad). PVDF 
membrane was cut into same size as gels and pre-wetted in methanol for 5 minutes 
for activation and then equilibrated in pre-chilled transfer buffer (25 mM Tris，192 
mM glycine, 20% methanol, pH 8.3) for 10 minutes. Gels removed from the gel 
sandwiches, together with fiber pads and filter paper of suitable size, were soaked in 
transfer buffer before blotting. The fiber pad-filter paper-gel-membrane-filter paper-
fiber pad transfer cassette sandwich was then assembled. To remove air bubbles that 
may block protein transfer, a 15-ml tube was rolled horizontally over the sandwich. A 
magnetic stir bar and a cooling unit were placed in the buffer tank to maintain even 
ion distribution and buffer temperature throughout the transfer. Electroblotting was 
carried out at 100 V for 1 hour or 30 V overnight depending on size of protein. 
3.7.5 Immunoblotting 
After blotting, non-specific proteins on the membrane were blocked by 
incubation in 5% (w/v) non-fat milk powder in Tris-buffered saline with Tween 20 
(TEST) buffer [20 mM Tris-HCl (pH 7.6), 0.1% (v/v) Tween 20, and 137 mM NaCl] 
for 1 hour with gentle shaking at room temperature. The blot was incubated with 
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Table 3.3 Components of polyacylamide gels for SDS-PAGE 
Stacking Resolving 
Reagent gel gel 
40/0 7.50/0 10% 12% 
40% acrylamide/bis-acrylamide (29:1) 0.4 ml 1.88 ml 2.5 ml 3 ml 
4X stacking buffer 1.0 ml - - -
8x resolving buffer - 1.25 ml 1.25 ml 1.25 ml 
10% (w/v) APS 40 |xl 100 |al 100 i^l 100 \i\ 
100% TEMED 20 |xl 20 i^l 20 
MilliQ water 2.6 ml 6.75 ml 6.13 ml 5.63 ml 
Total volume 4.0 ml 10.0 ml 10.0 ml 10.0 ml 
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diluted primary antibody (Table 3.4) in 5% (w/v) non-fat milk powder in TEST with 
shaking. After that, the blot was washed with TEST three times for 10 minutes each 
at room temperature with shaking. According to the source of primary antibody, 
horseradish peroxidase-conjugated sheep anti-mouse antibody (NA931V, GE 
Healthcare) or donkey anti-rabbit antibody (NA934V, GE Healthcare) were used as 
secondary antibodies and incubated with the blot in 1:5000 dilution in TBST with 5% 
milk for 1 hour with shaking at room temperature. The blot was then washed and 
subjected to chemiluminescence detection. 
Chemiluminescent signals were detected and visualized by using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, U.S.A.) 
according to the manufacturer's instructions. Briefly, substrate was applied onto 
membrane and the light emitted in the reaction was captured by Fuji Super RX Blue 
Medical X-Ray Films (Fujifilm, Tokyo, Japan). The intensity of bands on the film 
was quantified using ImageJ software (National Institutes of Health, Bethesda， 












































































































































































































































































































































































































































































3.8 Dual-luciferase reporter assay 
Dual-luciferase reporter assay (Promega, Madison, U.S.A.) was used to 
investigate whether miR-137 could interact with the predicted MRE in 3，UTR of 
/ 
target genes. Briefly, predicted miR-137 MRE was cloned downstream of the firefly 
luciferase gene in the pMIR-reporter vector. The recombinant plasmid would then be 
co-transfected with miR-137 into glioma cells and then assayed for luciferase activity. 
Reduced luciferase activity indicated an interaction between miR-137 and the MRE. 
3.8.1 Construction of reporter plasmids 
3.8.1.1 Experimental outline 
� To generate the reporter plasmid, a DNA fragment containing the predicted miR-
137 MRE of candidate gene was amplified from genomic DNA using primers linked 
with restriction enzyme sites. The fragment was first cloned into 
by TA cloning, sequenced and subcloned downstream of the luciferase gene at 
specific restriction sites in the pMIR-reporter vector. Additionally, plasmid DNA 
containing mutated miR-137 MRE was also created using in vitro site-directed 
mutagenesis to serve as negative control in the luciferase assay. 
3.8.1.2 PGR Amplification of MREs 
The 3’UTR fragment containing the predicted MRE was amplified from human 
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genomic DNA by PGR. Each 20-|il PGR mix contained 40 ng of genomic DNA, 1 x 
GeneAmp PGR buffer II，2.5 mM MgCb, 0.2 mM dNTP mix, 0.4 \xM of primer pair, 
and 1 U of AmpliTaq Gold® DNA polymerase (Applied Biosystems). PGR was 
carried out at 95°C for 10 minutes, followed by, 40 cycles of denaturation at 95°C for 
30 seconds, annealing at 52-58°C for 30 seconds, extension at 72°C for 1 minute, 
and a final extension at 72°C for 10 minutes. All primers were designed using 
Primer3 (http://frodo.wi.mit.edu/primer3/) and synthesized by Invitrogen (Table 3.2) 
The PGR products were resolved by electrophoresis in 1.5% agarose gel containing 1 
jil/ml RedSafe™ nucleic acid staining solution (iNtRON Biotechnology, Seoul, 
Korea) and visualized under ultraviolet light. 
For CDC42, since there are pseudogenes in the human genome, a nested PGR 
approach was employed to isolate the CDC42-specific 3'UTR fragment. First round 
PGR amplified a 904-bp fragment spanning intron 7 and exon 8 using CDC42-
specific primer pair CDC42-1 (Table 3.2). This fragment was gel purified using the 
MEGA-spin agarose gel DNA extraction kit (iNtRON Biotechnology), and then 
subjected to second round PGR using primer pair CDC42-2 to produce a 420-bp 
fragment containing the miR-137 MRE. 
3.8.1.3 TA cloning 
PGR products were cloned using the TOPO TA cloning® technology, which is 
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based on the efficient ligating activity of topisomerase I for single nucleotide 
overhang (Invitrogen). A 5-\x\ TA cloning mix contained 2 [l\ of PGR product, 0.5 jil 
pCR®2.1-T0P0® vector (linearized with topiosomerase I covalently bound to each 3’ 
phosphate), 0.5 |il salt solution and 2 \x\ H2O. The mix was incubated for 30 minutes 
at room temperature, and then placed on ice until transformation. 
3.8.1.4 Transformation 
Ligation mix was added to 100 of E. coli TOP 10 competent cells (Invitrogen), 
mixed gently and incubated on ice for 30 min. The cells were heat shocked at 42°C 
for 45 seconds and immediately cooled on ice for at least 2 minutes. Two hundred \x\ 
of Luria Bertani (LB) broth (USB) supplemented with 2 mM glucose was added to 
the cells and the mixture was incubated in a 37°C shaker with 250 rpm horizontal 
shaking for 1 hour. After incubation, 100 fil of cells was spread onto a LB agar plate 
supplemented with 100 |ig/ml ampicillin that had been pre-spread with 40 \i\ of 40 
mg/ml X-gal (dissolved in dimethyIformamide). The plates were incubated inverted 
at 37�C overnight. 
3.8.1.5 Blue/white screening and validation of recombinants 
The blue-white selection is an effective method for selecting recombinant clones 
containing insets (white colonies) versus those without inserts (blue colonies). From 
each LB plate spread with ligation mix, at least 5 white colonies and 1 blue colony 
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(as negative control) were picked individually into 20 |il of LB broth. After thorough 
mixing, 1 |il of cell suspension was transferred to 20 \i\ of PGR mix with 
composition identical to that described in section 3.8.1.2, except for the primers used 
(Table 3.2). PGR was carried out as stated in section 3.8.1.2 and products were 
resolved by 1.5% agarose gel electrophoresis. Clones that showed products of 
expected size were inoculated into 2 ml of LB broth supplemented with 100 |ig/ml 
ampicillin and allowed to grow overnight at 37°C with shaking at 250 rpm. A mini 
preparation of plasmid DNA from the culture was performed using DNA-spin"^^ 
plasmid DNA extraction kit (iNtRON). Quantity and quality of DNA were 
determined by spectrometry at 260 nm and 280 nm. Concentration of DNA (in |ag/|il) 
was calculated using the formula OD260nm x 50 ng l\x\ x dilution factor. A ratio of 
，• OD260nm/OD280nm in the range of 1.8-2.0 indicates a DNA prep of high quality. 
Positive recombinant clones were confirmed by restriction enzymes digestion and 
sequencing (Tech Dragon Limited, Hong Kong). For long-term storage, a 10% 
glycerol stock of cell culture was prepared and stored at -80 °C. 
3.8.1.6 Subcloning of 3'UTR fragments into pMIR-reproter vector 
Validated recombinant clones containing 3'UTR fragments of AKT2, CSEIL, 
ERBB4 and NRPl were digested with restriction endonucleases Spel and Hindlll 
(New England Biolabs, Ipwich, U.S.A.) to release the inserts. The digestion mixture 
of 20-|il volume containing 10 \xg of DNA, 20 U of Spel, 20 U of Hindlll and 0.1 
% 
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|ig/|il BSA in Ix NEBuffer 2 was incubated at 37�C for 90 minutes, followed by 
65°C for 20 minutes to inactivate the enzyme activity. To release the CDC42 3'UTR 
fragment, recombinant clones were treated with Sad and HindllL The pMIR-reporter 
vector was prepared for ligation by digesting with Hindlll and Spel or Sad. 
Restricted DNA was resolved by agarose gel electrophoresis and purified by MEGA-
spin Agarose Gel DNA Extraction Kit (iNtRON). To ligate the released 3'UTR 
fragment to pMIR-reporter, a 20-)il reaction containing � 3 0 0 ng of vector DNA,�60 
ng of each insert (molar ratio 1:3), 1 U of T4 DNA ligase (Invitrogen),. and Ix T4 
DNA ligase buffer was prepared and incubated overnight at 16�C. 
Bacterial transformation was conducted as described in section 3.8.1.4. Because 
blue-white selection was not feasible with the pMIR-reporter vector, a quick screen 
for recombinant clones by PGR was conducted using primer pairs as listed in Table 
3.2. Positive recombinant clones were validated by restriction mapping (Hindlll + 
BamHI, Hindlll + Xbal, Hindlll + Xhol) and sequencing. A large preparation of each 
validated recombinant plasmid DNA was prepared using PureLinkTM HiPure plasmid 
DNA purification kit according to manufacturer's recommendation (Invitrogen). 
Purified DNA was stored in aliquots at -20 °C. These clones were termed pMIR-
GENE, where GENE was the name of target gene. 
3.8.2 Site-directed mutagenesis 
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To generate mutated miR-137 MRE that could serve as negative control in 
reporter assay, specific bases in MRE of pMIR-GENE were mutated using in vitro 
site-directed mutagenesis. The method involves 2 steps: the synthesis of mutant 
strands of plasmid DNA using two synthetic oligonucleotides containing desired 
mutations and a proofreading DNA polymerase, followed by digestion of methylated 
non-mutated parental template with methylation-sensitive restriction endonuclease 
DpnI. 
The site-directed mutagenesis steps were conducted according to Strategene's 
Quickchange multi-site mutagenesis kit with modifications. The mutagenic 
oligonucleotide primers were designed in such a way that substituted nucleotides 
were introduced at sites in the UTRs bases of CSEIL and 
of ERBB4) that are thought to interact with the seed region of miR-137 (Table 3.5). 
To maintain GC content in the primers the nucleotides targeted for mutations were 
converted to complementary bases. The primers were allowed to hybridize to pMIR-
GENE and mutant strands were synthesized usingpjx DNA polymerase with 3' to 5' 
proofreading exonuclease activity. A 50-|il reaction consisted of Ix Pjx amplification 
buffer，0.3 mM dNTP mix, 1 mM MgSCU，0.3 |iM of each mutagenic primer, 100 ng 
of template plasmid (pMIR-GENE) and 2.5 U of Pjx DNA polymerase. The reaction 
was incubated at 94°C for 2 min followed by 18 thermal cycles of 95°C for 1 min, 
68°C for 10 min and a final extension at 68°C for 10 min. After chilling the reaction 
7 5 
on ice, 1 \d of Dpnl (New England Biolabs) was added and the mixture was 
incubated at 37°C for 1 hour to allow digestion of parental methylated DNA. The 
Dpnl-treated DNA was then subjected to bacterial transformation as described in 
section 3.8.1.4. Colonies selected were grown i;i culture and subjected to direct DNA 
sequencing to confirm mutations. 
3.8.3 Plasmid and miRNA mimic cotransfection 
Human glioblastoma LNZ308 cells were seeded at a density of 1.2x10^ 
cells/well on a 24-well plate. After incubation for 24 hours when the cell confluency 
reached -90%, cells were transfected with a DNA mixture containing 500 ng of 
pMIR-GENE or pMIR-reporter, 100 ng of pRL-TK renilla luciferase expression 
plasmid (as an internal control), 10 pmol of either miRIDIAN miR-137 mimic or 
miRNA negative control #1，1 \x\ of Lipofectamine 2000 reagent in 100 [x\ of Opti-
MEM® I and incubated at 37°C overnight. 
3.8.4 Determination of luciferase activity 
Dual-luciferase reporter assay (Promega) was performed 24 hours post 
transfection. After removal of media, cells were washed twice with PBS and lysed in 
100 (il Ix Passive Lysis Buffer. The plates were placed on an orbital shaker with 
gentle shaking at room temperature for 15 min to ensure complete and even "coverage 
of the cell monolayer. Sequential measurements of firefly and renilla luciferase 
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activities in cell lysates were then performed. The firefly luciferase substrate 
Luciferase Assay Reagent II was prepared by resuspending 1 vial of lyophilized 
Luciferase Assay Substrate in 10 ml of the supplied Luciferase Assay Buffer 11. The 
renilla luciferase substrate Ix Stop & Glo®,reagent，which quenched the firefly 
luciferase luminescence, was prepared by diluting 1 volume of 50x Stop & Glo® 
substrate in 50 volumes of Stop & Glo® buffer. For each measurement, 10 \x\ of cell 
lysate was transferred into a 96-well black plate followed by mixing with 50 \i\ 
Luciferase Assay Reagent II. The firefly luciferase activity was measured in the IVIS 
100 imaging system (Xenogen Corporation, Hopkinto, MA). Fifty \x\ of the Stop & 
Glo® reagent was added to the reaction mixture and the renilla luciferase activity was 
measured immediately. A lysate of nontransfected control cells was included to 
’ determine the background contribution. All experiments were performed in triplicate 
and repeated 3 times. The firefly luminescence was normalized to the renilla 
luciferase activity in the same sample. Results were expressed as relative firefly 
luminescence in cells transfected with pMIR-GENE and miR-137 mimic compared 









































































































































































































































































































































































































































































3.9 Functional assays 
3.9.1 Cell growth and proliferation assay 
Cell growth was evaluated by measuring cellular metabolic activity, whereas cell 
proliferation was assessed by cell counting and BrdU incorporation during DNA 
synthesis. 
3.9.1.1 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay 
The colorimetric MTT assay was used to monitor cell growth. This method is 
based on the principle that metabolically active cells can convert yellow tetrazolium 
� salt MTT to a water-insoluble violet formazan by succinate dehydrogenase in the 
mitochrondria. The amount of formazan crystals formed, after dissolution, can be 
quantified by spectrophotometry at 500-600 nm. Since succinate dehydrogenase is 
active in living cells, its activity level is a measure of cell growth. 
A total of 1500 cells were seeded in each well of a 96-well plate and allowed to 
grow for 24 hours in 100 of culture medium. Cells were transfected with miR-137 
mimic, CSElL-targeting siRNA or corresponding negative control RNA with 
Lipofectamine 2000 at optimized concentrations (see section 3.4.1). At 24, 48, 72 
and 96 hours after transfection, MTT assay was performed. Fifteen jol of MTT 
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reagent (5 mg/ml stock solution in PBS stored at 4°C and protected from light) was 
added to each well. After incubation at 37°C in a humidified atmosphere for 4 hours, 
culture medium was removed and the purple formazan crystals were dissolved in 100 
jil of DMSO with shaking on a horizontal sh^er for 15 min at room temperature. 
The optical density at 570 nm and 690 nm in each well was measured sequentially 
using Victor^ Multilabel Plate Reader. Wells with medium only served as background 
control. Each test was measured in triplicate and the experiment was repeated 3 times. 
3.9.1.2 Cell counting 
Viable cells with intact cell membrane were distinguished from dead cells by 
exclusion of trypan blue, which stained dead cells only. Eight thousand cells were 
plated in each well of a 24-well plate. After incubation for 24 hr, transfection with 
miR-137 mimic or siRNAs was performed as described in the MTT assay. Each day 
for 4 consecutive days cells were harvested by trypsinization and resuspended in 1 
ml medium. Equal volumes of cell suspension and 0.4% trypan blue solution (Sigma- ‘ 
Aldrich) were mixed and 10 \xl of stained cells were transferred to a hemocytometer. 
The number of unstained living cells was then counted. The total number of viable 
cells was calculated as the number of unstained cells counted X 2 X lO .^ 
Experiments were carried out in triplicates and repeated 3 times independently. 
3.9.1.3 5-Bromo-2'-deoxyuridine (BrdU) incorporation assay 
8 0 ‘ 
DNA synthesis is a useful indicator of cell proliferation. As an analogue of 
thymidine, BrdU is incorporated into DNA of replicating cells during the S phase of 
cell cycle. The amount of BrdU in the newly synthesized DNA can be detected with 
BrdU-specific antibody followed by an ELISA-based colorimetric assay. In this study, 
the Cell Proliferation ELISA，BrdU assay (Roche Diagnostics) was used to quantify 
cell proliferation. 
Cells were plated and transfected as described in section 3.9.1.1. At 24，48, 72 
and 96 hours post-transfection, 10 |il of 1 x BrdU labeling reagent (100 |aM BrdU in 
culture medium) was added to each well of a 96-well plate to a final BrdU 
concentration of 9.1 |iM. After incubation for 4 hours, the culture medium was 
removed. Cells were fixed and the DNA was denatured to expose the incorporated 
BrdU by adding 200 |il/well of FixDenat reagent, and the mixture was let stand for 
30 min at room temperature. The FixDenat solution was then removed thoroughly by 
flicking off and tapping. One hundred of mouse monoclonal anti-BrdU antibody 
conjugated with peroxidase (anti-BrdU-POD) (100-fold dilution from stock solution 
with antibody dilution solution provided in the kit) was added to each well and 
allowed to incubate for 90 min at room temperature. Cells were washed three times 
with PBS to remove unbound antibody. The immune complexes were detected by 
adding 100 |il of substrate (tetramethyl-benzidine) solution and mixture was 
incubated for 30 min at room temperature. The reaction product was quantified by 
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measuring the optical density at 370 nm (peak absorbance wavelength) and 490 nm 
(reference wavelength) using a multiwell spectrophotometer. Relative proliferating 
cell numbers were calculated as a ratio of optical density measured from cells 
transfected with miR-137 or siCSElL to cells transfected with negative control 
miRNA or siRNA. The data were obtained from triplicates in three independent 
experiments. 
3.9.2 Apoptosis assay 
During apoptosis, the 116-kDa nuclear poly (ADP-ribose) polymerase (PARP) is 
cleaved to amino-terminal DNA binding domain (24 kDa) and carboxy-terminal 
catalytic domain (89 kDa) fragments by activated caspases. The detection of the 89-
， kDa PARP catalytic fragment is a marker of apoptosis. 
Cells of 20-30% confluency in 60-mm culture dishes were transfected with miR-
137, CSEIL siRNA or negative control RNA as mentioned in section 3.8.1.1. At 48 
and 96 hours post-transfection, cell lysates was prepared and subjected to Western 
blotting as described in section 3.7. The 89-kDa PARP fragment was detected using 
an antibody specific to cleaved PARP (Cell Signaling; Table 3.4) 
3.9.3 Anchorage-independent growth assay 
The ability of cells to grow in an anchorage-independent manner was examined 
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using the soft agar assay. Agar solutions of 0.6% and 1% agar were prepared in 
distilled water and autoclaved. To prepare the base layer, 1% agar solution was 
melted in a microwave oven and cooled to 55°C in a water bath, mixed with equal 
volume of 2x culture medium wanned to 37°C to give a final concentration of 0.5, 
poured into each well (2 ml/well) in 6-well plates, and allowed to solidified at room 
temperature. Transfected cells were trysinized and resuspended in 37°C 2x culture 
medium. Cell suspension (2-4x10^) was mixed with equal volume of 0.6% agar 
(warmed to 42°C) and 1 ml of this mixture was layered on top of the base layer. After 
agar solidification, the plates were incubated at 37°C. Several drops of culture 
medium were added to the plate every 3 days to feed the cells. 
After three weeks of incubation, cell clusters of greater than 100 fim diameter 
% • 
were considered as colonies. The number of colonies was scored in 10 fields of view 
(200X) under a microscope. All experiments were performed in triplicates for 3 times. 
3.9.4 Wound healing assay 
The wound healing assay was performed to assess glioma cell motility in vitro. 
A172 cells (3x10^) were seeded on a 6-well plate and allowed to grow overnight. 
Cells of 70% confluency were transfected with 40 nM miR-137, 6 nM CSEIL 
siRNA, or negative RNA controls. After 16 hours, artificial wounds were "made by 
streaking a line in 100%-confluent cell monolayer using sterile 200-}j.l pipette tips. 
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Cell debris was removed by rinsing the plate with medium. Cells were then 
incubated as usual. Closure of the open gaps was monitored for 40 hours until 
wounds were completely closed. Photos were captured using a phase-contrast 
microscope under 40x magnification. Widths,of the wounds were measured using 
Image-Pro Plus software version 5.1 (Media Cybernetics, Silver Spring, U.S.A.). 
3.9.5 Matrigel invasion assay 
The invasive ability of glioma cells was evaluated using BD. BioCoat™ 
MatrigelTM Invasion Chamber (BD Bioscience, Bedford, U.S.A.) system. The 
chamber contains an 8-micron pore polyethylene terephthalate membrane covered 
with a thin layer of Matrigel basement membrane matrix. Cells that could pass the 
’ Matrigel and migrate through the pores to the underside of chamber were considered 
invasive. 
Briefly, the chamber was removed from -20°C storage, equilibrated to room 
V 
temperature for 1 hour, and rehydrated with 500 [i\ of warm semm-free culture 
medium for 2 hours at 37°C. After rehydration, medium was removed carefully, 
transfected cells were prepared in serum-free medium. Culture medium (750 |il) 
supplemented with 10% FBS was used as a chemoattractant and added to each well 
of a tissue culture plate (BD Falcon, Franklin Lakes, U.S.A.). Chambers were 
transferred to wells containing chemoattractant followed by addition of 500 i^l of cell 
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suspension containing different numbers of cells (2x10^ for TC620, 1x10^ for A172， 
U87MG and U373MG cells) into each chamber. After incubation for 16 hours, the 
non-invading cells on the upper surface of the membrane were removed by scrubbing 
using cotton tipped swab. Invaded cells on the lower surface of the membrane were 
fixed with 500 |il of methanol for 2 minutes and then stained with 500 fil of 1% 
Toluidine blue (in 1% borax; Sigma-Aldrich) for another 2 minutes. Cells were 
photographed using a phase-contrast microscope under 40 x magnification. Cell 
numbers in 3 randomly selected fields of each insert were counted. Experiments were 
performed in duplicates for 3 times. 
3.9.6 Cell differentiation assay 
In glioma cells transfected with miRNA for 48 hours, expressions of p-tubulin 
III and GFAP were detected as neuronal and astrocytic markers, respectively, by 
Western blotting as described in section 3.7. 
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3.10 Immunohistochemical analysis 
Expressions of CSEIL and Ki-67 were examined by immunohistochemistry in 
35 OTs. For controls, FFPE blocks of 5 autopsy samples and 8 non-neoplastic brain 
y 
tissues with medial temporal sclerosis or brain chronic inflammation were retrieved 
from Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, 
Hong Kong. FFPE tissues were cut into 5-|am thick sections and subjected to 
hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). 
3.10.1 H&E staining 
After heated on a 40°C hot plate, FFPE sections were deparafFinized with xylene 
three times for 5 minutes, rehydrated through a series of graded alcohol (100% x2, 
95% and 70%) and then washed briefly in distilled water. 
Sections were stained in Mayer's haematoxylin for 10 minutes and washed in 
running tap water for 5 minutes. Cytoplasmic component was decolorized with acid 
alcohol (1% HCl in 70% ethanol) for 2 seconds. After thorough rinsing in tap water, 
slides were treated in Scott's tap water substitute for 2 minutes to blue up and washed 
in running tap water again. The sections were thereafter stained with 1% eosin for 2 
minutes, followed by a running tap water wash. Stained sections were dehydrated in 
graded alcohol series (70%, 95% and 100% x2，5 minutes each), cleared in 2 changes 
of xylene for 5 minutes each, and finally mounted with xylene based mounting 
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medium. The H&E stained slides were subjected to histological review for diagnosis 
and localization of representative tumor area. 
3.10.2 Detection of Ki-67 expression 
Sections were deparaffinized and rehydrated as described in section 3.10.1. 
Antigen retrieval was carried out by boiling the sections in EDTA buffer (1 mM 
EDTA, pH 8.0) in a microwave oven. After antigen exposure, immunohistochemical 
staining was preceded with the program 32 min-i in Ventana NexES IHC automated 
slide stainers system using iVIEW DAB Detection Kit (Ventana Medical Systems 
Inc., Tucson, USA). Tissue sections were incubated with primary monoclonal 
antibody against Ki-67 antigen (clone MIB-1, 1:100 dilution, Dako，Carpinteria, 
USA) at 37°C for 32 minutes. Negative control sections were incubated in parallel 
without primary antibodies. A section of multi-tissue spring-roll block (including 
tonsil, thyroid, lung and colonic tissues, etc.) was mounted on slide as positive 
control to ensure that the immunostaining was working correctly. < 
3.10.3 Detection of CSEIL expression 
Deparaffinized and rehydrated sections were subjected to antigen retrieval in 
boiled citrate buffer (10 mM citric acid, pH 6.0) in a microwave oven. Endogenous 
horseradish peroxidase (HRP) activity was blocked 3% hydrogen peroxide (H2O2) 
for 5 minutes. After blocking in 2% normal swine serum (Dako, Carpinteria, USA) 
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for 5 minutes at room temperature, the CSEIL antibody (clone 3D8; 1:50 dilution; 
Abnova, Taiwan) were applied onto the specimens and incubated overnight at 4°C. 
Sections were then washed three times with TEST followed by incubation with Dako 
EnVision+ HRP labeled anti-mouse at room j;emperature for 50 minutes. Sections 
were then washed three times in TEST before the addition of 3,3'-diaminobenzidine 
(DAB) chromogen substrate in DakoCytomation EnVision+ System-HRP (DAB), 
allowed to react for 3 minutes and washed well in running tap water. The DAB 
chromogen resulted in a brown precipitate where antigen was located can be 
visualized under a light microscopy. Finally, sections were counterstained with 
Mayer's hematoxylin to stain the nucleus blue. A non-neoplastic specimen and a 
section of colorectal cancer tissue array showing positive CSEIL staining were 
， employed as positive staining control. 
3.10.4 Scoring methods 
For each case, a total of 1,000 cells in 5 high-power fields (400x) with the , 
maximal nuclear staining areas were counted. The Ki-67 labeling index was 
determined as the percentage of the number of stained nuclei over the total number 
of nuclei counted. 
The nuclear expression of CSEIL was evaluated by using an immunoreactive 
score (IRS) system, in which IRS = SI (staining intensity) x PP (percentage of 
positive cells). The staining intensity score was assigned for the intensity of positive 
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cells (0, negative; 1，weak; 2，moderate; 3，strong). The PP score was determined 
according to percentage of cells with positive nuclear staining (0，0%; 1，0-10%; 2, 
10-50%; 3，50-80%; 4, >80% positive cells). The resultant IRS scores ranged from 0 
to 12. The expression of CSEIL was categorized as negative (IRS=0, 1)，low (IRS=2, 
3)，medium (IRS=4, 6) or high (IRS=8，9, 12). 
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3.11 Bioinformatic analysis 
To identify putative downstream targets of hsa-miR-137, a total of 4 
computational programs based on different criteria were employed. These are 
microCosm (Griffiths-Jones et al, 2006), miRanda (Enright et al, 2003; John et al, 
2004), PicTar (Grun et al, 2005; Krek et al, 2005) and TargetScan (Lewis et al, 
2003; Lewis et al., 2005). Multiple features are taken into consideration by these 
algorithms to filter out false positive hits, including 1) base pairing pattern between 
miRNAs (especially the seed region) and target transcript, 2) thermodynamic 
stability of the miRNA-mRNA duplex, 3) evolutionary conservation in vertebrate of 
the target sites, and 4) relative position of binding sites in 3'UTR (Table 3.6). Four 
criteria were used for selection of candidate miR-137 targets. These included 1) 
genes predicted by at least 2 of the prediction algorithms, 2) conserved miR-137 











































































































































































































3.12 Statistical analysis 
Expressions of miR-137 in tumors, cell lines and normal brains were compared 
by Mann-Whitney U-test. Association of miR-137 expression levels with Ki-67 
labeling index was examined by the Spearman's correlation analysis. Dual-luciferase 
/ 
reporter analysis and functional effects of miR-137 or CSEIL knockdown were 
assessed by the Student's ,-test. 
Patient follow-up was conducted by telephone contact. Survival time was 
measured from the date of surgery to Janurary 2010 or to the time of death. Survival 
analysis between study groups was performed using the Kaplan-Meier survival curve 
with the log-rank test. A /7-value of less than 0.05 (2-sided) was considered 
statistically significant. All statistical analyses were performed using SPSS software 
version 16.0 (SPSS, Inc.，Chicago, U.S.A.). 
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CHAPTER 4 RESULTS 
4.1 Expression of miR-137 in glioma cells and clinical significance 
4.1.1 Description of 36 OT samples 
We have recruited a total of 13 oligodendrogliomas, 7 anaplastic 
oligodendrogliomas, 13 oligoastrocytomas and 3 anaplastic oligoastrocytomas 
according to WHO classification for our study (Representative H&E photos in 
Figure 4.1). The male/female ratio was 1.25:1 and the median age was 41.5 years, 
ranging from 10 to 77 years. There was 1 pediatric case among all 36 patients. 
As OT was characterized by chromosome Ip and 19q co-deletion, we also 
detected the status of Ip and 19q in these samples using dual-color FISH. Copy 
number of 1 p36.3 and 19ql3.3 in each case are listed in Table 4.1. 
There were 50.0% (18/36，including 10 of 20 ODs and 8 of 16 OAs) and 47.2% , 
(17/36，including 10 of 20 ODs and 7 of 16 OAs) of OTs showing allelic loss of 
\ 
lp36 and 19ql3, respectively. Among the 18 samples with loss of either region, 
co-deletion was observed in 17 (94%) cases, except for only 1 OA case (HS375). 
Chi-square or Fisher's exact test was employed to assess whether lp36 or 19ql3 
status was associated with clinical data. As shown in Table 4.2，no significant 
correlation was detected between allelic status of lp36 or 19ql3 and any clinical 
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parameter, such as histological subtype, tumor grade, patient sex and age. 
To evaluate the proliferative activity in these OTs, Ki-67 expression was 
examined by IHC analysis. Ki-67 immunoreactivity was observed in the nuclei of 
tumor cells and was quantified by nuclear labeling index (LI), which represents the 
percentage of positive staining nucleus. Ki-67 LI in OTs investigated showed great 
variation. The index ranged from 0.0% to 37.2% in 35 OTs with a median value of 
3.7% and a mean value of 6.5%. For the non-neoplastic brain tissues, the index was 
0% to 0.1%. Significant higher Ki-67 LI was found in 20 ODs (p=0.007) and 15 
OAs (p=0.045) when compared to non-tumorous tissues (Figure 4.2). Between 20 
ODs and 15 OAs, there was no significant difference in Ki-67 LI (p=0.386). 
When tumors of WHO grade II or III were compared, the Ki-67 LI in grade III 
tumors were significant higher than that in grade II tumors (p=0.014, Figure 4.3)， 
indicating that high grade tumor cells showed higher proliferative activity. 
Furthermore, statistical analysis revealed a correlation between Ki-67 LI and patient 
age (p=0.005), suggesting older patients having higher Ki-67 index. No significant 
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Figure 4.1 Histological appearance of OTs. (A) oligodendroglioms, HS303, (B) , 
anaplastic oligodendroglioma, HS302, (C) oligoastrocytoma, HS381, and (D) 
anaplastic oligoastrocytoma, HS364, under microscope (400xmagnification). 
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Table 4.1 Summary of clinical parameters, lp/19q status, Ki-67 labeling index and 
miR-137 expression level in 36 OTs examined. 
Case J Age Ip 19q Ki-67 LI miR-137 expression 
Diagnosis Sex , 2 ,…3 " ， �4 
number (years) status status (%) (fold change) 
HS467 OD F ^ R R I S ^ 
HS331 OD F 46 L L 1.2 -1.6 
HS469 OD F 36 L L 1.6 -2.0 
HS390 OD M 10 R ‘ R 0.7 -2.3 
HS378 OD F 38 R R 3.7 -2.5 
HS329 OD F 69 L L 1.0 -2.8 
HS303 OD M 48 L L 7.8 -3.0 
HS400 OD F 49 L L 1.2 -3.5 
HS466 OD F 40 L L 0.9 -3.7 
HS324 OD M 42 R R 0.5 -4.0 
HS332 OD M 53 L L 2.1 -8.6 
HS460 OD M 29 R R 0.2 -59.7 
HS380 OD M 35 L L 6.0 -119.4 
HS381 OA F 28 L L 0.0 -2.0 
HS301 OA M 43 L L 1.5 -2.7 
HS375 OA M 28 L R 0.0 -2.7 
HS393 OA F 49 R R 0.3 -5.4 
HS382 OA F 37 L L 2.0 -7.0 
HS368 OA F 61 R R 16.1 -7.4 
HS384 OA M 30 R R 2.1 -9.9 
HS394 OA F 31 L L 8.9 -11.0 
HS462 OA M 39 L L 5.5 -27.9 
HS362 OA M 41 R R N/A^ -77.2 
HS399 OA M 34 R R 12.1 -320.9 
HS314 OA F 38 R R 4.2 -401.8 ‘ 
HS458 OA M 37 L L 6.9 -955.4 
HS377 AOD M 77 L L 12.0 5.3 
HS302 AOD M 35 R R 23.7 -10.6 
HS312 AOD M 53 R R 37.2 -16.0 
HS360 AOD M 51 R R 17.5 -90.5 
HS333 AOD F 43 R R 8.5 -207.9 
HS461 AOD M 53 L/R^ L/R^ 20.7 -337.8 
HS358 AOD F 50 R R 4.9 -477.7 
HS366 AOA M 35 R R 1.7 -22.8 
HS457 AOA M 52 L L 5.7 -45.3 
HS364 AOA F 48 R R 0.0 
9 6 
1 OD, oligodendroglioma; AOD, anaplastic oligodendroglioma; OA, oligoastrocytoma; 
AOA, anaplastic oligoastrocytoma. 
2 L or R stands for allelic loss or retention determined by FISH. 
3 Ki-67 labeling index indicated percentage of positive staining nucleus examined by 
IHC. 
4 miR-137 expression fold change relative to 3 normal brain RNA samples was 
determined by qRT-PCR, + o r - represents upregulation or downregulation. 
5 Ki-67 labeling index is not available due to lack of FFPE section. 
6 Different chromosomes Ip and 19q status were shown in heterogeneous tumor cells 
in this case. 
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Figure 4.2 Ki-67 labeling index in OTs compared to non-tumorous brain samples 
by IHC. Both 20 oligodendrogliomas (ODs) and 15 oligoastrocytoma (OAs) showed 
significant higher Ki-67 expression than 3 non-neoplastic brain tissues. 
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Figure 4.3 Expression of Ki-67 in WHO grade n and m OTs and non-tumorous 
brain tissue. Representative IHC staining photos in a non-neoplastic brain sample 
(A), an oligodendroglioma, grade U, HS303 (B) and an anaplastic 
oligodendroglioma, grade III, HS302 (C) are shown here. D. Labeling index in ODs 
» 
and OAs are significantly higher than that in non-tumorous brain tissues. 
Furthermore, grade III tumors displayed higher Ki-67 expression than grade II 
tumors. 
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Table 4.2 Association analysis of Ip36/19ql3 status with clinicopathological 
parameters in 36 OTs. 
19ql3 Ip36/19ql3 
status p-value status p-value co-deletion p-value 
L R L R Yes No “ 
Tumor type 
OD 10 10 1.000 10 40 0.709 10 10 0.709 
OA 8 8 7 9 7 9 
WHO grade 
grade II 15 11 0.137 14 12 0.199 14 12 0.199 
grade III 3 7 3 7 3 7 
Gender 
male 10 10 1.000 9 11 0.765 9 11 0.765 
female 8 8 8 8 8 8 
Age 
<50 years 13 13 1.000 12 14 0.836 12 14 0.836 
>=50 years 5 5 5 5 5 5 
Ki-67 LI 
<3% 10 7 0.365 9 8 0.615 9 8 0.615 
>3% 8 10 8 10 8 10 
miR-137 
down-regulation 
„ <2-fold 2 1 1.000 2 1 0.593 2 1 0.593 
>2-fold 16 17 15 18 15 18 
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Table 4.3 Association analysis of Ki-67 labeling index with clinicopathological 
parameters in 35 OTs. 
Ki-67 labeling index (%) 
N p-value 
Range Median Mean 
Tumor type 
OD 20 0.2�37.2 . 4.3 8.0 0.385 
OA 15 0-16.1 3.2 4.5 
WHO grade 
grade II 25 0-16.1 2.0 3.8 0.014 
grade III 10 0�37.2 10.3 12 
Gender 
male 19 0-37.2 5.7 8.6 0.148 
female 16 0-16.1 1.8 3.9 
Age 
<50 years 25 0-23.7 1.7 4.0 0.005 
>=50 years 10 1.0-37.2 12.0 12.5 
Ip status 
loss 18 0 �20.7 2.1 4.7 0.507 
intact 17 0-37.2 4.2 8.3 
19q status 
loss 17 0 �20.7 2.1 5.0 0.884 
intact 18 0 �37.2 4.0 7.9 
lp/19q co-deletion 
yes 17 0-20.7 2.1 5.0 0.884 
no 18 0 �37.2 4.0 7.9 
miR-137 
down-regulation 
<2-fold 3 1.2-7.9 1.6 3.7 0.528 , 
>2-fold 32 0�37.2 4.0 6.7 
« 
101 
4.1.2 miR-137 level in oligodendroglial tumors and glioma cells 
Previous studies screening for miRNA expressions showed that miR-137 was 
significantly down-regulated in astrocytomas of different grades (Silber et al, 2008; 
Zhi et al, 2010) relative to non-tumorous‘brain tissues. In order to investigate 
whether miR-137 was involved in tumorigenesis of OT, qRT-PCR analysis was 
performed to evaluate the expression levels of miR-137 in 36 frozen OT specimens 
(composed of 20 oligodendrogliomas and 16 oligoastrocytomas), 10 glioma cell 
lines and 3 commercial normal brain RNA samples. Detection of miR-16, whose 
expression was more robust than small RNA U6B, was selected as an endogenous 
control for normalization. A significant downregulation of miR-137 level was 
observed in oligodendrogliomas (p=0.016), oligoastrocytomas (p=0.009) and glioma 
’ cell lines (p=0.007) when compared with that in normal brain samples (Figure 4.4). 
Downregulation of miR-137 (>2-fold decrease) was found in 17 out of 20 (85.0%) 
OD and all 16 (100%) OA cases, up to 478- and 955-fold, respectively. All 10 
glioma cell lines showed reduced miR-137 expression by 8,5- to 2190-fold. Among ‘ 
36 OTs, there was no significant difference of miR-137 levels between 20 ODs and 
16 OAs (p=0.220, Figure 4.4). These data indicated that reduction of miR-137 was a 
frequent event in human OT. 
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Figure 4.4 Expression levels of miR-137 in 20 ODs, 16 OAs and 10 glioma cell lines 
compared to that in 3 normal brain (NB) samples by qRT-PCR. Both primary OTs 
and glioma cell lines showed significant reduced miR-137 expression. 
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4.1.3 Association of miR-137 expression with clinicopathological features, 
lp/19q status and Ki-67 expression 
In order to test whether miR-137 expression was associated with clinical 
parameters of OT patients, the relative levels of miR-137 of OTs to normal brain 
samples were compared when 36 OTs are categorized into different groups. 
Mann-Whitney U analysis revealed that miR-137 levels was lower in grade III 
than grade II OTs (p=0.010, Table 4.4 and Figure 4.5). Moreover, miR-137 
expression was inversely correlated with Ki-67 LI in 35 OTs examined (p=0.009, 
r=-0.436, Figure 4.7). It was further confirmed by a significantly lower miR-137 
level in Ki-67 high expression (>3%) group (p=0.002, Figure 4.7). These suggested 
that miR-137 may play a role in regulating OT cell proliferation. 
Although located in chromosome Ip, miR-137 expression levels showed no 
significant difference between Ip intact or loss OT groups (p=0.115, Figure 4.6). In 
addition, no significant difference was found in miR-137 level when patients were ‘ 
grouped by tumor type (p=0.219), sex (p=0.092), age (50 years as a cut-off, 
p=0.533)，or 19q status (p=0.215) (Table 4.4). 
Survival analysis was also performed to study the clinical significance of above 
parameters in 19 OTs with available survival data (Figure 4.8). It was showed that 
there was significant association between tumor grade and overall or 
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progression-free survival (p<0.001). We also found elder patients with a worse 
prognosis than younger patients (p<0.001). No significant difference was observed 
between male and female patients. 
All the 19 cases showed concurrent status of chromosome Ip and 19q by FISH 
analysis. However, lp/19q status did not significantly correlate with patients' 
survival. Furthermore, patients with lower Ki-67 LI showed a better clinical outcome 
for both overall and progression-free survival (p=0.049 and p=0.017, respectively). 
Patients with higher miR-137 expression had more favorable prognosis, but it was 
not statistically significant in our study (p=0.215 and p=0.103, respectively). 
» 
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Table 4.4 Association analysis of miR-137 levels with clinicopathological 
parameters in 36 OTs. 
^ miR-137 expression (fold change) yglue 
Range Median Mean 
Tumor type ‘ 
OD 20 1.2 � -477.7 -4.6 -3.8 0.219 
OA 16 -2.0 � -955.4 -14.9 -7.9 
WHO grade 
grade II 26 1.2 � -955.4 -4.7 -3.8 0.010 
grade III 10 -5.3 � -477.7 -50.9 -22.2 
Gender 
male 20 -2.3 � -955.4 -18.8 -8.1 0.092 
female 16 1.2 � -477.7 -4.4 -3.3 
Age 
<50 years 26 -1.6 � -955.4 -8.2 -5.1 0.533 
>=50 years 10 1.2--477.7 -11.2 -4.7 
Ip status 
loss 18 -1.6 � -955.4 -4.4 -4.2 0.115 
intact 18 1.2 � -477 .7 -18.8 -6.0 
19q status 
loss 17 -1.6 � -955.4 -5.3 -4.4 0.215 
‘ intact 19 1.2 � -477.7 -16.0 -5.6 
lp/19q co-deletion 
yes 17 -1.6 � -955.4 -5.3 -4.4 0.215 
no 19 1.2 � -477.7 -16.0 -5.6 
Ki-67 LI 
< 3 % 1 7 - 1 . 6 〜 - 5 9 . 7 - 3 . 7 - 3 . 7 0 . 0 0 2 ， 
>3% 18 1.2 � -955.4 -34.5 -6.8 
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Figure 4.5 miR-137 levels in WHO grade II and III OTs and normal brain samples. 
Significant lower miR-137 expression was detected in grade III than grade II tumors. 
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Figure 4.6 Relationship of miR-137 and chromosome Ip status in OTs. No 
significant difference of miR-137 levels was observed between Ip intact and loss 




.2 ^ 1.2J. * 
85 T T 
0 . 6 - • 
(DC • 
T "S • p=0.009, r=-0.436 
/ 
¥ I 0.2-1 • I s s • • . ① 鲁 氣 • 
^ 0 . 0 - t ~ 办 • • � • "—I* 1 1 
0 10 20 30 40 
Ki-67 labeling index (%) 
B 
.2 _ I .2J. p=0.002 ‘ 
i g ^ T ‘ ^ ~ • 
0) V 
& % 0.6- • 
o E • 
5 1 0 . 4 - •:• ： 
E g ——V 
g E 0.2- • • 
iS S • • • • 
^ 0.0-^ H • • • • • , • • • • 
<3% (n=17) >3% (n=18) 、 
Ki-67 labeling index 
Figure 4.7 Relationship of miR-137 and Ki-67 expression in OTs. A. Significant 
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r=-0.436). B. Significant lower miR-137 levels in Ki-67 high expression group by 
Mann-Whitney U analysis (p=0.002). 
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Figure 4.8 Kaplan-Meier overall survival curves (left panel) and progression-free 
survival curves (right panel) with log-rank test for 19 OT patients with various 
clinicopathological parameters. ‘ 
\ 
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4.2 miR-137 levels in glioma cells after demethylation treatment 
Accumulating studies revealed that the promoter CpG islands region of miR-137 
was more frequently methylated in oral squamous cell carcinoma (Kozaki et al, 
2008; Langevin et al, 2010), gastric cancer cell lines (Ando et al, 2009) and 
colorectal cancer (Bandres et al, 2009; Balaguer et al, 2010) compared to 
corresponding normal controls. Moreover, the methylation status of miR-137 
promoter was found correlated with its low expression in oral squamous cell 
carcinoma cells (Kozaki et al, 2008), suggesting promoter methylation may 
contribute to miR-137 downregulation in cancers. This was supported by several 
evidence that miR-137 expression was restored after 5-aza-dC or TSA treatment in 
different cancers (Silber et al, 2008; Bandres et al, 2009; Balaguer et al, 2010), 
�- accompanied with the promoter region demethylation (Bandres et al, 2009; 
Balaguer et al, 2010). 
To investigate whether miR-137 was epigenetically regulated in glioma, 
miR-137 expression in TC620, A172 and U373MG glioma cells was measured 
followed by 5-aza-dC and/or TSA treatment. It has been determined that miR-137 
expression in the 3 cell lines was 478, 15 and 60-fold lower than that in normal brain 
samples, respectively in section 4.1.1. Quantitative analysis of miR-137 expression . 
revealed a significant increase by 5.0�9.6-fold after TC620 oligodendroglioma cells 
were incubated with 2, 5 or 10 \xm of 5-aza-dC for a period of 2 doubling time 
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compared to untreated cell (p<0.001). When cells were subjected to a subsequent 
treatment of TSA, the miR-137 expression was further enhanced to 11.2-17.4-fold 
significantly (p<0.001). A dose-dependent effect was observed in mean value of 
miR-137 expression, but the differences among 2，5 and 10 \xm of 5-aza-dC or 0.33 
and 1 iLim of TSA was not statistically significant. No significant increase of 
miR-137 expression was detected in TC620 cells treated only by TSA relative to 
untreated cells. (Table 4.5，Figure 4.9A) 
However, there was no significant change in miR-137 levels in A172 and 
U373MG cells treated after either drug treatment (Table 4.5, Figure 4.9B-C). 
These data suggested that miR-137 expression was reduced by DNA 
methylation and histone deacetylation in TC620 oligodendroglioma cells. miR-137 




Table 4.5 miR-137 expression fold change after 5-aza-dC and/or ISA treatment in 3 
glioma cell lines by qRT-PCR relative to untreated cells. Data shown are mean value 
from 3 independent experiments performed in triplicate. 
Relative miR-13 7 . 5-aza-dC ( _ 
expression 0 2 5 10 
TC620 0 LOO ^ ^ 
TSA(^iM) 0.33 1.53 11.57 12.02 17.05 
1 1.74 11.18 14.57 17.37 
Relative miR-137 5-aza-dC ( _ 
expression 0 2 5 10 
A172 0 L ^ ^ U 9 U 4 
TSA (|iM) 0.33 1.08 1.06 1.05 . 0.98 
1 0.89 0.99 1.00 0.83 
Relative miR-137 5-aza-dC ( _ 
expression 0 2 5 10 
U373MG 0 LOO " T ^ 0 9 5 ^ 
TSAOiM) 0.33 1.14 0.95 0.87 1.22 
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Figure 4.9 miR-137 expression fold change after 5-aza-dC and/or TSA treatment in 
TC620 (A), A172 (B) and U373MG (C) glioma cells by qRT-PCR relative to 
untreated cells. Data represent mean 士 SD from 3 independent experiments 
performed in triplicate. p<0.05 by student's t test. 
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4.3 Biological effects of miR-137 overexpression in glioma cells 
It has been reported that miR-137 inhibited cell proliferation in glioblastoma 
(Silber et al, 2008), oral squamous cell carcinoma (Kozaki et al, 2008) and 
colorectal cancer cells (Liu et al, 2010) arid suppressed invasive ability of colon 
cancer cells (Liu et al, 2010), indicating a role of miR-137 in tumorigenesis. To 
characterize the biological function of miR-137 in glioma, the effects of miR-137 on 
glioma cell malignancy variables including cell viability, cell cycle, 
anchorage-independent growth, cell apoptosis, invasion and differentiation were 
assessed following ectopic transient expression of miR-137 mimic or negative 
control miRNA. 
4.3.1 Cell growth 
4.3.1.1 Cell viability 
Our data in section 4.1 revealed the expression of miR-137 was inversely related 
to Ki-67 level in OTs in vivo. Therefore, we firstly tested whether miR-137 affected 
glioma cell growth. Effect of miR-137 expression on cell viability was assessed by 
MTT assay in 8 glioma cell lines, including TC620, HOG and GOS-3 OT cells and 
A172, U87MG，U373MG, LNZ308 and T98G GBM cells. The changes of relative . 
cell viability in subsequent 24，48，72 and 96 hours after cells were transfected with 
miRNA mimic or lipofectamine control were shown in Figure 4.10. 
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The effect of miR-137 was measured as percentage of cell metabolic activity in 
cells treated with miR-137 compared to that transfected with negative control 
miRNA. As shown in Table 4.6 and Figure 4.10，miR-137 induced significant 
decrease on cell viability at 48�72 hours post-transfection (p<0.05). Forced 
expression of miR-137 mimic resulted in a concordant suppression on cell viability 
in all 8 cell lines examined. The inhibition ranged from 30% to 74% at 96 hours in 
these cells. 
These data demonstrated that transfection of miR-137 significantly reduced cell 
growth in all cell lines tested, suggesting that miR-137 has a growth suppressor 
function in glioma cells. 
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Table 4.6 Effect of miR-137 on cell viability in 8 glioma cell lines relative to 
negative control miRNA. 
Cell viability Cell viability 
Time after Time after 
% of ^ % of 
Cell line transfection Cell line transfection . 
negative p value ,, � negative p value 
(hours) ^ ^ (hours) ^ 
control control 
24 90.0% 0.107 24 92.3% 0.074 
48 84.5% 0.098 48 89.5% <0.001 
XC620 A172 
72 79.7% 0.021 72 85.3% 0.006 
96 52.8% 0.035 % 49.2% 0.001 
^ 85.2% ^ 93.7% 0.404 
48 78.9% <0.001 48 69.2% <0.001 
U87MG U373MG 
72 46.4% <0.001 72 40.8% <0.001 
96 32.8% <0.001 % 26.10/0 <0.001 
^ 91.7% 0.202 ^ 101.9% 0.886 
48 77.2% 0.014 48 91.4% 0.017 
GOS-3 HOG 
72 75.4% <0.001 72 87.9% 0.008 
96 61.9% <0.001 % 79.6% 0.003 
^ 87.0% ^ 94.4% 0.611 
48 78.2% <0.001 48 80.3% 0.658 
“ LNZ308 T98G 
72 67.9% <0.001 72 68.6% <0.001 
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Figure 4.10 Effect of ectopic miR-137 expression on glioma cell viability. Cell 
metabolic activity of 8 glioma cell lines are measured by MTT assay 24-96 hours 
after transfected with miR-137, negative control miRNA or lipofectamine treatment. 
The points showed means 士 SD from 3 independent experiments performed in 
triplicate. Cell viability was significantly reduced in all cell lines. 
« 
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4.3.1.2 Cell number 
The effect of miR-137 on cell growth was further validated by cell count in 
these glioma cells. Transfection and time of cell number measurement are performed 
same as above in MTT assay. ‘ 
As shown in Table 4.7 and Figure 4.11, the cell number of all cell lines 
tranfected with miR-137 were significantly dropped when compared to cells 
tranfected with negative control miRNA viability since 48 � 7 2 hours 
post-transfection (p<0.05). The inhibitory effect ranged from 40% to 64% at 96 
hours in these cells. Consistent with data from MTT assay in section 4.3.1.1, this 
further confirming that ectopic expression of miR-137 suppressed proliferation of 
glioma cells. 
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Table 4.7 Effect of miR-137 on cell number in 8 glioma cell lines relative to 
negative control miRNA. 
Cell number ^ Cell number 
Time after Time after Cell % of . % of * transfection Cell line transfection . , line negative p value � negative p value (hours) (hours) control control 
S 82.4% 0.064 ^ 102.2% 0.776 
48 75.8% <0.001 48 69.4% 0.010 
72 55.2% <0.001 仏 : 72 71.0% 0.008 
% 45.0% <0.001 % 39.9% <0.001 
80.5% 0.072 T^ 91.2% 0.396 
48 69.5% <0.001 48 81.0% 0.023 
72 55 2Q/0 <0.001 72 46.6% <0.001 
% 40.3% <0.001 % 36.0% <0.001 
^ 94.7% 0.583 S 95.7% 0.694 
48 75.4% 0.003 48 89.1% 0.259 
72 62.7% <0.001 72 76.9% 0.012 
% 60.1% 0.015 % 62.0% <0.001 
^ 96.6% 0.762 ^ 93.6% 0.604 
48 91.8% 0.344 48 88.1% 0.021 
‘ 72 7970/^ 0.005 ^^^^ 72 79.4% 0.004 
% 67.7% <0.001 % 68.30/0 0.015 
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TC620 A172 
j： j ) ^ ^ ^ , 
n I 1 1 0-* 1 I 1 1 
^ T2 ^ 24 48 72 96 
Time after transfection (hrs) Time after transfection (hrs) 
U87MG U373MG 
qJ 1 1 —I 1 0-* 1 r 1 1 
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Figure 4.11 Effect of ectopic miR-137 expression on glioma cell growths. Growth 
curves represent glioma cells and cells transfected with miR-137 mimic, miRNA 
negative control or lipofectamine only. The numbers of viable cells at 24 to 96 hours 
after transfection were assessed by cell count. All lines show suppression of cell � 
growth upon miR-137 forced expression. The points showed means 士 SD from 3 
independent experiments performed in triplicate. 
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4.3.1.3 Cell cycle analysis 
Given that miR-137 inhibited glioma cell growth obviously in vitro, we tried to 
determine the potential mechanism by cell cycle and apoptosis analyses. Four glioma 
cells (TC620，A172, U87MG and U373MG), which showed more reduction of cell � 
growth following miR-137 transfection, were transfected with miR-137 mimic, 
negative control. BrdU incorporation at following 24-96 hours was determined by a 
colorimetric immunoassay to quantify DNA synthesis during cell proliferation. 
As shown in Table 4.8 and Figure 4.12，the cell proliferative activity dropped 
continuously in miR-137 transfected TC620 and U87MG cells compared with 
negative control since 24 hours post-transfection (p<0.05). Similar effect was 
observed in A172 and U373MG cells, whereas the significant difference started from 
48 hours (p<0.05). DNA synthesis was decreased by 24.7% to 86.2% in TC620, 8% 
to 56.9% in A172，47.6% to 86.2% in U87MG, and 1.5% to 84.0% in U373MG 
during 1-4 days afterwards. 
Moreover, a flow cytometry analysis showed that GO/Gl cell cycle arrest was 
induced in miR-137 transfected TC620 cells at 48 hours post-transfection. Above 
data indicated that miR-137 suppressed cell proliferation by blocking DNA 
replication in cell cycle progression. 
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Table 4.8 Effect of miR-137 on DNA synthesis in 4 glioma cell lines relative to 
negative control miRNA by BrdU incorporation assay. 
Time after BrdU incorporation 
Cell line transfection Average % of * 
(hours) negative control 
24 75.3% 0.009 
48 44.0% <0.001 
72 22.0% <0.001 
% 13.8% <0.001 
^ 92.0% OA^l 
… � 48 55.8% 0.004 
A 172 
72 50.2% <0.001 
_96 43.1% 0.010 
^ 52.4% <0.001 
TT。”、，r 48 40.0% 0.003 
72 19.2% <0.001 
% 13.8% <0.001 
^ 98.5% O l ^ 
U373MG < _ 1 
• 72 24.0% <0.001 
96 16.0% <0.001 
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Figure 4.12 Effect of ectopic miR-137 expression on glioma cell DNA synthesis. By 
BrdU incorporation assay, the relative proliferating cells at 24 to 96 hours after 
transfection were assessed. All lines show suppression of cell proliferation following ‘ 
miR-137 forced expression. The points showed means 士 SD from 3 independent 
experiments performed in triplicate. *，p<0.05 between miR-137 and negative 
control miRNA transfected group by student's t test. 
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4.3.2 Anchorage-independent cell growth 
To determine whether the miR-137 would aggravate the transforming potential 
of glioma cells, anchorage-independent soft agar growth assay was performed on 
V 
TC620, A172, U87MG and U373MG glioma cells. In our preliminary test for colony 
forming ability of these cells in soft agar, cell colonies were observed in all cell lines 
except for U373 MG cells in soft agar after a incubation time of 14 days 
(Representative images of colony showed in Figure 4.13). Therefore, TC620, A172 
and U87MG cells were included in this assay. 
miR-137 or negative control miRNA was transfected into the 3 cell lines and the 
numbers of colonies formed with diameter larger than 100 \im were counted. It was 
found that miR-137 was able to reduce the colony forming ability of TC620, A172 
and U87MG cells by 80.5%, 71.3% and 75.3% compared with the negative control, 
respectively (p<0.001, Figure 4.14). This result suggested that miR-137 could inhibit 





Figure 4.13 Microscopic views of glioma cell colonies in soft agar. Colonies were 
observed in TC620 (A), A172 (B)，U87MG (C)，but not U373MG (D) cells under 
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Figure 4.14 Effect of ectopic miR-137 expression on number of colonies formed in 
glioma cells. In TC620 (A), A172 (B) and U87MG (C) glioma cells transfected with 
miR-137, negative control miRNA or mock. Colonies with sizes of greater than 100 
fxm were counted. miR-137 led to a significant reduction in numbers of colonies in � 
all 3 cell lines when compared to the negative control. Results represent the average 
of three independent experiments done in triplicate. *，p<0.001. 
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4.3.3 Cell apoptosis 
Besides induction of cell cycle arrest, we also sought to identify whether 
miR-137 was involved in glioma cell apoptosis, which may also contribute to cell 
、、 
growth suppression. An apoptotic marker, deaved PARP, was examined by western 
blot in glioma cells following transfected with miR-137 compared to negative 
control. The protein level of cleaved PARP elevated gradually in TC620 and A172 
cells in subsequent 4 days following miR-137 transfection. A dramatic enhancement 
of cleaved PARP was observed at 48 hours in U87MG and U373MG-cells, whereas 
no further induction at 96 hours (Figure 4.15). The data indicated that miR-137 
forced expression resulted in cellular apoptosis in glioma cells. 
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Figure 4.15 Effect of ectopic miR-137 expression on cleaved PARP expression in 
glioma cells. Protein levels of cleaved PARP were remarkably up-regulated 
following miR-137 ectopic expression compared to negative control miRNA in 4 
glioma cells. GAPDH was included as loading control. 
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4.3.4 Cell motility 
It has been demonstrated that miR-137 could block colorectal cell invasion (Liu 
et al, 2010). Hence, to explore the roles of miR-137 in regulating glioma cell 
motility, we examined the cell migration ability of A172 cells by wound healing 
assay. As shown in Figure 4.16，the rate of wound closure was significantly slower 
in miR-137 transfected cells than negative miRNA transfectants at 16 hours 
(p=0.040). Note that negative miRNA tranfected cells closed the wound at 32 hours, 
miR-137 transfected cells closed 67% of the wound. This indicates that forced 
miR-137 expression led to suppression of glioblastoma cell migration. 
To further study the effect of miR-137 on glioma cell invasive capacity, matrigel 
invasion assay was also performed. Number of invaded cell in response to FBS 
enriched medium was significantly reduced by 38.9%~52.6% in all glioma cell lines 
tested upon ectopic miR-137 expression (Table 4.9 and Figure 4.17). It indicated that 
glioma cell invasion into extracellular matrix was affected by miR-137. Together, 
these results supported that miR-137 overexpressed glioma cells have lower ability 
of both migration and invasion. 
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Figure 4.16 Effect of miR-137 on A172 GBM cell migration. In wound healing 
• 
assay, wound was induced using a yellow pipette tip on the full confluent monolayer 
A172 cells transfected with miR-137 or negative control miRNA. A. The rate of 
wound closure was monitored at different time points afterwards. Representative 137 ‘ 
photos were taken under 40x magnifications. Lines indicated the differential 
migration rate of cells. B. The migration rate was significant slower in miR-137 
transfected cells. p<0.05. 
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Table 4.9 Effect of miR-137 overexpresssion on cell invasion of 4 glioma cell lines 
by matrigel invasion assay. 
Mean number of invaded cells o^ af 
Cell line negative negative p value 
mock miRNA control � 
TC620 251.2 15l4 61.1% <0.001 
A172 128.0 117.3 60.8 51.8% <0.001 
U87MG 329.0 321.1 167.4 52.1% <0.001 
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Figure 4.17 Effect of ectopic miR-137 expression on glioma cell invasion. The 
invasive ability of 4 glioma cell lines after transfected with miR-137 or negative 
control miRNA were assessed by matrigel invasion assay. Cells invaded to the lower 
surface of matrigel-coated chambers were quantified 16 hours after plating. A. � 
Invaded cells were stained and observed under microscopy at 40x magnification. B. 
Significant fewer cells were able to invade after transfected with miR-137 than 
negative control miRNA transfectants. *, p<0.001. 
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4.3.5 Cell differentiation 
To investigate the role of miR-137 in cell differentiation, neuronal and astrocyte 
marker were determined by western blot. P-tubulin III protein level was enhanced 
after miR-137 restoration in U87MG and U373MG cells compared to cells 
transfected with negative control miRNA. No change in GFAP expression was 
observed in any of these cells. Meanwhile, morphology of cells was also monitored. 
U87MG cells rounded up after miR-137 transfection compared to cells transfected 
with negative control miRNA. The well-defined boundary of TC620 cells was 
disrupted and cellular protrusion was observed. No prominent morphological change 
was observed in A172 and U373MG cells (Figure 4.18). This suggested that 
miR-137 may play a role in neuronal differentiation in glioblastoma cells. 
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Figure 4.18 Effect of ectopic miR-137 expression on neuronal and astrocytic 
marker expression in glioma cell. A. Protein levels of neuron-specific P-tubulin III 
and astrocyte marker, GFAP by western blot 48 hours after transfection with ‘ 
miR-137 or negative control miRNA. B. Microscopic views of cell morphology at 
48 hours. MiR-137 enhanced expression of P-tubulin III in U87MG and U373MG 
glioblastoma cells, without obvious neuronal-like morphological alteration. 
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4.4 Identification of miR-137 targets 
Above studies revealed multiple roles of miR-137 in glioma cells. To further 
elucidate the mechanism underlying observed miR-137 function, we attempted to 
identify downstream targets of miR-137 in'gliomas by a series of computational and 
experimental approaches. Briefly, potential targets were obtained from in silico 
prediction algorithms followed by experimental validation, such as dual-luciferase 
assay，qRT-PCR and western blot to determine whether miR-137 bind to the 
predicted targets and induce a negative regulation. 
4.4.1 In silico prediction of potential miR-137 targets 
Bioinformatic analysis of potential miR-137 target sites was performed by 4 
commonly used computational prediction algorithms, microCosm，miRanda，PicTar 
and TargetScan 
To reduce false positive results，we retrieved putative target genes with high 、 
level complementarity between the seed region of miR-137 and miRNA recognition 
elements (MREs) in 3'UTR, which were predicted by at least 2 of the programs. The 
predicted targets whose MRE was conserved across species (human, mouse, rat, dog 
and chicken) are also preferred. In addition, in order to address our observation of . 
miR-137 function in glioma cell, we search for candidates which were previously 
observed overexpressed in glioma or implicated in oncogenic behaviors, such as cell 
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proliferation, apoptosis, or migration. 
Based on these criteria, 6 potential miR-137 recognition sites located in 3'UTR 
of 5 gene transcripts were selected for further validation (Table 4.10). Chosen 
miR-137 target candidates were CSEl chromosome segregation 1-like (yeast) 
(CSEIL), v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 
(ERBB4), neuropilin 1 (NRPl), cell division cycle 42 {CDC42) and v-akt murine 
thymoma viral oncogene homolog 2 (AKT2). In the following sections, different 
experiments were performed to validate interaction and functional inhibition of 


















































































































































































































































































































































































































































































































































































































































































4.4.2 Experimental validation of miR-137 targets by dual-luciferase 
reporter assay 
Having identified 5 potential miR-137 targets using multiple computational 
V 
algorithms, we would like to screen and validate the target candidates by several 
experimental approaches in subsequent sections. First of all, luciferase reporter 
assay was employed to test whether miR-137 bind to predicted 3'UTR region of 
target candidates directly. 
In this assay, each predicted miR-137 MRE region located in 3'UTR of 
potential target genes was cloned downstream of the firefly luciferase gene in 
pMIR-REPORTER vector, respectively. Therefore, the luciferase activity 
‘ indicated the gene expression, which may be regulated by the interaction of the 
miR-137 with the potential binding sites after miR-137 and the construct were 
both introduced into glioma cells. Decreased firefly luciferase activity when 
miR-137 was transfected demonstrated a direct inhibitory effect of miR-137 to ‘ 
the expression of corresponding target gene. 
According to our previously observation, LNZ308 cells showed the lowest 
endogenous miR-137 expression among the set of glioma cell lines studied. 
Ectopic miR-137 expression may probably result in a noticeable effect in this 
cell line, so that it was chosen as the cell line model to perform this assay. 
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LNZ308 cells was co-transfected with miR-137 mimic or negative control 
miRNA, firefly luciferase reporter construct containing predicted miR-137 
binding site, along with a renilla luciferase vector, which serve as a control for 
normalization of transfection efficiency. The measurement of luciferase activity 
demonstrated that forced miR-137 expression exerted a significantly reduced 
normalized firefly luciferase activity by 44% and 40% on the constructs 
harboring CSEIL and ERBB4 3'UTR region relative to negative control miRNA, 
respectively (p<0.001). Meanwhile, no significant suppression of luciferase 
signal was observed on original vector and constructs containing 3'UTR of other 
genes upon miR-137 ectopic expression (Figure 4.19). This suggested that only 
potential miR-137 binding sites in 3'UTR of CSEIL and ERBB4 were probably 
targeted by miR-137 among the 6 potential target sites evaluated, 
To further validate the direct interaction, we introduced a 7-nucleotide and a 
8- nucleotide mutation on miR-137 binding sites of CSEIL and ERBB4 
corresponding to seed region of miR-137, which may be crucial in miRNA target * 
recognition (Figure 4.20A). The wild-type or mutant vector was cotransfected 
into LNZ308 cells with miR-137 or negative control miRNA, as well as renilla 
luciferase reporter vector. As shown in Figure 4.20B, miR-137 significantly 
decreased the relative luciferase activity of wild-type CSEIL and ERBB4 3'UTR, ‘ 
whereas the inhibitory effect was abolished when the 3'UTR are mutated. Taken 
together, these findings suggested that CSEIL and ERBB4 are direct 
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downstream targets of miR-137 in glioma cells. Moreover, the pairing between 
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Figure 4.19 Dual-luciferase reporter assay for 5 miR-137 target candidates. 
LNZ308 cells were cotransfected with luciferase reporter constructs containing 
predicted miR-137 MRE, miR-137 mimic or negative control miRNA, as well as 
renilla luciferase vector. Firefly luciferase activity was determined and 
normalized with renilla luciferase activity. A significant decrease of luciferase 
activity was detected in LNZ308 cells cotransfected with miR-137 and construct 
harboring predicted miR-137 MRE in CSEIL and ERBB4. For original vector ‘ 
and constructs containing 3'UTR of other genes, miR-137 showed no significant 
effect on luciferase activity. *,/?<0.05. 
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Figure 4.20 Validation of interaction between miR-137 and predicted binding 
sites in 3'UTR of CSEIL and ERBB4 by dual-luciferase reporter assay. A. � 
miR-137 and predicted binding sequences in CSEIL and ERBB4 3'UTR. 
Mutated binding sites (underlined) were designed corresponding to the miR-137 
seed region by site-directed mutagenesis. Vertical lines indicate Watson-Crick 
base pairing. B. Relative luminescence of LNZ308 cells following co-transfected 
with miR-137 or negative control miRNA along with wild type or mutated 
CSEIL or ERBB4 reporter constructs. *,/><0.001. 
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4.4.3 Expression of miR-137 candidate targets, CSEIL and ERBB4 
in glioma cells 
Having demonstrated that miR-137 interacted with the potential binding 
sites of CSEIL and ERBB4, we tried to investigate the involvement of CSEIL ‘ 
and ERBB4 by detecting their mRNA expression levels in 10 glioma cell lines 
firstly by qRT-PCR analysis. 
Our previous data in section 4.1.1 has revealed a common deregulation of 
miR-137 in all 10 glioma cell lines. In the same series of cell lines, 8 out of 10 
showed elevated CSEIL mRNA expression by 2- to 5.4-fold compared to normal 
brain samples (Figure 4.21 A). In contrast, ERBB4 displayed a markedly low 
transcript level by 6.5- to 2521-fold in all 10 cell lines below normal samples 
(Figure 4.2IB). Hence, it seems that as a potential miR-137 target, overexpressed 
CSEIL was observed when miR-137 was found down-regulated. In addition, we 
note that according to TargetScan and PicTar, which allow prediction of 
miRNAs that may target given gene, miR-137 is the only miRNA that may 
regulate CSEIL. Taken together, miR-137 was probably an important regulator 
of CSEIL in glioma. Therefore, we focused on validation of CSEIL as a 
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4.4.4 Effects of miR-137 on CSEIL transcript and protein levels 
Above results in section 4.4 strongly suggested CSEIL as a potential target 
of miR-137 in glioma. To further validate this and also investigate whether 
miR-137 exert its functions by inducing CSEIL transcript degradation or “ 
suppressing CSEIL translation, the mRNA and protein expression levels of 
CSEIL were measured in glioma cell lines following forced miR-137 
expression. 
Trasfection of miR-137 into LNZ308 glioblastoma and GOS-3 OT cells did 
not result in significant alteration of CSEIL transcript levels relative to negative 
control miRNA at 48 hours post-transfection (Figure 4.22A). However, at 
protein level, endogenous CSEIL in miR-137 transfected glioma cells was 
dramatically reduced when compared to those transfected with negative control 
miRNA in all 3 OT and 4 glioblastoma cell lines tested by western blot analysis 
at the same time point (Figure 4.22B). The observations suggested that miR-137 
inhibited CSEIL expression at translational, but not transcriptional level. 
Taken the luciferase reporter assay results into account, the evidence 
supported that miR-137 directly interacted with 3'UTR of CSEIL, leading to the 
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Figure 4.22 Alteration of CSEIL mRNA and protein expression in glioma cells 
following enhanced miR-137 transfection. A, CSEIL mRNA was quantified by 
qRT-PCR normalized to GAPDH. Transfection of miR-137 did not affect 
CSEIL mRNA transcript levels at 48 hours relative to cells transfected with 
negative control miRNA. B，CSEIL protein expression was markedly reduced as 
determined by western blot in response to miR-137 transfection. 
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4.5 Expression of CSEIL in OTs 
4.5.1 CSEIL expression in OTs by qRT-PCR and IHC 
Since CSEIL showed significant overexpression in glioma cell lines, this 
suggested an involvement of CSEIL in gliomagenesis. To determine CSEIL 
expression in OTs in vivo, the mRNA and protein levels in our cohort of 36 OTs 
were examined by qRT-PCR and IHC approaches, respectively. 
At mRNA level, CSEIL expression in 36 OT patient tissues and 3 normal 
brain samples was normalized by the expression of GAPDH in each sample. The 
overall distribution of CSEIL expression in the 20 ODs, 16 OAs and 10 glioma 
cell lines relative to 3 normal brain samples were shown in Figure 4.23 and 
Table 4.11. CSEIL was overexpressed more than 2-fold in 6 out of 20 (30%) OD 
and 12 of 16 (75%) OA cases, up to 3.3- and 12.7-fold, respectively. In glioma 
cell lines, 8 of 10 cell lines showed CSEIL overexpression by 2- to 5.4-fold. 
Statistical analysis showed that the CSEIL mRNA expressions was significantly ‘ 
higher in both ODs and OAs (p=0.039 and p=0.006, respectively), as well as in 
glioma cell lines (p=0.014). 
On the other hand, CSEIL protein expression levels in 35 OTs and 13 
non-tumorous brain tissues were assessed by IHC. Nucleus staining of CSEIL 
was observed in both tumor and non-neoplastic tissues. In non-tumorous tissues, 
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positive staining of CSEIL of neurons and glial cells was observed in both 
cortex and white matter areas. Neurons displayed a strong staining intensity, 
whereas surrounding glial cells showed negative or weak IHC activity (Figure 
4.24). The differential staining intensity was described as negative, weak, 
moderate or strong in scoring (Figure 4.25). 
Representative CSEIL staining pictures in non-tumorous brain tissue and 
OTs are showed in Figure 4.26. Take both percentage of positive staining cells 
and the intensity of staining into accounts, CSEIL expression was scored as 
negative, low, medium or high expression. Table 4.12 summerized the 
comparison of CSEIL expression distribution between non-tumorous brain 
tissues and subtypes of OT. Among the 13 non-neoplastic tissues, 11 (84.6%) 
.� showed negative�low CSEIL expression and only 2 (15.4%) cases showed 
medium expression. No case was defined as high expression. For the 35 tumor 
tissues, 6 of them (17.1%) displayed low CSEIL expression, 13 (37.1%) and 16 
cases (45.7%) showed medium and high expression of CSEIL, respectively. ‘ 
Chi-square analysis revealed a significant higher expression of CSEIL in OTs 
relative to non-tumorous tissues (p<0.001). This was also found in each 
histological subtype. These results suggest overexpression of CSEIL in OTs at 
• 
both mRNA and protein levels, implicating its involvement in human 
gliomagenesis. 
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Table 4.11 Summary of CSEIL mRNA and protein expression in 36 OTs. 
“ CSEIL m R N A “ Case . 1 Age • CSEIL protein , Diagnosis Sex , � expression (fold . 3 number (years) , �2 expression change) 
HS380 OD M 35 ^ h i ^ 
HS467 OD F 56 1.16 high 
HS466 OD F 40 1.18 high � 
HS460 OD M 29 1.32 high 
HS324 OD M 42 1.52 low 
HS378 OD F 38 1.63 low 
HS390 OD M 10 1.75 medium 
HS400 OD F 49 1.98 medium 
HS329 OD F 69 2.30 high 
HS332 OD M 53 2.47 medium 
HS469 OD F 36 2.65 high 
HS331 OD F 46 2.92 _ high 
HS303 OD M 48 3.26 low 
HS314 OA F 38 1.37 medium 
HS394 OA F 31 1.89 low 
HS462 OA M 39 2.66 medium 
HS381 OA F 28 3.19 high 
HS301 OA M 43 3.74 medium 
HS382 OA F 37 4.18 low 
HS362 OA M 41 4.36 N/A'* 
HS375 OA M 28 4.92 high 
HS399 OA M 34 5.72 high 
HS384 OA M 30 6.45 high 
HS458 OA M 37 6.80 medium 
HS393 OA F 49 8.39 medium , 
HS368 OA F 61 12.70 medium ‘ 
HS333 AOD F 43 0.31 low 
HS461 AOD M 53 1.15 medium 
HS360 AOD M 51 1.30 medium 
HS377 AOD M 77 1.42 medium 
HS312 AOD M 53 1.52 high 
HS302 AOD M 35 1.87 high 
HS358 AOD F 50 2.54 medium 
HS457 AOA M 52 1.35 high 
HS366 AOA M 35 1.72 high 
HS364 AOA F 48 ^ high 
1 OD, oligodendroglioma; OA, oligoastrocytoma; AOD, anaplastic 
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oligodendroglioma; AO A, anaplastic oligoastrocytoma. 
2 CSEIL expression fold change relative to 3 normal brain RNA samples was 
determined by qRT-PCR. 
3 CSEIL protein expression based on IRS by IHC. 
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Figure 4.23 mRNA expression levels of CSEIL in OTs and glioma cell lines. 
Both primary OTs [20 oligodendrogliomas (ODs) and 16 oligoastrocytomas 
(OAs)] and 10 glioma cell lines showed significant CSEIL overexpression than 
3 normal brain samples by qRT-PCR. CSEIL mRNA levels were significantly 
higher in OAs than in OTs. 
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Figure 4.24 Representative CSEIL staining in non-neoplastic brain tissue by 
mC. Positive staining was observed in both cortex (A) and white matter (B) 
areas. Neuron (arrow) and glial cell (arrowhead) showed nuclear CSEIL 
expression. Photos were taken under microscopic view of 400x magnification. 
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Figure 4.25 CSEIL staining in OT tissues by IHC. Differential CSEIL staining 
intensity was described as negative (A, HS378), weak (B, HS458), moderate (C, 
HS384) or strong (D, HS460). Photos were taken under microscopic view of 
400x magnification. 
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Figure 4.26 Comparison of CSEIL and Ki-67 expression in OTs and 
non-tumorous tissue by IHC. 
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Table 4.12 CSEIL protein expression in 20 ODs and 15 OAs compared to that 
in 13 non-tumorous brain samples by IHC. Both ODs and OAs showed 
significant higher CSEIL expression, as well as each subtype. 
N CSEII^ expression by IHC chi-square ^ 
negative low medium high p-value 
Non-tumorous tissue 13 7 4 2 0 
OT 35 0 6 13 16 <0.001 
OD 20 0 4 7 9 <0.001 
OD，grade II 13 0 3 3 7 <0.001 
OD, grade III 7 0 1 4 2 <0.001 
OA 15 0 2 6 7 <0.001 
OA, grade II 12 0 2 6 4 <0.001 
OA, grade III 3 0 0 0 3 <0.001 
s 
164 
4.5.2 Correlation of CSEIL expression with clinicopathological 
features 
To identify the clinical significance of CSEIL, the relationships between 
CSEIL expression level and clinicopathological characteristics of the 36 OT 
patients were investigated. As summarized in Table 4.13, CSEIL mRNA levels 
in 16 OAs were significant higher than those in 20 ODs (p=0.007, Figure 4.23). 
However, protein expression was not significantly different between these 2 
histological subtypes (p=0.867). As summarized in Table 4.13, there is no 
significant correlation between CSEIL overexpression and tumor grade, patient 
sex, lp/19q status, miR-137 down-regulation or Ki-67 expression (p>0.05). 
Although CSEIL acted as a miR-137 target in glioma, the abundance of CSEIL 
mRNA or protein showed no significant correlation was miR-137 level in OTs 
(p=0.326 and p=0.300, respectively). 
To study the association of CSEIL expression and prognosis, survival , 
analysis was performed. There was no significant relationship between CSEIL 
mRNA expression and patient overall survival (p=0.516) or progression-free 
survival (p=0.355). When patients were grouped by CSEIL protein expression of 
negative-low or medium�high，no significant difference in overall survival 
(p=0.346) or progression-free survival (p=0.310) was found (Figure 4.27). 
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Table 4.13 Association analysis of CSEIL expression with clinicopathological 
parameters, lp/19q status, miR-137 down-regulation and Ki-67 expression in 36 
OTs. 
CSEIL expression 
mRNA “ ！ 
, . D protein expression n 
upregulation ^ , 
value T value 
<2-fold >2-fold negative low medium high 
Tumor type 
OD 14 6 0.006 0 4 7 9 0.867 
OA 4 12 0 2 6 7 
WHO grade 
grade II 10 16 0.060 0 5 9 11 0.777 
grade III 8 2 0 1 4 5 
Gender 
male 11 9 0.502 0 2 8 9 0.506 
female 7 9 0 4 5 7 
Age 
<50 12 14 0.457 0 6 7 12 0.107 
>=50 6 4 0 0 6 4 
Ip status 
loss 7 11 0.182 0 3 7 8 0.976 
intact 11 7 0 3 6 8 
19q status 
loss 7 10 0.317 0 3 7 7 0.861 
intact 11 8 0 3 6 9 
lp/19q 
co-deletion ‘ 
yes 7 10 0.317 0 3 7 7 0.861 
no 11 8 0 3 6 9 
miR-137 
down-regulation 
<2-fold 1 2 1.000 0 0 0 3 0.143 
>2-fold 17 16 0 6 13 13 
Ki-67 LI 
<3% 6 11 0.063 0 2 5 10 0.312 
>3% 12 6 0 4 8 6 ‘ 
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Figure 4.27 Kaplan-Meier overall (left panel) and progression-free (right panel) 
survival curves with log-rank test for 19 OT patients with low and high CSEIL 
mRNA (upper) or protein (bottom) expression. 
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4.6 Effects of CSEIL knockdown in glioma cells 
Given that CSEIL showed overexpression in glioma cells and was a direct 
target of miR-137, the function of CSEIL in development of gliomas was 
examined. To further determine the functional role of CSEIL in gliomagenesis “ 
and whether CSEIL contribute to our previously demonstrated effects of 
miR-137, the effect of CSEIL knockdown on glioma cell proliferation, 
anchorage-independent growth, apoptosis and motility were evaluated. 
Here，two specific siRNAs against CSEIL mRNA were used. As shown in 
Figure 4.28, both siRNAs dramatically reduced the protein level of CSEIL at 24 
and 48 hours post-transfection. 
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Figure 4.28 siRNA-mediated knockdown effect of CSEIL. Efficient 
knockdown of CSEIL was observed at 24 and 48 hours after glioma cells 
transfected with either siCSEIL as compared to negative control siRNA. 
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4.6.1 Cell growth 
4.6.1.1 Cell viability 
Effect of CSEIL knockdown on cell viability in 1 oligodendroglioma cell 
V 
and 3 glioblastoma cell lines was assessed by MTT assay at 24, 48, 72 and 96 
hours after cells were transfected with siCSElL，siNegative or lipofectamine 
control. Results showed that knockdown of CSEIL led to significant decrease of 
cell viability compared to siNegative since 72 hours post-transfection in all 4 cell 
lines studied (p<0.05, Table 4.14 and Figure 4.29). Most significant inhibitory 
effect was observed at 96 hours, ranging from 32% to 44% for siCSElL-1 and 
from 19% to 34% for siCSElL-2, respectively. 
% 
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Table 4.14 Effect of CSEIL knockdown on cell viability in 4 glioma cell lines 
relative to negative control siRNA. 
Cell viability 
Time after siCSElL-1 siCSElL-2 � 
Cell line transfection % of % of 
(hours) negative ^ negative p value 
control control 
^ 9 5 . 6 % 0 . 2 1 7 94.1% 0.147 
48 94.8% 0.356 93.4% 0.242 
72 80.1% 0.010 82.8% 0.013 
96 63.2% <0.001 80.9% 0.001 
S 9 9 . 8 % O T O 1 0 1 . 7 % 0.873 
48 91.2% 0.349 96.6% 0:754 
72 80.0% <0.001 83.8% 0.028 
96 56.2% 0.001 66.1% 0.002 
S 9 4 . 1 % 0 J 5 3 1 0 0 . 2 % 0.963 
48 87.6% 0.561 91.6% 0.277 
72 74.9% 0.002 74.8% 0.032 
96 66.9% <0.001 69.2% 0.001 
^ 9 6 . 4 % 0 . 2 7 6 1 0 1 . 1 % 0.723 
48 93.2% 0.105 90.3% 0.136 
72 79.4% <0.001 85.6% 0.018 
96 67.6% <0.001 68.9% <0.001 
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Figure 4.29 Effect of CSEIL knockdown on cell viability in 4 glioma cell lines. 
s 
Metabolic activity of 4 glioma cell lines were measured by MTT assay 24-96 
hours after transfected with siCSElL-1 or -2, negative control siRNA or 
lipofectamine treatment. The points showed means±SD from 3 independent 
experiments performed in triplicate. Cell viability was significantly reduced upon 
knockdown of CSEIL in all cell lines at 72 and 96 hours. 
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4.6.1.2 Cell number 
Alteration of glioma cell growth following siCSElL or siNegative 
transfection was also evaluated by cell counting at same time points as MTT 
assay. As shown in Table 4.15 and Figure 4.30，cell number in CSEIL 
knockdown cells was significant less than cells transfected with siNegative at 72 
and 96 hours (p<0.05). The suppression increased up to 27% to 49% for 
siCSElL-1 and from 26% to 43% for siCSElL-2 when compared to siNegative, 
respectively. This is in line with data from MTT assay, further confirming that 
CSEIL knockdown suppressed glioma cells growth. 
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Table 4.15 Effect of CSEIL knockdown on cell number in 4 glioma cell lines 
relative to negative control siRNA. 
Cell number 
Time after siCSElL-1 siCSElL-2 — � 
Cell line transfection ~ % of % of 
(hrs) negative p value negative p value 
control control 
24 98.9% 0.416 99.6% 0.564 
48 87.0% 0.149 93.3% 0.312 
72 75.3% 0.001 83.2% 0.033 
96 51.4% <0.001 61.3% <0.001 
^ 98.2% 0 . 8 6 4 1 0 5 . 8 % 0 . 1 8 0 
48 83.5% 0.063 89.1% 0'.091 
72 80.9% 0.004 84.9% 0.012 
96 59.0% <0.001 65.4% <0.001 
S 90.2% 90.0% 0.404 
U87MC} 48 76.8% 0.068 83.7% 0.081 
72 74.2% <0.001 76.2% <0.001 
96 73.0% <0.001 74.2% <0.001 
S 97.9% 0T45 98.7% 0.901 
48 93.5% 0.211 94.8% 0.524 
U373MG 
72 87.0% 0.041 87.0% 0.046 
96 60.9% <0.001 57.5% <0.001 
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Figure 4.30 Effect of CSEIL knockdown on cell growth in 4 glioma cell lines. 
By cell count, growth curves indicated viable glioma cells transfected with 
siCSElL, siRNA negative control or lipofectamine only at 24 to 96 hours. All 
lines showed suppression of cell growth upon miR-137 forced expression. The 
points showed means 土 SD from 3 independent experiments performed in 
triplicate. 
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4.6.1.3 Cell cycle analysis 
To further elucidate the mechanism underlying cell growth inhibition by 
CSEIL knockdown, change of DNA synthesis during cell cycle progression was 
assessed by BrdU incorporation activity. ‘ � 
As shown in Table 4.16 and Figure 4.31，the BrdU incorporation activity 
significantly reduced in CSEIL knockdown TC620 and A172 cells compared 
with negative control since 48 hours post-transfection (p<0.05). Significant 
effect was observed in U87MG and U373MG cells started from 72 hours 
(p<0.05). DNA synthesis was decreased up to 45%~63% at 96 hours. These 
results indicated that CSEIL knockdown could inhibit glioma cell proliferation 
through suppression of DNA synthesis. 
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Table 4.16 Effect of CSEIL knockdown on DNA synthesis in 4 glioma cell 
lines relative to negative control siRNA by BrdU incorporation assay. 
Time after siCSEIL 
Cell line transfection , % of negative 
(hours) control 
^ 102.4% 0.626 
TC620 48 74.40/0 0.020 
72 57.8% <0.001 
96 49.5% <0,001 
S 82.9% O ^ 
48 80.5% 0.008 
72 64.2% 0.006 
96 37.5% <0.001 
S 92.7% 0 . 0 8 8 ^ 
U87MG 48 88.90/0 0.176 
72 84.6% 0.029 
96 55.5% <0.001 
^ 104.0% 0 . 7 6 8 ^ 
U373MG 48 104.5o/o 0.166 
72 88.3% 0.024 
96 49.2% 0.001 
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Figure 4.31 Effect of CSEIL knockdown on DNA synthesis in 4 glioma cell 
lines, By BrdU incorporation assay, the relative BrdU incorporation at 24 to 96 
hours after transfection were assessed. All cell lines show suppression of cell 
proliferation following siCSElL transfection compared to siNegative. The points 
showed means 士 SD from 3 independent experiments performed in triplicate. *, 
p<0.05 between siCSElL and siNegative transfected group by student's t test. 
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4.6.2 Anchorage-independent cell growth 
To study whether the transforming potential of TC620, A172 and U87MG 
cells could be affected by CSEIL, anchorage-independent soft agar assay was 
performed in siCSElL or siNegative transfected cells. After growing in soft agar ‘ 
for 3 weeks, the numbers of colonies formed in siCSElL transfected cells were 
significantly lower than those of cells transfected with siNegative (p<0.001, 
Figure 4.32). The number of colonies decreased to 31.7% and 31.1% inTC620 
cell, 42.0% and 39.3% in A172 cell, 34.3% and 39.7% in U87MG.cell of those 
in siNegative transfected cells for siCSElL-1 and -2, respectively. This result 
suggested that CSEIL knockdown reduce the anchorage-independent cell growth 
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Figure 4.32 Effect of CSEIL knockdown on number of colonies formed in 3 
glioma cell lines. In TC620 (A), A172 (B) and U87MG (C) glioma cells 
transfected with siCSElL，negative control siRNA or mock. Colonies with sizes 
of greater than 100 were counted. CSEIL knockdown showed a significant 
reduction in numbers of colonies in all 3 cell lines when compared to the 
negative controls. Results represent the average of three independent 
experiments. *，p<0.001. 
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4.6.3 Cell apoptosis 
To identify whether CSEIL was involved in glioma cell apoptosis, cleaved 
PARP, was examined by western blot in glioma cells following transfected with 
siCSEIL compared to negative control'siRNA. The protein level of cleaved � 
PARP elevated in all 4 cells at both 48 and 96 hours following CSEIL 
knockdown. The enhancement of cleaved PARP was similar between 48 and 96 
hours. However, a further induction was observed for siCSElL-2 treatment in 
TC620 cells at 96 hours (Figure 4.33). The results indicated .that CSEIL 
knockdown led to cellular apoptosis in glioma cells, which also contributed to 
suppression of cell growth. 
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Figure 4.33 Effect of CSEIL knockdown on cleaved PARP expression in 4 
glioma cell lines. Protein levels of cleaved PARP were remarkably up-regulated 
following CSEIL knockdown compared to negative control siRNA in 4 glioma 
cells. GAPDH was included as loading control. 
« • 
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4.6.4 Cell motility 
We next investigated the effect of siCSElL on the migration and invasion of 
glioma cells. Results from wound healing assay showed that A172 cells 
exhibited a significant reduction in migration rate at both 16 and 32 hours after ‘ 
CSEIL knockdown as compared with the siNegative control (p<0.05, Figure 
4.34). Notably, the wound almost closed at 32 hours in siNegative transfected 
A172 cells. There was 29.1% of wound left in CSEIL knockdown A172 cells, 
suggesting an involvement of CSEIL in glioblastoma cell migration. 
Moreover, cell invasive ability in response to FBS enriched medium was 
quantified by matrigel invasion assay. Results demonstrated that number of 
invaded glioma cell was significantly decreased by 15%�40% and 20%~69% in 
all glioma cell lines examined following CSEIL silencing by 2 siCSElL 
transfection, respectively (Table 4.17 and Figure 4.35). This indicated that 
glioma cell invasion through extracellular matrix was impaired by CSEIL 
knockdown. Together, these results supported that CSEIL inactivated glioma 
cells have reduced ability of both migration and invasion. 
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Figure 4.34 Effect of CSEIL knockdown on A172 GBM cell migration. In 
wound healing assay, wound was induced using a yellow pipette tip on the full 
confluent monolayer A172 cells transfected with CSEIL siRNA or negative 
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control siRNA. A. The rate of wound closure was monitored at different time 
points afterwards. Representative photos were taken under 40x magnifications. 
Lines indicated the differential migration rate of cells. B. The migration rate was 
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Figure 4.35 Effect of CSEIL knockdown on cell invasion in 4 glioma cell lines. 
The invasive ability of 4 glioma cell lines after transfection with siCSElL or 
negative control siRNA were assessed by matrigel invasion assay. Cells invaded 
to the lower surface of matrigel-coated wells were counted 16 hours after plating. 
A. Invaded cells were stained and observed under microscope at 40x 
magnification. B. Significant fewer cells were able to invade after transfected 
with siCSElL than negative control siRNA transfectants. *, p<0.05. 
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CHAPTER 5 DISCUSSION 
5.1 Expression of miR-137 transcript level in OTs and glioma cell 
lines 
.Allelic loss of chromosome Ip is characterized as a major hallmark of OTs, � 
suggesting the existence of tumor suppressive gene(s) or miRNA(s) involved in 
development of OT. Among all 38 miRNAs residing on chromosome Ip, miR-137 
was found downregulated in WHO grade I-IV astrocytomas (Godlewski et al, 2008; 
Silber et al, 2008; Zhi et al” 2010). Functionally, expression of miR-137 inhibited 
proliferation of GBM cells and induced neuronal-like differentiation in mouse neural 
stem cells and tumor stem cells derived from mouse OT and human GBM (Silber et 
al, 2008). Therefore, we focused on this miRNA to investigate its role in 
pathogenesis of OT and GBM. 
In the current study, it was demonstrated for the first time a significantly 
reduced miR-137 transcript level in 34 out of 36 (94%) OTs examined with a median 
of 9.3-fold reduction compared with normal brain samples. Similarly, in cultured OT 
and GBM cells, notable decrease in miR-137 expression was observed in all 10 cell 
lines studied. In line with my findings, remarkable downregulation of miR-137 has 
been earlier uncovered in astrocytoma of all WHO grades as compared to normal or 
non-tumor brain tissues (Godlewski et al, 2008; Silber et al, 2008; Zhi et al, 2010). 
Therefore, miR-137 downregulation is common in both astrocytic and 
oligodendroglial tumors. Moreover, the preferential expression of miR-137 in brain 
(Sempere et al, 2004; Beuvink et al, 2007; Landgraf al, 2007; Liang et al, 2007) 
also emphasizes the importance of miR-137 in glioma pathogenesis. 
190 
Downregulation of miR-137 is not limited to glioma. It has also been involved 
in other cancer types, such as neuroblastoma (Chen et al, 2007), colorectal cancer 
(Bandres et al, 2006; Balaguer et al, 2010)，oral squamous cell carcinoma (Kozaki 
et al, 2008), lung adenocarcinoma (Dacic et al, 2010) and uveal melanoma (Chen et 
al, 2010). In combination with these findings, it is reinforced that miR-137 may be 
involved in cancer development including glioma. 
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5.2 Association of miR-137 expression with OT clinical and 
molecular parameters 
To evaluate the clinical significance of miR-137 in OTs, association analysis 
was performed to correlate miR-137 expression level to clinicopathological 
information, including sex, age, tumor subtype, tumor grade as well as Ip status and � 
Ki-67 LI. 
Here, the abundance of miR-137 transcript was found dramatically lower in 10 
WHO grade III OTs than those of 26 OTs diagnosed as WHO grade II (p=0.010), 
suggesting that inactivation of miR-137 may contribute to progression of OT. This 
association was concordant with study showing more pronounced miR-137 
repression in 76 high-grade astrocytomas than those of 48 low-grade astrocytomas 
(Zhi et al, 2010). Thus, reduction of miR-137 may play a role in both development 
and progression of gliomas. 
On the other hand, high-grade OTs displayed a higher Ki-67 labeling index than 
those of low-grade in our study (p=0.014). Ki-67 is a nuclear antigen expressed in all 
phases during the cell cycle except the Go phase and widely used as a proliferative 
marker in FFPE samples using IHC (Gerdes et al, 1983; Gerdes et al, 1984). High ， 
mitotic activity is one of the features of anaplastic OT (Reifenberger et al, 2007). 
The survival analysis demonstrated a prognostic role of Ki-67 in OTs, which is in 
parallel with previous reports (Heegaard et al, 1995; .Kayaselcuk et al, 2002; Kuo et 
aL, 2009). 
It is notable that association analysis uncovered a novel relationship that miR-
137 expression level was inversely correlated with Ki-67 immunoreactivity (p=0.009) 
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in the 35 OT cases. It was further illustrated by the significantly different miR-137 
expression of two groups based on Ki-67 LI of less or greater than 3% (p=0.002). 
This is the first study showing an inverse correlation between miR-137 levels to 
proliferative activity in primary tumor, providing a high possibility that miR-137 
involvement in OT cell proliferation. 
In the current study, the chromosomes Ip and 19q statuses in OTs were 
determined by FISH analysis. The probe specifically bind to lp36.3 and 19ql3 
region respectively, which represent the minimally deleted region (Husemann et al, 
1999; Smith et al., 1999; Smith et al, 2000; Dong et al, 2004). Furthermore, the 
allelic loss mostly affect the entire lp/19q arm (Felsberg et al, 2004; Barbashina et 
al, 2005)，probably due to the unbalanced translocation involving chromosomes 1 
and 19 (Griffin et al, 2006; Jenkins et al, 2006). Hence, it is believed that 
examinination of one loci in each chromosome arm region in FFPE section by FISH 
is a reliable method to investigate the status of Ip and 19q arm in glioma. According 
to our comparison of miR-137 levels in OTs with or without LOH Ip, despite 
located on chromosome Ip, reduction of miR-137 did not show a correlation with Ip 
loss in OTs. For other clinical characteristics, sex, age or tumor subtype seems do 
not associate with miR-137 expression. These data suggest that deregulation of miR-
137 may be a frequent event in OTs of all sex，age and histological groups. 
. 會 
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5.3 Prognostic significance of clinical features and miR-137 
expression in OTs 
By Kaplan-Miere survival analysis, favorable prognosis of the 19 OT patients in 
our study is statistically associated with younger patient age and low tumor grade at 
the time of diagnosis. In line with the results, such correlation has been reported in 
earlier population-based investigations (Okamoto et al, 2004; Ohgaki et al, 2005; 
Reifenberger et al, 2007). 
Investigations have indicated that lp/19q codeletion is a prognostic marker for 
OT patients including clinical trials involving hundreds of cases (Caimcross et al, 
1998; Bauman et al, 2000; Ino et al, 2001; Caimcross et al, 2006; Jenkins et al, 
2006; Kanner et al, 2006; van den Bent et al, 2006; van den Bent et al, 2007). 
However, in our panel of 19 OT patients (14 WHO grade II and 5 WHO grade III) 
whose follow-up data were available, the overall or progression-free survival time 
was not statistically different between lp/19q loss and intact groups. I did not look 
into survival data in only grade II or grade III OTs, due to the small sample size 
(Capelle et al, 2009; Kuo et al, 2009). 
In this study, a Ki-67 LI of more than 3% was associated with shorter overall ‘ 
(p=0.049) and progression-free survival (p=0.017), which is consistent with previous 
studies (Heegaard et al, 1995; Kros et al, 1996; Coons et al, 1997; Dehghani et al, 
1998; Kuo etal, 2009). 
For clinical relevance of miR-137, a trend was observed between longer overall 
and progression-free survival in miR-137 high-expressed OT patients (p=0.215 and 
；7=0.103，respectively). The result is in accordance with the observation that miR-
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5.4 Inactivation mechanisms of miR-137 in glioma 
As miR-137 resides within a highly unstable chromosome arm in glioma (Bello 
et al, 1995; Bigner et al, 1999; Husemann et al, 1999; Smith et al, 1999; Ohgaki 
et al, 2009) and promoter hypermethylation results in silencing of miR-137 in 
various cancers (Kozaki et al, 2008; Silber et al, 2008; Ando et al, 2009; Bandres � 
et al, 2009; Balaguer et al, 2010; Chen et al, 2010; Langevin et al, 2010), I sought 
whether chromosome Ip deletion or epigenetic regulation was responsible for miR-
137 down-regulation in OTs and GBM cells. 
In comparison with normal brain samples, the resulted showed miR-137 was 
downregulated in OT patients with intact chromosome Ip as well as Ip loss, 
indicating there are other mechanisms repressing miR-137 expression in OTs. 
To investigate whether epigenetics played a role in modulating miR-137 
expression, miR-137 level in OT and GBM cells was quantified following treatment 
of demethylating agent, 5-aza-dC and/or histone deacetylase inhibitor, TSA. A 
restoration of miR-137 level was observed in a dose-dependent manner in cultured 
TC620 oligodendroglioma cells when treated with 5-aza-dC of different 
concentrations. The elevation reached approximately 10-fold. Subsequent histone ‘ 
deacetylase inhibitor TSA treatment induced a further enhancement of miR-137 up 
to nearly 20-fold as compared to parental untreated cells. These indicated the control 
of miR-137 by synergetic DNA hypermethylation and histone deacetylation. 
From the above 2 aspects, miR-137 downregulation in OTs with LOH Ip may 
result from both Ip loss and epigenetic modulation including DNA hypermethylation 
and histone deacetylation. For OTs with intact Ip, miR-137 might be inactivated by 
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epigenetic aberration. 
Promoter hypermethylation controlled miR-137 expression was uncovered in 
other tumors, such as gastric (Ando et al, 2009), colorectal (Bandres et al, 2009; 
Balaguer et al, 2010) and oral squamous cell carcinoma (Kozaki et al, 2008; 
Langevin et al, 2010). Nonetheless, whether the mechanisms in glioma directly ’ 
involve miR-137 promoter region or through indirect regulation requires further 
investigation. 
In the 2 GBM cell lines examined, miR-137 expression was 15-fold and 60-fold 
below normal level in A172 and U373MG cells, respectively. Neither 5-aza-dC (or 
TSA) nor combined treatment altered miR-137 expression in both cell lines. Earlier 
investigation revealed 3�12-fold increased miR-137 expression in U87 and U251 
GBM cells following similar treatment (Silber et al, 2008). Therefore, epigenetic 
repression of miR-137 may occur in some of GBMs, and the underlying molecular 
mechanism remains unclear. 
« 
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5.5 Biological effects of miR-137 overexpression in glioma cells 
Having demonstrated that miR-137 deregulation was frequent and associated 
with tumor progression and proliferative activity in OTs, it was subsequently 
questioned whether miR-137 played a role in gliomagenesis. 
In the present study, delivery of miR-137 into miR-137-deficient OT and GBM 
cells inhibited cell growth as evaluated by cell number and metabolic activity. The 
results of the 2 assays were in well agreement. The suppressive effect is also 
significant when cells grew in soft agar. Hence, we have proved that miR-137 
inhibited glioma cell growth under both anchorage-dependent and -independent 
conditions. 
Three possible cellular processes responsible for the growth inhibition affected 
by miR-137 were thereafter investigated. First, miR-137 suppressed DNA synthesis 
and induced GO/Gl cell cycle arrest in OT and GBM cells. In agreement with this, 
inhibited cell proliferation by miR-137 has been observed in several tumors, such as 
GBM (Silber et al, 2008)，colorectal cancer (Balaguer et al, 2010; Liu et al, 2010)， 
oral squamous cell carcinoma (Kozaki et al, 2008) and uveal melanoma (Chen et al, 
2010). Second, miR-137 induced programmed cell death as indicated by markedly ‘ 
elevated cleaved PARP levels in all glioma cell lines examined, which was a novel 
effect for miR-137 in human tumors. Above elucidation suggested that miR-137 
exerted the cell growth suppressive effect in OT cell via cell cycle arrest and 
apoptosis. 
The infiltrating property is a hallmark of diffuse gliomas, which make wholly 
surgical resection difficult and lead to high recurrence of this malignancy. In our • 
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functional study, miR-137 affected migrating and invasive ability of glioma cells by 
monolayer cell wound healing assay and matrigel chamber invasion assay, which 
was demonstrated in colorectal cancer cells as well (Liu et al, 2010). 
Moreover, miR-137 may induce neuronal-like differentiation as indicated by 
notably increased expression of neuronal marker Tujl in U87MG and U373MG " 
GBM cells, although no neuronal morphological alteration observed meanwhile. The 
expression of astrocytic marker, GFAP was not induced in both GFAP+ (U373MG) 
and GFAP- (A 172, U87MG and TC620) cell lines. This result was supported by 
previous reports revealing neuronal differentiation promoting effect of miR-137 in 
glioma TSCs’ NSCs (Silber et al, 2008) as well as ESCs (Tarantino et al, 2010). 
Taken together, our data indicated that high tumor grade and proliferative 
activity in primary OT were associated with deregulation of miR-137 and miR-137 
inhibited malignant behaviors in glioma. 
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5.6 CSEIL is a novel miR-137 target in glioma 
MiRNAs execute diverse functional roles via post-transcriptional silencing of 
gene targets by interacting with 3'UTR of target transcript. Thus it is crucial to 
identify miRNA downstream targets for our understanding miRNA-mediated 
regulation. With respect to miR-137 targets, several targets has been reported in � 
various normal and malignant cell types (Bemis et al, 2008; Kozaki et al, 2008; 
Silber et al, 2008; Chen et al, 2010; Liu et al, 2010; Smrt et a!., 2010; Szulwach et 
al, 2010; Tarantino et al, 2010). Given that mammalian miRNA can have multiple 
targets (Lewis et al, 2005; Lim et al, 2005)，I subsequently sought to identify novel 
miR-137 target gene(s) which is implicated in pathogenesis of glioma. In this study, 
CSEIL is established as a novel miR-137 target in glioma by integrated strategies 
constituting bioinformatic prediction and experimental validation. 
Since mammalian miRNA exerts gene silencing via partial complementary with 
3'UTR region of target mRNAs, the basic step in our screening is in silico prediction 
by 4 bioinformatic algorithms, miRanda (Enright et aL, 2003; John et al” 2004), 
PicTar (Grun et al,, 2005; Krek et al, 2005) and TargetScan (Lewis et al, 2003; 
Lewis et aL, 2005) and microCosm (Griffiths-Jones et al, 2006). As different , 
criteria are covered in each of these programmes (Table 3.6)，potential targets 
predicted by more algorithms may have higher chance to be true targets. 
Here, CSEIL is predicted by all 4 programmes utilized. The putative miR-137 
binding sites perfectly match the first 8 nucleotides at the 5'end of miR-137, 
covering the seed region (the 出 nuleotides) which is essential for. miRNA target 
recognition (Bartel 2004; Lewis et al, 2005; Bartel 2009). The thermodynamic 
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stability of the miRNAimRNA hybrid is demonstrated by the free energy of -14.8 
kcal/mol. In addition, the MRE region in the 3'UTR of CSEIL is conserved across 
different species including human, chimp, mouse, rat and dogs. These results suggest 
that CSEIL is a candidate target of miR-137 in glioma. 
‘Moreover, despite there are dozens 'of human miRNAs predicted to potentially � 
target CSEIL by all 4 bioinformatic algorithms, miR-137 is the only one hit with a 
broadly conserved MRE among vertebrates according to PicTar and TargetScan. 
MiR-137 also ranks the among the 19 miRNAs which may regulating CSEIL as 
assessed by miRanda score, suggesting miR-137 might be a regulator for CSEIL. 
Subsequent experimental validation, including dual-luciferase reporter assay, 
qRT-PCR and western blotting, have verified the suppression of CSEIL by miR-137 
through direct interaction between miR-137 and predicted MRE in CSEIL 3'UTR. 
We observed a significantly reduced abundance of CSEIL protein in all 3 OT and 4 
GBM cell lines after transfection with miR-137 mimic by western blot. Meanwhile, 
the CSEIL transcript level was not affected as determined by qRT-PCR analysis.. 
Hence, CSEIL was negatively regulated by miR-137 via translational inhibition 
rather than mRNA degradation in glioma cells. Moreover, dual-luciferase reporter , 
assay have confirmed this repression was mediated by the binding of miR-137 to the 
putative MRE in 3'UTR of CSEIL mRNA, where the base pairing at the seed region 
is essential for the interaction. Therefore, miR-137 directly suppressed CSEIL at 
translational level in glioma. 
. 身 
A previous study by Balaguer et al attempted to identify miR-137 targets in 
colorectal cancer and took CSEIL as a candidate as well. In contrast to our result, 
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CSEIL protein expression was not altered following ectopic miR-137 expression in 
colorectal cancer cells (Balaguer et al, 2010). This is probably due to human CSEIL 
transcript isoforms express in a tissue-specific manner (Brinkmann et al, 1999). The 
MRE of miR-137 lies only in CSEIL mRNA variants those harboring an extended 
3'UTR region. This isoform was found uniquely expressed in brain, spinal cord, 
peripheral nerves as well as fetal liver, but not in colon (Brinkmann et al, 1999). 
The tissue-specific expression pattern of CSEIL may give rise to the tissue-




5.7 Expression of CSEIL in glioma 
Having demonstrated the tumor suppressive role of miR-137 and its negatively 
control of CSEIL in glioma, we subsequently wondered whether CSEIL displayed a 
enhanced expression in our panel of OTs and furthermore whether there was an 
inverse correlation between miR-137 an4 CSEIL expression level. * 
CSEIL transcript expression was enhanced in 50% (18/36) of OTs up to 12.7-
fold elevation as compared to normal brain by qRT-PCR analysis. More than 2-fold 
overexpression of CSEIL mRNA was observed in 2 of 3 OT cells and 6 of 7 GBM 
cells. At protein level, IHC indicated a significant upregulation of CSEIL in the 
series of 36 OTs in comparison of 13 non-neoplastic brain tissues. Thus, CSEIL is 
overexpressed in OTs at both mRNA and protein levels. 
CSEIL is the human homologue of the yeast gene chromosome segregation 1 
(CSEl), which plays an essential role in the mitotic spindle checkpoint and therefore 
ensuring genomic stability during yeast cell division (Xiao et al, 1993; Brinkmann 
et al, 1995). Among normal human tissues, CSEIL preferentially expresses in testis 
and fetal liver, which contain lots of actively proliferating cells (Brinkmann et al, 
1995). Human CSEIL gene maps to chromosome 20ql3.13，a locus with frequent 
gains in gliomas, especially in astrocytomas of all grades (Weber et al, 1996; 
Nishizaki et al, 1998; Paunu et al, 2000; Weber et al, 2001; Koschny et al, 2002; 
Yakut et al, 2007). Of particular interest, high resolution-CGH studies have 
unveiled an increased CSEIL copy number in 57% (8/14) of GBM and cell lines 
(Hui et al, 2001), as well as during the progression of low-grade OTs (50%, 4/8) and 
astrocytomas (33%, 2/6) (Idbaih et al, 2008). Such chromosomal gain of CSEIL is 
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observed in a spectrum of other tumor types, such as medulloblastoma (Tong et al, 
2004), nasopharyngeal carcinoma (Hui et al, 2002)，prostate cancer (Bar-Shira et al, 
2002), cervical cancer (Narayan et al, 2010), primary cutaneous B-cell lymphoma 
(Mao et al, 2002), gastro-esophageal cancer (Rosenberg et al, 2002), leukemia, 
colorectal and breast cancers (Brinkmann et al, 1996). 
Apart from gene copy number gain, upregulation of CSEIL mRNA and protein 
products was documented in cancers of various origins, including hepatocellular 
carcinoma (Wellmann et al, 2001; Shiraki et al, 2006), colon cancer (Brinkmann et 
al, 1995; Seiden-Long et al, 2006)， lung cancer (Brinkmann et al, 1995), 
lymphoma (Brinkmann et al, 1995; Wellmann et al, 1997), melanoma (Boni et al, 
1999) and endometrial carcinoma (Peiro et al, 2001). In combination of our findings, 
it is suggested that CSEIL may play a role in carcinogenesis. 
The overexpression of CSEIL in glioma may attribute to several possible factors. 
In this study, CSEIL is identified negatively controlled by miR-137 in glioma. The 
results also demonstrated that among 33 OTs with a reduced miR-137 level and . 
available CSEIL protein expression, 87% (29/33) of cases displayed an elevated 
CSEIL protein level. This suggested that miR-137 was a key regulator of CSEIL in , 
OT. 
In addition, although the genomic status of CSEIL has not been described to 
date, one potential explanation is copy number gain, which has been extensively 
demonstrated in various tumors as mentioned above in this section. More 
significantly, Peiro et al. has uncovered a correlation between CSEIL upregulation 
and chromosome 20ql3 amplification in ovarian cancer (Peiro et al, 2002). In GBM, 
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gain of CSEIL gene is observed in 57% of GBMs (Hui et al, 2001), whereas we 
have shown an overexpression of CSEIL in 8 of 10 GBM cell lines. It is therefore 
suggested that copy number gain may result in the elevation of CSEIL transcript and 
protein in gliomas. 
• Another plausible molecular mechanism is elevation of CSEIL transcript and 
protein by hepatocyte growth factor (HGF) and its receptor MET signaling activation 
in colon cancer cells (Seiden-Long et al, 2006). The CSEIL transcript expression 
showed strong correlation with MET in 30 normal and 93 colorectal tumors, 
suggesting the transcriptional regulation of CSEIL by MET. Moreover, the protein 
abundance of CSEIL is also KRAS-dependent, which may explain the differential 
expression pattern of CSEIL mRNA and protein observed in vitro as well as in vivo 
(Seiden-Long et al, 2006). In concordance with our observation of CSEIL 
upregulation, HGF and proto-oncogene MET are highly expressed in glioma 
(Abounader et al, 2005), supporting the potential enhance of CSEIL by activated 
HGF/MET signaling in glioma. 
In addition, CSEIL may be regulated by other miRNAs besides miR-137, as the 
CSEIL 3'UTR region carries potential MREs for miR-19a, -19b, -23a, -23b, -128,- , 
182，-194，-203, -377 and -384 according to miRanda and microCosm. Whether 
these miRNAs contribute to modulation of CSEIL in glioma remains to be explored. 
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5.8 Intracellular distribution of CSEIL in OTs 
The IHC results clearly showed a nucleus staining of CSEIL in cells of OTs and 
non-neoplastic brain tissues. It differed from localization of CSEIL in cells of other 
tumors indicated by IHC. Cytoplasmic distribution of CSEIL is reported in 
hepatocellular carcinoma (Shiraki et al, 2006)，lymphoma (Wellmaiin et al, 1997), , 
melanoma (Boni et al, 1999) and endometrial carcinoma cells (Peiro et al, 2001). 
Two independent investigations revealed CSEIL IHC activity at nucleus and 
cytoplasm of ovarian cancer cells, respectively (Peiro et al, 2002; Brustmann 2004). 
In colon cancer, several studies indicated cytoplasmic CSEIL IHC staining (Tsao et 
al, 2009; Tung et al, 2009; Tsai et al, 2010)，while both nucleus and cytoplasmic 
CSEIL expression was described by another research group (Seiden-Long et al, 
2006). Particularly, Behrens et al discovered invasive breast cancers display a 
nuclear CSEIL expression pattern. In the contrary, benign lesions along with in situ 
carcinomas exhibited a predominately cytoplasmic CSEIL staining (Behrens et al, 
2001). More detailed characterization of the variable distribution of CSEIL came 
from Scherf et al. describing that CSEIL might be associated with microtubules in 
interphase cells while colocalized with the chromosome segregation spindle 
apparatus in mitotic cells by immunofluorescent staining in breast cancer cells ’ 
(Scherf a/., 1996). 
The molecular basis of the diversity in CSEIL intracellular expression pattern 
may attribute to a role of CSEIL as a nuclear transport factor, which is necessary for 
recycling importin-a from the nucleus to the cytoplasm (Kutay et al, 1997). Another 
study further elucidated that CSEIL intracellular distribution is determined by its 
phosphorylation via MAPK/ERK kinase 1 (MEK-1). Phosphorylated or „ 
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dephosphorylated CSEIL accumulates predominantly in the cytoplasm or in the 
nucleus, respectively (Scherf et al, 1998). It was speculated that the cytoplasmic 
microtubule-associated CSEIL may act as a reservoir of CSEIL protein, the nuclear 
CSEIL however is related to the mitotic spindle during cell division. 
.Overall, the divergent localization pf CSEIL in tumors of various origins, or � 
even in differential degree of malignancy of same tumor suggested the distribution 
of CSEIL in cells may lead to alternative CSEIL functional role in cell proliferation 
and thereby affect the development of human tumors. 
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5.9 Correlation of CSEIL expression with clinicopathological and 
molecular features in OTs 
Apart from the consistent upregulation of CSEIL in various tumors including 
glioma, CSEIL transcript level has been shown to positively correlated with higher 
metastatic and tumorigenic ability of nasopharyngeal carcinoma cells (Fang et al, � 
2005) and metastatic property of colorectal tumors (Seiden-Long et al, 2006). IHC 
analysis revealed correlation of CSEIL expression with i) tumor grade of 
hepatocellular carcinoma (Wellmann et al, 2001)，endometrial carcinoma (Peiro et 
al, 2001) and ovarian cancer (Peiro et al, 2002; Bmstmann 2004); ii) tumor stage of 
melanoma (Boni et al, 1999) and ovarian cancer (Peiro et al” 2002); and iii) 
invasive capability of breast cancers (Behrens et al” 2001). 
More importantly, CSEIL showed strong correlation with Ki-67 staining in 
lymphoma (Wellmann et al, 1997), proliferating cell nuclear antigen (PCNA) 
staining in hepatocellular carcinoma (Shiraki et al, 2006) as well as cyclin D1 and 
mitotic activity in ovarian cancer (Peiro et al, 2002; Bmstmann 2004). Above 
reports implied a role of CSEIL in tumor progression as well as cell proliferation. 
Unlike these findings, no significant correlation was observed between CSEIL ， 
expression and tumor grade or Ki-67 labeling index in OTs, suggesting the link may 
be tumor-specific. Meanwhile, to achieve a more accurate conclusion, more samples 
is required. 
The survival analysis demonstrated CSEIL expression at mRNA or protein level 
was not associated with outcome of OT patients. It was previous illustrated that high 
expression of CSEIL has been linked with a shorter survival in endometrial 
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carcinoma (Peiro et al., 2001) and ovarian cancer (Peiro et al, 2002), but not in 
nasopharyngeal carcinoma (Kim et al, 2010). The results suggested a variable 
prognostic significance of CSEIL in different tumor types. Larger sample size may 
lead to a more promising result. 
V 
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5.10 CSEIL mediates effects of miR-137 in glioma cells 
The next question to be resolved is to determine whether inhibition of CSEIL 
mediates the tumor suppressive role of miR-137 observed in glioma cells. 
Here, CSElL-specific siRNAs successfully knocked down CSEIL expression in 
CSElL-abundant OT and GBM cells. Our results demonstrated that attenuation of 
CSEIL led to reduced proliferation, induced apoptosis and suppressed invasiveness 
in both OT and GBM cells. It was notable that these effects were similar to those 
observed after miR-137 overexpression, but to a less extent, suggesting that miR-137 
may mediate its effect partly through CSEIL repression. 
It is also implicated the existence of other target genes of miR-137, which may 
contribute to biological roles of miR-137 in glioma. CDK6 and MITF belong to such 
candidates. Earlier investigations have shown that CDK6 is inhibited by ectopic 
expression of miR-137 in U251 GBM cells (Silber et al, 2008), oral squamous cell 
carcinoma (Kozaki et al, 2008) and uveal melanoma cells (Chen et al, 2010), where 
miR-137 resulting in cell cycle arrest. CDK6 is a well-known cell cycle regulator, 
which promotes Gl-S transition and is important in cell proliferation (Meyerson et 
al, 1994; Grossel et al, 2006). Consistently, elevated CDK6 expression has been 
detected in 85.6% (12/14) of GBMs (Lam et al, 2000). Therefore, it was highly 
possible that CSEIL and CDK6 act together to mediate the inhibitory effect of miR-
137 on glioma cell proliferation. 
In addition, miR-137 exerts its effect of reducing cell proliferation via 
suppressing MITF expression in uveal melanoma cells (Chen et al, 2010). The 
expression of MITF is present in GBM according to TCGA microarray data. 
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Whether these miR-137 targets validated in other cell types are still repressed by 




5.11 Biological roles of CSEIL in glioma cells 
In my study, knockdown of CSEIL in glioma cells inhibited cell proliferation, 
induced cellular apoptosis and suppressed cell motility and invasiveness, suggesting 
multiple functions of CSEIL. These observations were in line with involvement of 
CSEIL with cancer cell proliferation, apoptosis as well as invasion in previous 
reports (Brinkmann 1998; Behrens et al., 2003; Tai et al., 2010). 
5.11.1 CSEIL in glioma cell proliferation 
CSEIL is the human homologue of the yeast gene CSEl with a protein product 
sequence showing 59% overall homology to the yeast CSEl protein (Brinkmann et 
al, 1995). Mutation of CSEl induced G2 phase or mitotic arrest and deficient cyclin 
B proteolysis (Xiao et al., 1993; Imiger et al, 1995). Later study showed depletion 
of CSEl resulted in disrupted DNA replication (Yu et al, 2006). CSEl is therefore 
considered as an essential gene for yeast replication, giving rise to the postulation 
that CSEIL might be involved in mammalian cell proliferation. 
In mouse model, Csell expression increased during mouse embryo development 
with high levels in adult proliferating tissues (Bera et al, 2001). In regard to human 
CSEIL, Brinkmann et al observed an abundant CSEIL expression in human 
leukemia, lymphoma, colon and lung cancer cells as well as some of human normal 
tissues containing many proliferating cells by northern blot analysis, such as testis, 
fetal liver and lymphoid, but only low levels in tissues those do not actively 
proliferate. In vitro, CSEIL expression levels changed in accompany with the 
proliferation status of WI-38 human fibroblasts (Brinkmann et al, 1995). In 
concordance to the observation in the yeast, another study demonstrated that ectopic 
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expression CSEIL antisense cDNA led to arrest in G2 phase or mitosis along with 
cyclin B accumulation in HeLa human cervical cancer cells (Ogryzko et al., 1997). 
Thus, CSEIL might be necessary in human cell cycle progression. Consequently, 
mounting evidence have indicated highly CSEIL expression in various cancers, with 
positive correlation with tumor grade or cell proliferation index in some of them as 
summarized in section 5.7 and 5.9. CSEIL was thus thought as a proliferation-
associated protein, probably participating in tumor cell proliferation during cancer 
formation and progression. 
In concordance with these findings, our results showed interruption of CSEIL in 
glioma cells induces a suppressed cell proliferation as evaluated by cell number, 
metabolic activity and DNA synthesis. This was in contrast to enhanced CSEIL 
expression in HT-29 colon cancer and MCF-7 breast cancer cells were not able to 
increase cell proliferation (Jiang et al, 2004; Liao et al., 2008). I therefore 
speculated that CSEIL might be necessary in cell cycle progression, but not 
sufficient alone to stimulate cancer cell proliferation. It is also plausible that the role 
of CSEIL in cell proliferation is cancer-specific. A better understanding of the 
underlying mechanisms for the differential phenotype deserves further investigation. 
5.11.2 CSEIL in glioma cell apoptosis 
Our study has revealed CSEIL inactivation in glioma cells resulted in elevated 
cellular apoptosis, which was in line with several previous finding. Bern et al 
generated homozygous and heterozygous Csell knockout mice and observed that the 
Csell heterozygous mice were still phenotypically normal and fertile, homozygous 
Csell depleted mutant is however embryonically lethal. The in vivo experiments 
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emphasized the essential role of Csell for mouse embryonic growth and 
development (Bera et al, 2001). In addition, CSEIL protein expression inversely 
correlated with apoptotic activity in human hepatocellular carcinoma by IHC 
analysis (Shiraki et al.，2006). These suggested that CSEIL might be cell survival-
related and protected cells from programmed cell death. 
CSEIL has been widely implicated in chemotherapeutic drug-induced apoptosis. 
In MCF-7 breast cancer cells, however, CSEIL reduction conferred cell resistance to 
the ADP-ribosylating toxins pseudomonas exotoxin, diphtheria toxin and tumor 
necrosis factors, but showed no effect on the cell death induced by etoposide, 
staurosporine or cycloheximid (Brinkmann et al, 1996). Interferon- y treatment 
induced CSEIL expression in HT-29 colon cancer cells, where CSEIL 
overexpression enhanced interferon-y-induced apoptosis (Jiang et al, 2001). CSEIL 
knockdown also attenuated MCF-7 and HT-29 cell apoptosis induced by UV light as 
well as a series of chemotherapeutic drugs, including oxombicin，5-fluorouracil, 
cisplatin, and tamoxifen, with a concurrent p53 protein accumulation (Tanaka et al, 
2007; Liao et al, 2008). The positive effects of CSEIL in drug-induced apoptosis 
may be mediated by its association with promoter of some p53 targets (Tanaka et al, 
2007) and/or enhancement in apoptosome formation (Kim et al, 2008). 
In contrast, CSEIL inhibited paclitaxel-induced apoptosis, G2/M phase cell 
cycle arrest and aster formation of cancer cells (Liao et al, 2008). Paclitaxel serves 
as a chemotherapy drug by targeting the microtubule assembly and activating pro-
apoptotic signaling pathways (Yvon et al, 1999; Zhou et al, 2005). It was in well 
agreement with the earlier observed CSEIL association with microtubule (Scherf et 
al, 1996)，which appears in turn to protect microtubule from paclitaxel binding and 
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thereby escape from apoptosis. 
5.11.3 CSEIL in glioma cell invasion 
In my study, CSEIL knockdown reduced glioma cell mobility, which was in 
line with CSEIL function in other tumors. Expression of CSEIL correlated with 
metastatic ability in nasopharyngeal carcinoma cells (Fang et al, 2005) and colon 
cancer (Seiden-Long et al, 2006). It was also shown that sera CSEIL was most 
prevalent in a collection of metastatic cancers, followed by invasive and primary 
cancers of various origins (Tung et al, 2009; Tsai et al, 2010). 
Functional assays gave evidence that CSEIL overexpression enhanced cell 
migration, invasion and matrix metalloproteinase 2 (MMP2) secretion in MCF-7 
breast cancer cells, where CSEIL and MMP2 colocalized (Liao et al, 2008; Tai et 
al, 2010). CSEIL reduction inhibited the metastasis of B16-F10 melanoma cells in 
mice, validating the effect in vivo (Liao et al., 2008; Tsai et al, 2010). 
MMP2 is a member of MMP family, which possess proteolytic activity against 
extracellular matrix (ECM) components and herein plays critical role in glioma cell 
invasion. Elevated MMP2 expression was found in gliomas, whereas inhibition of 
MMP2 led to reduced glioma cell invasion. (Fillmore et al, 2001; Rao 2003) 
Together with our results in glioma, it is speculated that CSEIL is important in 
modulation of glioma cell invasion, potentially through regulating MMP2. 
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CHAPTER 6 CONCLUSIONS 
The main aim of my study was to elucidate the role of miR-137, a chromosome 
Ip encoded miRNA in gliomas with a focus on OTs. 
The expression level of miR-137 was demonstrated to be frequently down-
regulated in 94% (34/36) of OTs as compared to those of normal brains. A 
statistically significant difference was observed in miR-137 expression between 
normal brain samples and 20 oligodendrogliomas (p=0.016) or 16 oligoastrocytomas 
0=0.009). All 3 OT and 7 GBM cultured cells displayed decreased miR-137 
expression (p=0.007). The miR-137 level was significantly lower in WHO grade III 
OTs than those of WHO grade II (p=0.010). The expression of miR-137 was 
inversely correlated with Ki-67 labeling index in OTs 0=0.009). These results 
strongly suggest reduced miR-137 level may play a role in OT development and 
progression. 
The mechanisms responsible for reduced miR-137 expression were investigated. 
In OT cells, DNA demethylation and histion deacetylating inhibition treatment 
induced a synergetic miR-137 restoration (p<0.001). Expression of miR-137 showed 
no correlation with loss of chromosome Ip (/?=0.115), where miR-137 is mapped. 
Therefore，miR-137 inactivation in OTs may result from aberrant epigenetic 
modification rather than Ip allelic loss. 
Ectopic expression of miR-137 significantly inhibited both anchorage-dependent 
and -independent cell growth, through suppressing cell proliferation and inducing 
apoptosis in one OT and three glioblastoma cells (p<0.015). Cell invasiveness was 
repressed by enhanced miR-137 expression in these cells as well (p<0.001). In 
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addition, neuronal-like differentiation was induced by miR-137 ectopic expression in 
two GBM cells. These observations strongly suggested that miR-137 is a potential 
tumor suppressive miRNA in OT and GBM. 
CSEIL, ERBB4, NRPl, CDC42 and AKT2 were predicted as miR-137 target 
candidates by bioinformatic analysis. Among the 5 genes, miR-137 specifically 
interacted with 3'UTR of CSEIL and ERBB4 transcripts in glioma cells. CSEIL 
protein, but not mRNA, levels were reduced after miR-137 transfection in glioma 
cells. The results indicated that miR-137 binds to 3'UTR of CSEIL mRNA and 
negatively regulated CSEIL through translational inhibition in glioma. 
Examinations of CSEIL encoded product expression were subsequently 
performed. Elevated CSEIL transcript level was detected in 30% (6/20) of 
oligodendrogliomas and 75% (12/16) of oligoastrocytomas cases, up to 3.3- and 
12.7-fold, when compared to normal brains, respectively (p=0.022). CSEIL mRNA 
was overexpressed in 2 of 3 OT cells and 6 of 7 GBM cells 0=0.014). At protein 
level, a significant upregulation of CSEIL in the cohort of 36 OTs in comparison of 
13 non-neoplastic brain tissues was observed (p<0.001). However, the abundance of 
CSEIL mRNA or protein showed no significant correlation with miR-137 level in 
OTs (p=0326 and /7=0.300, respectively). These data have revealed overexpression 
of CSEIL in OTs at both mRNA and protein levels, suggesting CSEIL is potentially 
implicated in gliomagenesis. 
Investigations on functional role of CSEIL in OT and GBM cells were carried 
out using CSEIL loss-of-function approach. CSEIL knockdown led to significant 
reduced proliferation, induced apoptosis and suppressed invasiveness in glioma cells 
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(p<0.00\). These effects were similar to those observed after miR-137 
overexpression, but to a less extent, suggesting that miR-137 may mediate its effect 
partially through CSEIL. 
In summary, we present the first study on miR-137 in human OTs, suggesting 
that miR-137 plays an important role in the development of OT and GBM. Our 
results increased the understanding of pathogenesis of gliomas, and the miR-137-
CSEIL pathway may serve as a potential therapeutic target in treatment of gliomas. 
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CHAPTER 7 FUTURE STUDIES 
7.1 Molecular mechanisms for miR-137 inactivation in glioma 
Our results in this study along with previous findings have uncovered a reduced 
miR-137 expression in oligodendroglial and astrocytic gliomas (Silber et al., 2008; 
Zhi et al., 2010). The mechanisms underlie miR-137 silencing are poorly understood. 
Our data raise aberrant epigenetic modification as a plausible reason rather than 
chromosome Ip loss in OTs. However, whether miR-137 promoter hypermethylation 
or an indirect regulation is responsible remains elusive. Therefore, analysis of miR-
137 promoter methylation in OTs is required. Bisulfate sequencing and methylation-
specific PGR on the CpG islands located within putative miR-137 promoter region 
can be utilized to determine the miR-137 promoter methylation status, and to test 
whether miR-137 downregulation shows a correlation with promoter 
hypermethylation. Alteration of miR-137 promoter methylation status after DNA 
demethylating treatment can also provide hints to understand this regulation in OT 
cells. 
In addition, other potential mechanisms, such as VNTR variation upstream pre-
miR-137, defects in miR-137 biogenesis machinery and mutation at coding sequence, 
deserve further investigation to explain silencing of miR-137 in glioma. 
7.2 Identification of more miR-137 targets in glioma 
Given that CSEIL partially mediated miR-137 effects in glioma, it is worthwhile 
to study other target genes of miR-137 to explore the miR-137 regulated pathways. 
In other tumor types or stem cells, several miR-137 target genes have been 
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documented, including MITF, LSDl and Ezh2 (Bemis et al, 2008; Balaguer et al, 
2010; Szulwach et al, 2010). Whether these genes are controlled by miR-137 and 
moreover, account for miR-137 effects in glioma needs to be verified. 
On the other hand, high-throughput array analysis can provide potential targets 
with decreased expression following miR-137 ectopic expression in glioma cells. By 
coupling such gene expression profiling results with bioinformatic predictions, more 
promising targets can be discovered. Those validated targets may probably establish 
a miR-137 regulatory network, which will largely enhance our knowledge on role of 
miR-137 in gliomagenesis. 
7.3 Role of miR-137 and CSEIL in drug-induced apoptosis in 
glioma 
As chromosome Ip deletion is predictive of chemosensitivity in OT patients and 
CSEIL has been implicated in drug-induced cellular apoptosis, whether miR-137 
and CSEIL render glioma cells sensitive to chemotherapeutic drugs becomes an 
important but unsolved question. To test this issue, miR-137 or siCSElL transfected 
glioma cells can be exposed to several chemotherapeutic drugs, such as procarbazine, 
lomustine，vincristine, TMZ, paclitaxel and cisplatin. The cell survival after drug 
treatment can reflect the chemotherapeutic drug sensitivity as evaluated by MTT 
assay. If the potential significance of miR-137 and CSEIL here is proved, it may 
help to improve outcome following chemotherapy. 
7.4 Deciphering dysregulated and clinical relevant miRNAs in 
glioma 
Up to data, the pool of miRNA database is continuously increasing since 
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discovery of this class of tiny molecules nearly 2 decades ago. Although some earlier 
miRNA profiling studies have uncovered a series of miRNAs with abnormal 
expression levels in glioma compared to normal brains or lower-grade gliomas, 
suggesting an important role these miRNAs play in glioma development and 
progression, our understanding of aberrant expressed miRNA in gliomagenesis is 
still inadequate. Further miRNA expression profiling containing probes specific to 
newly discovered miRNAs is necessary to characterize the roles of these short 
mRNAs in pathogenesis of glioma. 
On the other hand, by correlate miRNA expression with patient survival time, 
some miRNAs with prognostic significance may be identified. This would provide 
novel clues for clinical relevance of miRNA in glioma. 
7.5 Effects of miR-137 in vivo and the therapeutic potential in 
glioma treatment 
Our Study has shown a potential tumor suppressive role of miR-137 in vitro, but 
the in vivo biological effects has not been defined. By using an induced intracranial 
glioma model in mouse, we can test whether miR-137 restored expression can be 
employed as a potential therapeutic strategy for glioma treatment in the future. 
Nowadays, miRNA or siRNA as a feasible therapeutic approach for glioma is 
challenged by numerous issues, including selection of suitable miRNA or gene 
targets, development of efficient and specific delivery systems, determination of 
optimized treatment dose and administration schedule as well as measurement 
system of a validated clinical response (Guo et al, 2010). Future testing and clinical 
trials are required to resolve these existing problems with a hope. 
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